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Prologue
Three case histories 
A.
An 86-year old woman, Mrs A, had fallen about twice a month during the past year. Six months 
ago she had broken her hip and only partially recovered; since that event she walked with a 
stick and was very fearful of falling. Her painful knees add to her reluctance to mobilize, leading 
to a maximum walking distance of only a few hundred metres. Eventually, it was a distortion 
of her ankle caused by her most recent fall that brought her into contact with her new general 
practitioner, who sent her to the geriatric outpatient clinic for an evaluation of her falls. 
Multidisciplinary assessment revealed mild cognitive impairment with problems in performing 
concurrent tasks during walking, a deformity of her left foot, an impaired vision, even after 
correction by glasses, osteoarthritis of her knees with an anthalgic gait pattern, fear of falling, 
and inappropriate use of her walking stick. After explanation and discussion of all these 
underlying problems, Mrs A agreed to buy orthopaedic shoes and new glasses and to start with 
exercise and fall-reduction training at the local physiotherapy group. She was also instructed to 
do only one thing at a time: walk, or talk, but not both together. To further increase her walking 
ability and reduce her fear, she switched from walking with a stick to a walking frame and tried a 
different type of analgetic for her knee pain. During a visit six months later, she happily reported 
to be much more mobile now; she had only fallen twice in this period and could participate in 
neighbourhood activities again.
B. 
An 84-year old lady, Mrs B, was admitted to the geriatric ward for analysis of her dyspnoea. 
She had a history of several episodes of depression and falls. The falls were caused by multiple 
factors, such as use of sedative drugs, gait and balance impairment, orthostatic hypotension, 
glaucoma and mild cognitive impairment. During admission, it became clear that her dyspnoea 
had diminished her ability to perform activities of daily living independently and to walk more 
than 10 metres. Presumably this had also led to an insufficient intake of food and fluids at home. 
As a complicating factor, her previously mild cognitive impairment had progressed to dementia 
(probably Alzheimer’s disease), which may also have interfered with a correct intake of drugs 
and sufficient nutrients. Taken together, she suffered from dehydration, malnutrition, an acute 
episode of heart failure, chronic obstructive pulmonary disease (COPD), dementia, low stamina, 
and recurrent falling. After treatment of her heart failure and COPD, improvement of nutritional 
status, and additional training of gait, balance and endurance by the physiotherapist, she felt 
better and recovered enough to go home with additional home care. 
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C. 
An 81-year old man, Mr C, was admitted to the geriatric ward because of unexplained functional 
decline and a gait disorder. He had a history of myocardial infarctions, vascular dementia, 
hypertension and diabetes mellitus. On admission he had a long list of problems: for two weeks 
visual hallucinations, agitation, anxiety at night, fluctuating alertness, shuffling gait. He grabbed 
the furniture during walking and had fallen twice in the past week; he ate and drank less and 
developed incontinence of urine. Because of all these problems he used 13 drugs. On top of 
these, his general practitioner had started haloperidol to decrease his agitation; which helped, 
but also caused further deterioration of his gait disorder.
After treatment of a urinary infection and revision of his drug regimen, the delirium subsided and 
it became clear that the remaining anxiety and agitation were behavioural problems associated 
with his vascular dementia. 
Mr C’s wife did not understand the reasons for her husband’s behaviour and her irritated 
reprimands led to clashes between them. The increased agitation of Mr C led to dangerous 
situations in which he swayed with his walking stick, nearly hitting people approaching him. As 
long as this interaction between husband and wife had such disastrous effects on the behaviour 
of Mr C, the haloperidol used to dampen his agitation, could not be stopped and continued 
to influence his gait negatively. Progression of his vascular dementia, the likely cause of his 
gait disorder, was minimised as far as possible by optimal treatment of his cardiovascular 
risk factors, balancing their effects and adverse events. Because of his severe dementia Mr C 
could not be taught how to safely handle his walking stick or how to use other fall prevention 
strategies. He was transferred to the old age psychiatry unit to try to influence his agitation with 
behavioural interventions.
Cases like these are more the rule than the exception in geriatric medicine. They underscore 
the clinical relevance of the combination of gait and cognitive problems: both are common and 
incapacitating for patients and their environment. Furthermore, their pathophysiology, clinical 
presentation and treatment is complex because of the many interactions with other health 
problems and their treatments. 
These and similar observations raise several scientific questions:
– With which methods can gait and cognitive function and their possible interaction be 
assessed best in elderly people? 
– Do gait disturbances and cognitive dysfunction really interact or is their co-occurrence merely 
a coincidental appearance of two common problems?
– If they do interact, how does cognition influence gait, balance and mobility in elderly 
people?  
– Which specific cognitive domains are involved?
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The interplay between gait and cognition in older people forms the basis for the research 
described in this thesis, a fascinating and clinically relevant area. Hopefully the basic insights 
described in this thesis may ultimately lead to improved treatment strategies and a better quality 
of life of patients with gait and cognitive problems and their carers.
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Key concepts in this thesis
Gait
Locomotion is the self-powered, patterned motion of limbs by which an individual customarily 
moves himself/herself from place to place. A gait is a particular way of moving on foot: walking 
and running are the two basic human gaits. In principle even very old people can have a normal 
gait.1 
Cognition
Cognition is a broad concept that consists of several domains, such as alertness, attention, 
concentration, executive function, memory and orientation.2
Interaction
In this thesis the term interaction is primarily used to describe the interplay between two 
functions: gait and cognition.
Not meant is interaction as the synergistic effect of gait and cognition on a third variable or 
interaction as term in statistical models.
References
1.  Bloem BR, Haan J, Lagaay AM, van Beek W, Wintzen AR, Roos RA. Investigation of gait in elderly 
subjects over 88 years of age. J Geriatr Psychiatry Neurol 1992; 5:78-84.
2.  Persoon A, Joosten L, van d, V, Olde Rikkert MG, van AT. [Dutch observation scales to assess cognitive 
abilities of the aged]. Tijdschr Gerontol Geriatr 2006; 37:184-194.
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General introduction
In youth we run into difficulties. In old age difficulties run into us. 
- Josh Billings -
In this introduction I will first outline the general context of health problems in vulnerable older 
people and then continue with the focus of this thesis: the interplay between gait and cognition 
in older people. I will highlight the extent of the problem and the consequences for patients, 
geriatric medicine and research. Because the methods to measure gait, cognition and their 
interaction play an important role, these will be described in the second part of this chapter. The 
chapter ends with the general research aims and an outline of this thesis. 
1.  Geriatrics: the land of multiple morbidity and interactions 
In the next 10 years the number of Dutch people aged 65 and over will increase by 650,000 
to 3.0 million people (CBS 2006). This group of older persons is very heterogeneous in health, 
ranging from very fit to very vulnerable. Most people have a gut feeling for which older person is 
vulnerable. However, to capture this feeling in an unequivocal and universally accepted definition 
is hard1 and searching it resembles the quest for the holy grail of geriatrics. Vulnerability is often 
described as frailty, which partially overlaps with the concepts of comorbidity and disability (See 
Figure 1). 
Figure 1. Partially overlapping concepts of frailty, comorbidity and disability 
Each of the three concepts indicates an increased risk at adverse outcomes from which vulnerable 
people recover more slowly and often incompletely.2-5 
Comorbidity is usually defined as the co-existence of two or more diseases6, but in the context 
of geriatrics (and thus in this thesis) it is defined as the co-existence of two or more health 
problems. Six percent of people aged 65-69 years to 50% in people aged 85 and over have 
two or more chronic diseases.6;7 Also, nearly 40% of older people aged 65-69 years have one 
or more disabilities, defined as difficulty or dependency in carrying out activities essential to 
Frailty  
Disability
Co-
morbidity  
Vulnerable
people  
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independent living. This percentage doubles to 80% in people aged 85 and over.7 The definition 
of frailty varies widely, as do the underlying hypotheses about its pathophysiology: from purely 
physical to an all-embracing bio-psycho-social model. With the often used criteria of Fried, seven 
to 35% of community-living elderly people aged 65 and over are found to be frail.2;8  
Despite the high prevalence of multiple and often interacting problems in elderly people and their 
adverse effects on health and quality of life9, almost all current research projects and guidelines 
are directed at isolated problems or diseases.10 Unfortunately, disease-specific guidelines can have 
conflicting interests and are likely to introduce more problems than they solve when used in 
patients with comorbidity: they may result in adverse interactions between drugs and diseases 
and lead to a very complex regimen of pharmacological and non-pharmacological actions.6;10 To 
improve care for vulnerable older people, and to improve methods for  research directed at this 
group, I aimed to acquire knowledge about the interplay between problems in gait and cognition: 
two geriatric ‘giants’ that are both common, important and debilitating in elderly people. 
2.  Gait and cognitive function 
2A.  Extent of the problem: prevalence, impact and costs for society
Of community-living elderly people aged 65 to 69 years, 2% have dementia, increasing to 25% in 
elderly people of 85 and above.11 The prevalence of gait disorders also increases with age from 
24% in people aged 70-74 to 59% in people aged 80 and over.12 
Gait and cognitive disorders each have a great impact on the quality of life and functioning of 
older people and their carers and increase the risk of falling.13-15
Dementia care alone currently costs Dutch society 3.1 billion Euros a year and mobility care another 
1.8 billion Euros. Dementia and mobility problems often occur together and a musculoskeletal 
and neurological problem is the second most frequent combination of health problems.9 Patients 
with comorbidity use more health services and have a large financial impact, although exact data 
on health economic aspects of this comorbidity are still lacking.15 
Thus, gait disorders and cognitive problems are common, often co-exist and have consequences 
for health service organisation and costs.
2B.  Gait and cognition: do they interact?
In general, four combinations of comorbidity can be distinguished: 
1.  Causal comorbidity, diseases with a common pathophysiology 
2.  Disease-specific complicating comorbidity 
3.  Concurrent, co-existing chronic comorbidity without a known causal relation to the index 
disease and 
4.  Intercurrent comorbidity, referring to an interacting acute illness, usually limited in time, such 
as the flu.6
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Gait and cognitive problems can co-occur by coincidence (type 3 comorbidity), but more often 
they are likely to really interact (type 1 and 2 comorbidity). Figure 2 shows a model for how gait 
and cognition may interact in older patients.
Figure 2. A model for the interplay between gait and cognition framed within the multimorbidity of vulnerable 
older people. The numbers refer to relations explained in the text.
Without aiming to be comprehensive, I will sum some effects of disease on gait and cognition and 
then focus on their interaction; first with epidemiological data and thereafter with a discussion 
of the possible pathophysiological mechanisms.
2B.1  Epidemiology
As depicted by the framework of figure 2, an older person often has many health problems that 
all may influence cognition, gait or both. The result of all health problems (and the subsequent 
compensation strategies) determines the cognitive performance and gait pattern that can be 
observed.
1.  The influence of disease on gait
 There are many health problems that can influence gait. Often a division between neurological 
and non-neurological problems is made. Examples of neurological problems are stroke and 
Parkinson’s disease. Non-neurological diseases such as osteoarthritis of the hip or knee can 
also change the gait pattern, or in the case of cardiopulmonary problems, may limit the 
maximum walking distance of patients. Furthermore, diabetes mellitus may cause gait and 
mobility problems through the complication of peripheral polyneuropathy. 
Relevant diseases:  
 
Neurological  
 
 
 Non-neurological
 
Gait Cognition
1  2 
4 
3 
Treatment
    Diseases not related to gait and cognition    
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2.  The influence of disease on cognition
 Similarly, many health problems and their treatments can influence cognition. To name 
some: Alzheimer’s disease pathology, hypertension, diabetes, psychotropic drugs, vascular 
problems and the amount of comorbidity.16-19
3.  Cognitive performance influences gait and mobility 
 Compared with healthy older adults, elderly people with dementia more often have gait 
disorders. The exact prevalence depends on the severity and type of dementia: gait disorders 
are more common in non-Alzheimer dementia (the prevalence of gait disorders in vascular 
dementia is 79%; 75% in Lewy Body Dementia and 25% in Alzheimer’s disease).20 They 
occur early in the disease process of vascular dementia and late in Alzheimer’s dementia.20 
Compared to cognitively normal elderly fallers, elderly patients with dementia have a two-
fold higher rate of falls, sustain more fractures and have a reduced life expectancy.21;22 The 
chances of successful rehabilitation are also less in patients with cognitive impairement.23 In 
case-control studies, dementia is associated with a decrease in gait velocity and an increase in 
stride variability.24;25 In non-demented older people, a deterioration in cognitive performance 
is associated with a decline in the successful execution of both novel or attention-demanding 
and routine physical tasks.26 Other mental functions, such as depression, anxiety and delirium 
can also influence gait, mostly through cognitive impairments. For example, in severe cases 
a depressive mood can be characterized by its subcortical cognitive problems and resemble 
a ‘pseudodementia’. The effects of mental functions other than cognition on gait have not 
been investigated thoroughly and most literature is directed at the effect of fear of falling on 
gait.27-30 
4.  Gait influences cognitive performance
 Gait disorders can precede non-Alzheimer’s dementia.31;32 Older people with a neurological 
gait disorder have a hazard ratio of 3.5 (95%CI 2.0-6.2) of developing non-Alzheimer’s 
dementia in the next six years. Furthermore, regular walking compared with almost no 
walking is associated with a 58% (0.33-0.96 95% CI) reduced risk of dementia in older men 
and less cognitive decline (OR 0.66; 0.54-0.82 95% CI) and 20% lower risk of cognitive 
decline in physically active older women.33-35 
Apart from these mutual influences, problems in gait and cognition can also interact and 
cause other health related problems (not depicted in Figure 2). Van Bonsdorff36 showed the 
synergistic effect of cognitive problems and mobility limitations on institutionalisation rate: 
The institutionalisation rate for older people with a mobility limitation was 16/1000 person-
years, with cognitive deficits 10/1000 person-years and for people with the combination of a 
combined mobility limitation and cognitive deficits 35/1000 person-years. Also, global cognitive 
performance (Mini Mental State Examination scores) and gait velocity are both predictors of 
combined cognitive and physical decline.37  
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2B.2 Pathophysiology
Another way to look at the interplay between gait and cognition is to focus on the underlying 
pathophysiology. For clarity: In healthy older people coordination of gait, balance and mobility 
requires cognitive input, but gait and mobility are not a necessary requirement for normal 
cognitive function. Arguments for pathophysiological mechanisms of the interaction between gait 
and cognition can be found at different levels and will be related to the model in figure 2. 
‘Disease’ and arrow 1 and 2 
Neuropsychiatric disorders 
With ageing, there is an overall increase of structural vascular brain lesions (such as infarcts and 
white matter lesions, WML), with a prevalence of WMLs of around 30% in community-living older 
people aged 65 to 84.38 These WML may be one of the common pathophysiological pathways 
that lead to cognitive disorders and gait and balance disturbances in elderly people.39 The 
amount and localisation of WML corresponds with impairments in cognition (periventricular), 
gait and balance, and possibly mood (subcortical).40 Cerebral ischemia may be an important 
etiological factor for the development of cerebral WML in elderly people: Cardiovascular risk 
factors and other, still unknown factors may cause cerebral ischemic microangiopathy and 
abnormal cerebral blood flow with decreased cerebral autoregulation. In turn they can disrupt 
frontal-subcortical circuits that can lead to the clinical symptoms of gait and balance disturbance, 
executive dysfunction, depression and urinary urge incontinence. 
Other evidence that supports a crucial role for the frontal cerebral cortex in the regulation of gait 
and balance is the correlation of postural and gait disturbances with decreased frontal cerebral 
blood flow in Alzheimer disease.41 Furthermore, neurofibrillary tangles in the substantia nigra are 
associated with gait impairment in older persons with and without dementia.42 
Non-neuropsychiatric comorbidity 
Other, non-neuropsychiatric health problems can also influence the interplay between gait and 
cognition, both directly and indirectly. Treatments beneficial for the target problem may have 
adverse effects on gait and cognition. For example, heart failure is very common in elderly 
people, occurring in 200.000 patients in the Netherlands with a mean age of 78 years. Heart 
failure can decrease working memory and executive function, for example by cerebral emboli 
and decreased systolic cardiac output that decreases cerebral perfusion and cerebrovascular 
reactivity. It can influence gait and mobility by decreasing exercise capacity and fluid retention in 
the legs, which can interfere with the fitting of shoes and with ankle movements. Other examples 
of relevant non-neuropsychiatric problems are hypoxia in pulmonary problems and systemic 
vasculitis that affect cerebral function as well as many other organ systems.
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Arrow ‘treatment’ towards ‘disease’ 
Antipsychotic drugs used to treat behavioural and psychological problems in patients with 
dementia can cause extrapyramidal symptoms and somnolence that can impair gait and increase 
the risk of falling. Other psychotropic drugs may also impair gait and increase the risk of falling, 
probably through muscle weakness and somnolence.43
Arrow 3 and 4
Central processing of a simultaneous gait and cognitive task
The simultaneous performance of a cognitive and mobility task (dual tasking) can influence the 
performance on one or both tasks44 and can be used to investigate the risk of falling.45-47 The 
explanation of this phenomenon may be that the execution of the second task interferes with 
gait and balance control; probably because attention has to be divided or through structural 
inference in neural networks of the frontal and motor cortex.44;48 Another explanation is that the 
demands of cognition and gait go beyond the limited central processing capacity, resulting in an 
suboptimal performance in gait, cognition or both. The effect of a dual task on gait and cognition 
also depends on prioritization by the researcher and participant.49
Complete figure 2
Lability in regulatory systems  
Complex physiological regulatory systems safeguard a stable organ output. Stable in this 
sense means that all organ systems show some biological variation in their functioning, but 
homeostatic mechanisms keep this within tight boundaries. Old age and disease often result 
in lability in these homeostatic mechanisms50, which is caused by an impaired ability of organs 
to adapt to stress. This is seen in increased biological variation (increased intra-individual 
variability) in general and in increased responses to stress,51 which can be a good predictor of 
adverse events. Focussing on gait and cognition: a high intra-individual variability in step length 
and time is associated with an increased risk of falling.52 Furthermore, patients with dementia or 
neural system decline show a higher day-to-day intraindividual variability in cognitive test results 
than do healthy older people.53;54  It is likely that the general lability in regulatory mechanisms 
in vulnerable older people simultaneously influences gait and cognitive performance, but this 
has not been investigated yet.
In conclusion, gait and cognition interact, through a combination of type 1 and 2 comorbidity. 
However, the clinical presentation of gait and cognitive problems is the result of a multifactorial 
process with many of interactions. This means that the exact contribution of separate factors and 
mechanisms to the clinical presentation cannot be disentangled completely.
In the remainder of this thesis, the interaction between gait and cognition is investigated at a 
functional level.
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2C.  Consequences of the interaction between gait and cognitive dysfunction for 
patient care and research
As already described in the first paragraph of this chapter, patients with both gait and cognitive 
dysfunction have a reduced quality of life and a low cognitive performance often coexists with 
multiple chronic conditions and many disabilities. These multiple problems require complex 
treatment regimes in people who are poorly equipped to handle them.55 
Frailty, multimorbidity and multiple interactions are key factors of geriatric patient care; 
they are well known and receive attention in the comprehensive geriatric assessment by the 
multidisciplinary team. For other specialties, the evidence for an interaction between gait and 
cognitive function can serve to emphasize the importance of comorbidity and teaches them that 
patients with a mobility problem should also be assessed for cognitive problems and vice versa. 
In all cases, knowledge about the interaction can help in the diagnostic process. It may give 
more precise estimates of the risk of falling and recovery rates and can facilitate the evaluation 
of treatment options. However, there are currently no guidelines and almost no literature on best 
practice in the treatment of combined gait and cognitive problems. Therefore, new knowledge 
to develop intervention studies directed at both problems and their interaction is urgently 
needed.
Despite their importance, research directed at interactions is scarce56 and frail older people 
are often excluded from research projects. The reasons are numerous and include the high 
attrition rate, difficulties with adherence to protocols, mobility limitations, transport problems, 
heterogeneity of the study population and cognitive impairment. These can preclude participation 
in studies based on self-assessment. This thesis explores methods of investigating gait and 
cognition and their interaction in frail older people. As such, the studies can also serve as a 
model of how to perform patient-related research on complex diseases-disease interactions in 
geriatric patients.
3.  Measurement of gait, cognition and their interaction
To be able to investigate the interplay between gait and cognition, it is necessary to know how 
to measure its components. 
3A.  Measurement of gait
Clinicians can use qualitative observation and quantitative gait and mobility measures for 
diagnostic purposes and to monitor gait and mobility. Qualitative observation of gait can 
give information about the underlying disease, but it is subjective and highly depends on the 
discipline and level of experience of the physician or therapist. Decisions about clinical relevant 
changes are difficult when time-intervals between visits are long or with changes in physicians. 
Quantitative gait assessment with functional performance tests and electronic walkways are 
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objective, give an indication of the risk of falling and the severity of mobility impairment and can 
be used to monitor gait, balance and mobility. The qualitative and quantitative measurements of 
gait, mobility and balance will be discussed further in the following sections.
Qualitative observation
Although important in the diagnostic process to detect whether something with gait and balance 
is wrong, qualitative observation of gait and balance is less clear and unequivocal in what 
exactly is wrong. Several classification systems exist, based on anatomical substrates (lower, 
middle and higher level gait disorders)57;58, gait and balance patterns  (‘cautious’, ‘marché-a-
petit-pas’ or ‘wide based’ in dementia) and the clinical diagnostic process.59 Unfortunately, no 
classification system is perfect. For example, the descriptions of higher-level gait patterns, as 
seen in dementia, are unclear and overlap. Furthermore, the initial gait pattern is modified by 
the compensatory strategies of the patient; different impairments may evoke clinically similar 
compensatory gait patterns. The observation of gait in older people is further complicated 
because multiple non-neurological impairments influence their gait pattern, mixed with the 
effects of fear of falling, deconditioning and the use of a walking aid.  
To facilitate the systematic evaluation of gait and balance without the aim of classification, 
Tinetti developed a method of observing and quantitatively scoring relevant elements of gait 
and balance in geriatrics, the Performance Oriented Mobility Assessment (POMA) or Tinetti gait 
and balance test.60 
Quantitative measurements
Gait and mobility can be measured quantitatively by questionnaires, functional mobility tests 
and (simple) laboratory gait assessments. 
Questionnaires and functional mobility tests measure related but slightly different constructs 
that can complement each other;61 For example, asking for ‘can do’ versus ‘do do’, and asking 
for how much ‘effort’ or ‘help’ is needed gives different results. Furthermore, the answer on the 
questions can differ with the actual performance of the activity when tested. Mobility tests can 
be used to detect a preclinical stage of disability that is not revealed by questioning alone62 or 
purely qualitative observations; with observations clinicians can only discriminate severe from 
no or mild impairments. 
There are many functional mobility scales, of which the Timed Up and Go-test (TUG) is well known 
and widely used. During the test the participant has to get up form a chair, walk as quickly as 
possible for 3 metres, turn around, walk back to the chair and sit down again. This task is timed. 
The time itself gives an indication of the risk of falling (>13.5 seconds to complete the TUG has 
a sensitivity of 80% and specificity up to almost 100% in small groups for a future fall (within 12 
months) in older people).63 The observations that can be made during the execution of the task 
give an additional, subjective idea of the risk of falling.64;65 The TUG requires minimal amounts 
of time, place and tools, which makes it suitable for clinical practice. Other functional tests of 
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gait, balance and mobility are Tinetti’s Gait and Balance Test (range 0-28)60 and the Berg Balance 
Score (BBS; range 0-56).66 Cut-off points that indicate an increased risk of falling are a Tinetti 
score below 19 and a BBS score below 45.  
Of the laboratory instruments, treadmills and platforms are not feasible and reliable in frail 
elderly people. For example, after half an hour practicing even healthy older people are not yet 
used to walking on a treadmill.67 New instruments, such as pressure sensitive insoles, electronic 
walkways and accelerometers (worn on the limbs, trunk or both), have been developed to 
measure gait and balance without influencing the normal gait pattern. These instruments can 
also be used in participants who walk with a walking aid. The most important outcomes of the 
electronic walkway and pressure sensitive insoles are gait velocity and stride variability (stride 
length, stride time and stride width) and mediolateral body sway for the trunk accelerometer, 
because they are associated with an increased risk of falling. 29,68 The clinimetric features of these 
instruments in older people were not known at the start of this thesis.
3B.  Measurement of cognition
Cognitive impairments can be tested globally or more specifically by in-depth neuropsychological 
tests. Cognitive abilities and impairment can be screened with global tests of memory (e.g. 
Mini Mental State Examination).69 A diagnosis of dementia, including its aetiology, requires 
assessment by a multidisciplinary team with careful clinical assessment, neuroimaging and 
neuropsychological assessment, all in accordance with the international guidelines.70-73 However, 
this is not always feasible because of time and financial constraints. 
Separate cognitive functions, such as executive function, can be assessed separately and more in-
depth by using specific neuropsychological tests. An advantage of specific cognitive tests is their 
provision of more detailed information. However, a disadvantage of testing separate cognitive 
functions is that many tests are needed for a global impression of cognition. Furthermore, each 
cognitive function can be tested with many different tests and each test often relies on more 
than one aspect of cognitive function. For example mental flexibility can be tested with the 
Go-No Go test and the Trail Making test, but apart from mental flexibility the execution of tests 
also require intact vision and reading skills, concentration and motor skills. The cognitive tests 
may also do not resemble situations in normal daily life and they require a sufficient vision and 
understanding of the language for reliable and valid test results. 
All these aspects have to be evaluated against the limited attention span of frail elderly 
participants, whose performance on multiple tests can be negatively influenced by fatigue and 
decreased motivation. 
3C.  Measurement of the interplay between gait and cognition
The interplay between gait and cognition can be investigated directly, by observing the effect of 
dual tasks on gait and cognition. Another method is to test whether cognition is independently 
associated with gait performance in cross-sectional or longitudinal studies. 
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The ‘archetype’ of the dual task paradigm is the phenomenon termed ‘Stops walking when 
talking’.74 When present, a person stops walking when he starts talking. The test reveals clinically 
relevant information, as ‘stopping’ is a strong predictor of falls. The essential element of a dual 
task is that a person performs two tasks, walking and a cognitive or physical secondary task, at 
the same time. The gait and cognitive performance during the dual task can be compared with 
the performance during the single task condition to show the additional effect of the secondary 
task. A prerequisite is that the secondary task is difficult enough to interfere, but not too difficult 
that subjects will ignore it in favour of maintaining their gait and balance. Many other variants 
in tasks and types of instruction with different effects on the gait and cognitive tasks can be 
thought of.49
4.  General research aims and outline of this thesis
Many older people have multiple problems that often interact. To be able to give frail older 
patients with multimorbidy the best available treatment, more information is needed about 
the interaction of common problems. However, so far this has received little research attention. 
Therefore this thesis focusses on aspects of the interaction between two major health problems 
of elderly people: impairments in gait and cognition. In addition, it elaborates on methodological 
issues and introduces and evaluates new measurement methods for gait and balance in (frail) 
older people. 
The thesis starts with literature reviews of the pitfalls of gait observation, quantitative gait 
analysis in elderly patients with dementia and the adverse events of antipsychotic drugs used 
to treat behavioural and psychological symptoms in dementia (Chapter 2). Thereafter, the results 
of three studies in different groups of elderly people follow. First, the group of geriatric patients 
(Chapter 3): in this group the association of dementia with gait velocity was investigated as 
well as methodological issues concerning the reliability and responsiveness of quantitative gait 
analysis and functional mobility scales, the different frailty criteria, and the effect of depression 
on gait. Because the research questions generated from the first project were physically too 
demanding to be tested in geriatric patients, a second study in very fit elderly people followed 
(Chapter 4). In this group we tested the effects of different cognitive dual tasks on gait and 
balance and developed a standardization method of gait and balance variables for gait velocity. 
It seemed likely that of all the cognitive functions, executive function would be one of the key 
ones in coordinating and adjusting gait. Therefore, in community-living elderly people, the effect 
of executive function on gait and balance during walking was tested (Chapter 5).
In the final chapter (Chapter 6) the results are summarized and put in a broader context. This 
thesis concludes with ideas and options for future research directions. 
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Abstract
Introduction
Diminished mobility often accompanies dementia and has a great impact on independence 
and quality of life. New treatment strategies for dementia are emerging, but the effects on gait 
remains to be studied objectively. In this review we address the general effects of dementia on 
gait as revealed by quantitative gait analysis.
Methods
A systematic literature search with the (MESH) terms: ‘dementia’ and ‘gait disorders’ in Medline, 
CC, PsychInfo and CinaHL between 1980-2002. Main inclusion criteria: controlled studies; patients 
with dementia; quantitative gait data.
Results
Seven publications met the inclusion criteria. All compared gait in Alzheimer’s Disease (AD) with 
healthy elderly controls; one also assessed gait in Vascular Dementia (VaD). The methodology 
used was inconsistent and often had many shortcomings. However, there were several consistent 
findings: walking velocity decreased in dementia compared to healthy controls and decreased 
further with progressing severity of dementia. VaD was associated with a significant decrease 
in walking velocity compared to AD subjects. Dementia was associated with a shortened step 
length, an increased double support time and step to step variability. 
Discussion
Gait in dementia is hardly analyzed in a well-designed way. Despite this, literature suggests 
that quantitative gait analysis can be sufficiently reliable and responsive to measure decline 
in walking velocity between subjects with and without dementia. More research is required to 
assess, both on individual and group level, how the minimal clinically relevant changes in gait 
in elderly demented patients should be defined and what would be the most responsive method 
to measure these changes.  
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Introduction
Gait disorders are common in dementia. In Alzheimer’s disease (AD) gait disorders occur late in 
the course of the disease. In vascular dementia gait disorders present earlier or even precede 
dementia.1;2 Gait disorders result in decreased mobility and an increased risk of falling.3-6 The 
consequences of gait disorders and falls can be severe, including fractures, worsening of 
immobility, loss of independence and increased cardiovascular morbidity and mortality.7-10 
Recent studies show that gait abnormalities are not only part of the clinical syndrome of 
dementia, but also an independent predictor of the risk to develop non-Alzheimer dementia.11;12 
Gait disorders in dementia can be classified as higher level gait disorders.13;14 In higher level 
gait disorders the patient can execute the separate movements necessary to walk, but the 
cerebral integration and processing of sensory (visual, vestibular and proprioceptive) information 
necessary to execute an optimal gait pattern is decreased. This results in reactions and gait 
patterns that are not suited for that specific situation. Higher level gait disorders are usually 
diagnosed by clinical observation. Although this clinically useful classification is widely accepted, 
it is subjective and not tested on reliability. Furthermore this classification provides only the 
type of gait disorder and is not helpful in monitoring changes in patients with progressive gait 
disorders. Quantitative gait analysis, for example by means of electronically equipped carpets, is 
quick, easy and non-invasive and therefore suitable for use in demented subjects. Further, this 
method provides reliable, objective quantitative data which can be used to measure changes in 
gait disorders, for example in order to examine the effects of interventions. 
However, before clinical application of quantitative gait analysis we need to know the general 
effects of dementia on gait, the clinical relevance of such changes and the responsiveness of 
simple quantitative methods of gait analysis to measure these changes. The aim of this study is 
to assess whether there currently is an evidence base on which gait patterns in dementia can be 
differentiated from gait patterns in healthy elderly people.
Methods
We performed a systematic literature search in the English, Dutch and German languages in the 
databases Medline, Current Contents, PsychInfo and CinaHL for the period of 1980-2002. The 
following search terms (MeSH and free search terms) were used: dementia, cognitive impairment, 
Alzheimer Dementia, Vascular Dementia, Lewy Body Dementia, FrontoTemporal Dementia, Mixed 
type Dementia, Mild Cognitive Impairment; gait, fall(s), ambulation, walking, (im)mobility. We 
also searched the references for relevant articles. 
In order to be selected for our review, the articles had to fulfil the inclusion criteria. Inclusion criteria 
were: 1. Population: Patients with the diagnosis of Mild Cognitive Impairment (MCI) or dementia 
(Alzheimer Dementia, Vascular Dementia (VaD), Lewy Body Dementia (LBD), FrontoTemporal 
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Dementia (FTD) or Mixed Dementia (MD). 2. Type of outcome measures: quantitative analysis of 
gait variables (for example velocity, stride length, variability) or mobility assessment scales. 
After this first selection, during the second selection studies were excluded which did not have 
a healthy elderly control group. We did not select the studies on (correction for) confounding 
factors or statistical methods.
Two of the authors (MvI and WH) decided independently on inclusion and exclusion. In case of 
disagreement, the articles were discussed with the other authors to make the definite decision. 
After inclusion, we judged the articles on methodological issues concerning study population 
and methods. We scrutinized the articles on the following items: clear and complete description 
of population and in- and exclusion criteria, recruitment process, informed consent, reproducible 
methods and correction for confounding factors. Data on balance will not be reported here to 
keep this article focused and legible.
Results
We found 1798 articles in Medline, 793 in Current Contents, 484 in PsychInfo and 1031 in Cinahl. 
After applying our inclusion criteria on the abstracts, we had 14 articles left to analyze. We 
excluded 7 articles of this group because they did not have a control group with healthy elderly 
subjects. 
The finally included 7 articles15-21 all compared gait in AD with healthy elderly controls. One also 
studied VaD. An overview of included studies is given in table 1. No study compared quantitative 
gait variables of Lewy Body Dementia or Frontotemporal Dementia with those in healthy elderly 
controls.
With regard to recruitment and selection of patients, most articles used widely accepted 
international criteria to diagnose the type of dementia. Only Visser included AD by excluding 
VaD and other forms of dementia without specifying how.21 We did not exclude this study for this 
reason, as this is the only major shortcoming of this study. Recruitment rates were only given 
by Alexander.15 However, he did not specify which part of the target population was excluded or 
why eligible subjects did not (want to) participate.
The study of Tanaka was the only study that did not report values of the Mini Mental State 
Examination (MMSE) nor the Clinical Dementia Rating scale (CDR) of their population.20 Visser 
used so-called Set Test scores as a measure of the severity of dementia.21 Her subjects had a 
moderate to severe dementia. Patients with extra pyramidal symptoms (EPS) were excluded in 
two studies.15;17 Three of the 7 studies stated that the subjects gave informed consent16;18;20, but 
none described how this was obtained from the demented subjects.
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In most of the 7 studies the exact method of registration of gait variables was unclear and the 
specific walking instructions given to the subjects studied (eg. walk at your preferred speed, or 
walk as fast as possible) were not specified. (Table 1)
However, all studies in which walking velocity was measured consistently showed that walking 
velocity in subjects with probable AD is significantly lower than in healthy elderly controls (table 
2). The decrease in walking velocity ranges from no difference for subjects with questionable 
dementia (CDR 0.5)17 to major decreases in severe AD.17;18 Mean velocity in subjects with AD 
across all trials ranged from 0.57 to 0.93 meter/second compared to 0.97 to 1.40 meter/second 
in healthy elderly controls. Tanaka et al. were unique in also testing subjects with VaD. They 
defined VaD as patients with dementia with a Hachinski ischemia score of 7 or more. In their 
study subjects with VaD had the lowest walking velocity (mean 0,52 m/s), which was even slower 
than their subjects with AD.
Camicioli and Ott used cadence, the number of steps per second, as measure of walking velocity. 
Camicioli found a mean cadence in AD of 1.6 (standard deviation ± 0.25), not significantly 
different compared to 1.8 (± 0.28) in healthy elderly controls. Ott found a cadence of 0.9 steps/
second (± 0.02) in AD which did significantly differ from 1.0 (± 0.03) in healthy elderly controls. 
Stride length showed the same results as walking velocity: it was shorter in subjects with AD 
compared to healthy elderly controls (table 2). Patients with a more severe dementia had a 
shorter stride length. The shortest stride lengths were observed in VaD. In none of the studies 
stride length was corrected for the slower walking velocity in AD and VaD.
In the study of Visser the stride length variability was increased in AD, but the difference with 
controls did not reach statistical significance. In the study of Nakamura only the subjects with 
AD, CDR 2 and 3 had a significantly increased stride length variability. Again these values were 
not corrected for the slower walking velocity in AD.
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Discussion 
The methods used in the studies that were included in this review are heterogeneous and not 
rigidly described. Therefore, meta-analysis of the results of these studies will be impossible, even 
if the original data were all available. Despite the many flaws in methodology, this systematic 
review of quantitative gait studies in elderly subjects with and without dementia still showed 
that there are consistent differences in quantitative gait variables between both groups: patients 
with AD had a slower walking velocity and a decreased step length. Step length variability was 
rarely studied, but seemed increased in comparison to healthy elderly controls. Gait disorders 
increased with increasing severity of the AD. Patients with VaD appear to have the lowest walking 
speed, even lower than AD patients, but this was studied only once. So far, no quantitative 
gait measures of patients with other types of dementia (LBD, MD, FTD) have been reported in 
comparison with a healthy elderly control group. 
These results cannot be used immediately in daily practice. There are possible confounders in 
the articles included in this review, such as the history of falls, and recruitment and selection that 
has not been discussed in sufficient detail. Strong selection is likely to have occurred because 
none of the AD patients included had other impairments. This probably caused selection bias 
that will influence the results 22 and jeopardizes the external validity of these results for the 
larger population of geriatric patients suffering from dementia and multiple impairments. 
The decreased stride length and increased double support ratio reported in AD and VaD are 
correlated with gait velocity15;23. Because the studies did not correct stride length and double 
support time for gait velocity, it is unclear whether these variables are independent characteristics 
of gait impairment in dementia. Furthermore, the studies matched AD patients with controls for 
age and gender, but not for body height or leg length, although this influences step length.24;25
EPS may be another important confounding factor, as it is common in later stages of AD and 
influences gait. However, EPS were not examined in 5 of the 7 included studies. Depending 
on the definition of EPS, the percentage of AD patients with EPS varies from 51 to 78% for 
bradykinesia, from 20 to 67% for rigidity, and from 20 to 47% for postural instability26-28 The 
prevalence of EPS in AD increases with increasing disease severity and this makes it difficult to 
extract the gait characteristics specific for AD. LBD, a dementia with prominent EPS, illustrates 
how EPS can influence gait. Waite et al. studied patients with AD, VaD and LBD29 and found that 
patients with LBD had a significantly worse mobility compared to AD and VaD patients. Overall, 
decrease in gait velocity possibly is an early marker of the EPS characteristics in dementia.
Drug use is another confounding factor that has to be taken into account. Only Alexander used 
psychotropic medication as exclusion criterion. Epidemiological and intervention studies30-32 
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showed that psychotropic medication increases the risk of falling by causing sedation and postural 
hypotension. The effects of these and other drugs on gait itself have not been investigated 
thoroughly to date.
The recent development of instruments for quantitative gait analysis that are easily applicable 
as bedside tools, have uncovered a challenging field of research. Changes in gait may be 
quantified for early detection of drug side effects or beneficial effects of non-pharmacological 
therapy. Furthermore, as gait disorders seem to be a predictor of dementia, gait analysis may 
offer clinicians the opportunity to select a population at risk for dementia and to easily monitor 
secondary prevention measures.
However, before quantitative gait variables can be used as outcomes in clinical practice and 
research, the minimal clinically relevant changes in gait in elderly demented patients should be 
defined. Next, responsiveness of clinical rating scales and quantitative gait analysis should be 
determined.33 Responsiveness quantifies the ability to measure change over time and has to be 
assessed separately in diagnostic validation studies. The fact that significant differences can be 
detected in gait variables between rather small groups, suggest that the internal responsiveness 
of the applied measures is sufficient. Not known is, if these changes are clinically relevant. 
Unknown are also the minimal clinically important changes in other often used mobility scales 
their relation with relevant clinical changes in quantitative gait variables. It is important that 
future research focuses on these aspects.
Reference List
1.  McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s 
disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and 
Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34:939-944.
2.  Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH et al. Vascular dementia: 
diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 
1993; 43:250-260.
3. Nevitt MC, Cummings SR, Kidd S, Black D. Risk factors for recurrent nonsyncopal falls. A prospective 
study. JAMA 1989; 261:2663-2668.
4. Shaw FE. Falls in cognitive impairment and dementia. Clin Geriatr Med 2002; 18:159-173.
5.  Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. 
N Engl J Med 1988; 319:1701-1707.
6.  Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med 2003; 348:42-49.
7.  Bloem BR, Gussekloo J, Lagaay AM, Remarque EJ, Haan J, Westendorp RG. Idiopathic senile gait 
disorders are signs of subclinical disease. J Am Geriatr Soc 2000; 48:1098-1101.
8. Boers I, Gerschlager W, Stalenhoef PA, Bloem BR. Falls in the elderly. II. Strategies for prevention. Wien 
Klin Wochenschr 2001; 113:398-407.
9.  Hakim AA, Petrovitch H, Burchfiel CM, Ross GW, Rodriguez BL, White LR et al. Effects of walking on 
mortality among nonsmoking retired men. N Engl J Med 1998; 338:94-99.
10. Wilson RS, Schneider JA, Beckett LA, Evans DA, Bennett DA. Progression of gait disorder and rigidity 
and risk of death in older persons. Neurology 2002; 58:1815-1819.
Marianne van Iersel.indb   42 27-08-2007   15:17:29
43
Literature review
11.  Marquis S, Moore MM, Howieson DB, Sexton G, Payami H, Kaye JA et al. Independent predictors of 
cognitive decline in healthy elderly persons. Arch Neurol 2002; 59:601-606.
12.  Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ, Buschke H. Abnormality of gait as a predictor of 
non-Alzheimer’s dementia. N Engl J Med 2002; 347:1761-1768.
13.  Alexander NB. Gait disorders in older adults. J Am Geriatr Soc 1996; 44:434-451.
14.  Nutt JG, Marsden CD, Thompson PD. Human walking and higher-level gait disorders, particularly in the 
elderly. Neurology 1993; 43:268-279.
15. Alexander NB, Mollo JM, Giordani B, Ashton-Miller JA, Schultz AB, Grunawalt JA et al. Maintenance of 
balance, gait patterns, and obstacle clearance in Alzheimer’s disease. Neurology 1995; 45:908-914.
16.  Camicioli R, Howieson D, Lehman S, Kaye J. Talking while walking: the effect of a dual task in aging 
and Alzheimer’s disease. Neurology 1997; 48:955-958.
17.  Goldman WP, Baty JD, Buckles VD, Sahrmann S, Morris JC. Motor dysfunction in mildly demented AD 
individuals without extrapyramidal signs. Neurology 1999; 53:956-962.
18.  Nakamura T, Meguro K, Yamazaki H, Okuzumi H, Tanaka A, Horikawa A et al. Postural and gait 
disturbance correlated with decreased frontal cerebral blood flow in Alzheimer disease. Alzheimer Dis 
Assoc Disord 1997; 11:132-139.
19.  Ott BR, Ellias SA, Lannon MC. Quantitative assessment of movement in Alzheimer’s disease. J Geriatr 
Psychiatry Neurol 1995; 8:71-75.
20.  Tanaka A, Okuzumi H, Kobayashi I, Murai N, Meguro K, Nakamura T. Gait disturbance of patients with 
vascular and Alzheimer-type dementias. Percept Mot Skills 1995; 80:735-738.
21.  Visser H. Gait and balance in senile dementia of Alzheimer’s type. Age Ageing 1983; 12:296-301.
22.  Cohen-Mansfield J. Recruitment rates in gerontological research: the situation for drug trials in dementia 
may be worse than previously reported. Alzheimer Dis Assoc Disord 2002; 16:279-282.
23.  Ebersbach G, Sojer M, Valldeoriola F, Wissel J, Muller J, Tolosa E et al. Comparative analysis of gait 
in Parkinson’s disease, cerebellar ataxia and subcortical arteriosclerotic encephalopathy. Brain 1999; 
122:1349-1355.
24.  Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values 
and determinants. Age Ageing 1997; 26:15-19.
25.  Dobbs RJ, Charlett A, Bowes SG, O’Neill CJ, Weller C, Hughes J et al. Is this walk normal? Age Ageing 
1993; 22:27-30.
26. Lopez OL, Wisnieski SR, Becker JT, Boller F, DeKosky ST. Extrapyramidal signs in patients with probable 
Alzheimer disease. Arch Neurol 1997; 54:969-975.
27.  Molsa PK, Marttila RJ, Rinne UK. Extrapyramidal signs in Alzheimer’s disease. Neurology 1984; 34:1114-
1116.
28.  Tsolaki M, Kokarida K, Iakovidou V, Stilopoulos E, Meimaris J, Kazis A. Extrapyramidal symptoms and 
signs in Alzheimer’s disease: prevalence and correlation with the first symptom. Am J Alzheimers Dis 
Other Demen 2001; 16:268-278.
29.  Waite LM, Broe GA, Grayson DA, Creasey H. Motor function and disability in the dementias. Int J Geriatr 
Psychiatry 2000; 15:897-903.
30.  Ensrud KE, Blackwell TL, Mangione CM, Bowman PJ, Whooley MA, Bauer DC et al. Central nervous 
system-active medications and risk for falls in older women. J Am Geriatr Soc 2002; 50:1629-1637.
31. Koski K, Luukinen H, Laippala P, Kivela SL. Physiological factors and medications as predictors of 
injurious falls by elderly people: a prospective population-based study. Age Ageing 1996; 25:29-38.
32.  Thapa PB, Gideon P, Fought RL, Ray WA. Psychotropic drugs and risk of recurrent falls in ambulatory 
nursing home residents. Am J Epidemiol 1995; 142:202-211.
33.  Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review 
and recommendations. J Clin Epidemiol 2000; 53:459-468.
Marianne van Iersel.indb   43 27-08-2007   15:17:29
Marianne van Iersel.indb   44 27-08-2007   15:17:30
Chapter 2B
What is a waddling gait?
Marianne B van Iersel 
Graham P Mulley
Disabil Rehabil 2004; 26:678-682
Marianne van Iersel.indb   45 27-08-2007   15:17:30
46
Chapter 2
Marianne van Iersel.indb   46 27-08-2007   15:17:30
47
Literature review
Abstract
Introduction
A patient’s gait can give important diagnostic and functional information. Though waddling 
gait is a long-established concept, we question whether this description is precise or clinically 
useful.
Methods
We searched ‘waddling gait’ in all main medical specialties core textbooks, in animal locomotion 
books and in Medline, Healthstar and Embase. Further we obtained expert advice on the gait 
of ducks.
Results
Many names are used for ‘waddling gait’ and its description is imprecise and inconsistent. 
Trendelenburg described it as a pelvic drop on the side of the swinging leg and compensatory 
lateral trunk bending towards the side of the standing leg. Many conditions have been described 
as producing a waddling gait.
We accepted the gait pattern of ducks as being true waddling. This often-used comparison does 
not accurately reflect the gait pattern seen in humans with a range of medical disorders, nor is 
it the same as a Trendelenburg gait. 
Conclusion
As we have found no condition in which patients have a truly duck-like gait, we propose 
that the phrase ‘waddling gait’ should be abandoned. We suggest that for clarity and good 
communication clinicians should describe the observed elements of the gait rather than using 
imprecise and unhelpful terms such as ‘waddling gait’.
Marianne van Iersel.indb   47 27-08-2007   15:17:30
48
Chapter 2
Introduction 
The assessment of a patient’s gait can be important in diagnosis and in planning rehabilitation. 
There is no satisfactory comprehensive way of classifying gait in the ward or clinic1,2: gait patterns 
are variously described according to site, system, functional impairment, diagnosis or by pattern 
recognition. Before gait can be classified, it must be described precisely and unambiguously. 
We have investigated the accuracy of published descriptions of waddling gait. Waddling gait is 
a gait pattern in which people are said to have a duck-like ambulation. The term ‘waddling gait’ 
is widely used and has featured in medical textbooks for over a century. 
We asked three questions:
a) How has the gait pattern known as a waddling gait been described?
b) Which diagnoses are associated with a waddling gait?
c) Does waddling gait ever occur in humans?
Methods
To obtain information about the gait pattern known as waddling gait, we did an index search of 
the terms ‘walking’, ‘gait’ and ‘waddling’ in the latest edition of all available core textbooks of 
general medicine, geriatrics, neurology, orthopaedics, paediatrics, physiotherapy, rehabilitation, 
rheumatology and in the medical dictionaries in the medical library of St James’s University 
Hospital, Leeds and the Health Sciences Library of the University of Leeds, England.
We also searched the Internet using the terms ‘waddling’ and ‘gait’.
We conducted a search in the English and Dutch languages in Medline (1966 – 2001), Healthstar 
and Embase (1980-2001), using these MeSH terms: gait, waddling, duck(s), geese, penguin(s), 
and Trendelenburg.
To obtain information about the gait of ducks, geese and penguins (which have been described 
as having waddling gait patterns), we scrutinized the index pages in all books about animal 
locomotion available in the library of the University of Leeds and we checked our list of books 
about animal locomotion on completeness by the database of the British Library. 
We also did an internet search using the terms ‘duck’, ‘geese’ and ‘waterfowl’.
We contacted R. McNeill Alexander, emeritus professor of Zoology, University of Leeds; F. 
Steinheimer, bird curator of the Natural History Museum, London; bird curators of London Zoo 
and Zoological Society, London and Chester Zoo, Chester, England to obtain expert information 
about the gait of ducks and geese.
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Results
How is a waddling gait described?
Of the 50 standard textbooks and medical dictionaries searched, 27 used the term waddling gait. 
We found that other names were used for the same allegedly waddling gait pattern (for example 
myopathic gait or dystrophic gait).3-5 Some specialties used as many as ten different terms for 
a waddling gait pattern. Medical dictionaries also use many different descriptions and describe 
both an uncompensated gluteus medius gait and a compensated gluteus medius gait as being 
waddling.5,6 Often, no description was given on what is said to constitute a waddling gait.
Another source of confusion is the fact that many different names are used for the same gait 
pattern associated with a specific disease. For example, bilateral congenital dislocation of the 
hips has six different names for its gait pattern: waddling gait, Trendelenburg gait, gluteal gait, 
gluteus medius gait, duck-like gait and sailor gait. 
The description of what constitutes a waddling gait differs in different books, with varying 
combinations of the elements of this gait abnormality. The most often cited elements are a wide 
base, lateral trunk bending, increased lumbar lordosis and pelvic drop. The word “rolling” is 
often used, but nowhere defined. 
In 1895 Trendelenburg7 described waddling in patients with bilateral congenital dislocation of the 
hips. In his opinion, this gait consisted of two elements (Figure 1):
1. The trunk bends to the side of stance.
2. There is falling and rising of the pelvis on the horizontal axis. The pelvis falls to the swinging 
side (ie the side in which the leg is off the ground).
 
Left: Positive sign
Right: Negative sign
Figure 1. Trendelenburg’s sign
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The pelvis drops to the side of swing because the abductors of the standing leg cannot keep the 
pelvis horizontal. Trendelenburg proposed that the swinging of the pelvis was the crucial event. 
The movements of the trunk were compensatory, to bring the centre of gravity back to a point 
vertically over the standing foot and restore balance. 
A Trendelenburg gait occurs when there are anatomical changes in hip joint configuration, causing 
muscle weakness: the gluteus medius muscle is reduced to a third of its normal size; there is 
an altered direction of muscle fibres so the abductors cannot abduct and the gluteus minimus 
cannot exert its usual action. Other factors that can cause this gait abnormality are a painful hip 
joint, the absence of a femoral neck or a mobile head of femur. 
The same gait can be seen in a person with an intact articular apparatus but with muscular 
weakness of mainly the gluteus medius muscle due to an intrinsic muscular problem of whatever 
cause (examples include Duchenne muscular dystrophy and osteomalacia).5
Which conditions are associated with a ‘waddling gait’? 
Trendelenburg identified bilateral congenital dislocation of the hips and progressive muscular 
atrophy as underlying diseases associated with his eponymous gait pattern, which he described 
as a waddling gait. Many other medical conditions are said to be characterized by a waddling 
gait, for example myopathy, hypothyroidism, bilateral osteoarthritis and vitamin D deficiency. 
(The complete list can be requested from the authors).3-6, 8-75  In our survey of standard textbooks, 
we found that the most often mentioned diseases said to cause waddling are myopathies - 
specifically the progressive muscular dystrophies and Duchenne muscular dystrophy - and bilateral 
congenital dislocation of the hips. Other diseases are less often cited as being associated with 
a waddling gait. Most are genetic disorders and many are rare. Although osteomalacia is one of 
the diseases which may come to a physician’s mind first when observing a  waddling-like gait in 
a patient, we only found two citations to this when we used waddling gait as a search term.44, 47 
Obesity is not mentioned as a cause in any on the textbooks that we inspected, though standard 
dictionaries describe waddling gait in humans as a walk with short steps and a swaying motion 
‘as done in a stout, short-legged person’.76-78 and  fat people are often said to ‘waddle’.
Does waddling gait ever occur in clinical practice?
The gait of ducks, geese and penguins
A waddling gait is said to resemble the way ducks walk. Some clinicians have also likened a 
waddling gait to that of geese and penguins or even to that of a sailor.3, 18, 21, 47 The comparison 
with ducks was already well-established in 1895 when Trendelenburg wrote his seminal article 
on the specific gait abnormality that bears his name.7 Therefore, we took the gait of ducks as 
being true waddling.
Why do ducks waddle? They take small steps and have relatively short legs and a broad trunk. 
The broadness of the trunk sets the legs wide apart and gives a wide walking base. These two 
features make it hard for ducks to place their legs under the centre of gravity. To overcome this 
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problem, they displace their trunk laterally to the leg of stance. They also rotate in their knees 
further to assist bringing their trunk in that direction (Figure 2).79  
Geese also have a waddling gait. As their legs are longer than ducks, their waddle is less 
marked.
 
A: goose standing  
S = centre of gravity
Figure 2. The walking of duck and goose
The gait pattern of penguins differs from ducks and geese.80 Penguins use a form of “waddling” 
- a back and forward movement together with a side-to-side motion.  Penguins have short legs in 
comparison to their total body length and this means that the leg muscles must generate force 
very quickly when they walk. They use this form of waddling to retain energy. 
Therefore true waddling consists of taking short steps and having a broad walking base, 
combined with lateral movements of the trunk and rotation in the knees. 
‘Waddling gait’ in humans
Which of the associated disorders, if any, fulfil the criteria for true waddling? If we apply the 
components of a duck’s gait, none of the disorders has every feature of a ‘waddling gait’. Many 
have characteristics over and above the features of a duck’s gait as lumbar lordosis and pelvic 
drop. (An exact list can be requested from the authors). Moreover, humans rotate their pelvis 
and feet, not their knee joints.
The factors, which cause waddling in birds, are the short legs and the wide base of stance. 
This contrasts with the essential feature in Trendelenburg’s description, which is a downward 
movement of the pelvis on the side of swing. This dropping of the pelvis does not occur in 
birds with a waddling gait. The gait is not typically broad-based and there is no truncal rotation 
(though it is characterized by leaning to the side of stance.) 
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Conclusion 
We found that different authors have varying views on what constitutes a waddling gait and that 
textbooks give inconsistent accounts of it.
Our concept of a waddling gait was simple: can a patient have a duck-like walking pattern? 
The answer is no. Furthermore, a Trendelenburg gait is often mistakenly called a waddling gait. 
But, as argued above, these two terms are not synonymous. Trendelenburg gait is not a true 
waddling gait.
Our search strategy limited our results to ‘waddling’ caused by single conditions. Multi-causal 
gait disorders (often seen in elderly patients) could not be identified because they were not 
described in the sections about waddling gait and because of the conventional organization of 
most textbooks and their indexes. 
For practical reasons we did not read every clinical symptoms section of every disease entity in 
every book. Therefore, we could have missed some descriptions of waddling gait. For example, 
each clinical symptom section of osteomalacia named waddling gait. But by index search on 
waddling gait we only found two references to osteomalacia. 
With clinical observation, it is not possible to see all details of a gait pattern. A pelvic drop is 
often seen in kinematic gait analysis, but can be difficult to detect with the naked eye. Lateral 
trunk bending is easier to detect. This can be the reason that the gait pattern of so many 
diseases is described as a ‘waddling gait’ and that ‘waddling gait’ itself is described in so many 
different ways.
If we are to make progress in clinical gait assessment, we need to clarify our thinking and the 
words we use. 
As no human gait disorder is exactly like the gait of a duck and as the term waddling gait is used 
imprecisely and inconsistently, we propose that we should stop using it altogether. However, the 
term ‘waddling gait’ is so deeply embedded in the medical vocabulary that it may be difficult 
to eradicate. 
We propose that gait patterns should be described by their key elements - for example, wide 
base, increased lumbar lordosis and/or pelvic drop. This obliges the clinician to observe the gait 
carefully and give a precise description rather than unhelpfully grouping a range of gait disorders 
under a single imprecise heading. 
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Abstract 
Introduction 
Antipsychotics are important in the treatment of behavioural and psychological symptoms of 
dementia (BPSD), but have moderate efficacy and often cause adverse events. Recent safety 
warnings about more cerebrovascular adverse events in elderly patients who use atypical 
antipsychotics have turned the weighing of benefits versus risks of antipsychotics into a dilemma. 
This study systematically reviews the reporting of adverse events of antipsychotics used to treat 
BPSD in randomized controlled trials (RCTs). 
Methods 
From Medline, EMBASE, PsychInfo, Cinahl (1980-April 2005) databases and Cochrane controlled 
trials register (2005) we selected RCTs with intention-to-treat analysis that evaluated efficacy and 
harms of antipsychotics used to treat BPSD. Two reviewers assessed independently reporting of 
adverse events. 
Results 
930 abstracts were screened, which resulted in inclusion of 12 RCTs (2809 patients). Most 
participants were elderly people (mean age 80.0 years) and had Alzheimer, vascular or mixed 
dementia. Studies lasted for 3 to 16 weeks. Adverse events, though common, were described 
heterogeneously and incompletely. No RCT fulfilled all CONSORT requirements for the reporting 
of harms.  Atypical antipsychotics caused fewer extrapyramidal symptoms and somnolence 
than typical antipsychotics, but with increasing dose the difference disappeared. Only one trial 
reported cerebrovascular adverse events with a Number Needed to Harm of 14 (95% confidence 
interval 8-41). 
Conclusions 
In lower doses atypical antipsychotics may cause fewer adverse events in the treatment of 
BPSD, but uncertainty is raised on their cerebrovascular safety profile. The included RCTs 
described adverse events too incompletely and heterogeneously to warrant clear treatment 
recommendations and do not provide sufficient evidence for the recent safety warnings. Better 
reporting on harms in RCTs is needed to enable rational treatment decisions. 
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Introduction
Dementia is a multifaceted disorder, not only characterized by cognitive decline, but also 
frequently complicated by a wide variety of behavioural and psychological symptoms, such 
as hallucinations, wandering and depression.1;2 These symptoms have a major impact on the 
patient’s quality of life, are a primary predictor of caregiver burden and often underlie the 
decision for institutionalization.3
To date, antipsychotics are the most important pharmacological treatment of behavioural and 
psychological symptoms in dementia (BPSD), specifically for agitation, aggression and psychosis. 
Extrapyramidal symptoms (EPS) are important and frequent adverse events of antipsychotics, for 
which frail elderly people are even more prone.4 In recent years, atypical antipsychotic agents 
(i.e. risperidone, olanzapine, quetiapine, clozapine) have been advocated for the treatment 
of BPSD, because they may cause less EPS. This was confirmed in two recently published 
systematic reviews that were primarily focused on efficacy.5;6 The reviewers concluded that, 
although evidence is limited, atypical antipsychotics have equal efficacy and cause fewer EPS 
compared with typical antipsychotics. 
Recently, safety regulation offices sent out safety warnings for olanzapine and risperidone, as 
these drugs are associated with a higher frequency of cerebrovascular adverse events and a higher 
mortality rate in elderly patients with dementia.7-11 However, two recent retrospective studies did 
not find an increased incidence of stroke or mortality for risperidone in this population.12;13 These 
safety warnings on atypical antipsychotics together with the conflicting evidence have turned 
weighing of benefits versus risks of atypical and typical antipsychotics into a real dilemma 
and causes confusion14 This dilemma is subject of a heated debate in which some experts15 
and the Committee on Safety of Medicines advices not to use olanzapine (not registered for 
this indication) and to be very careful with risperidon.16 Recently, the FDA also extended their 
warning to all atypical antipsychotics17, while others plea not to abandon antipsychotics for this 
indication.18;19
Physicians do not have access to the data on file of drug companies and safety regulation offices. 
They have to rely on publications of randomized controlled trials (RCTs) or systematic reviews as 
the first and currently best method of appraising benefits and harms of an intervention. So far, 
systematic reviews in this area did not focus on the safety profile of antipsychotics in these frail 
patients. However, given evidence of equal efficacy of typical and atypical antipsychotics and the 
recent safety warnings, the safety profile will determine which drug will be first choice. Therefore, 
we conducted a systematic review of RCTs that tested antipsychotic treatment in BPSD to 
analyze the frequency and severity of adverse events, with special focus on EPS, cerebrovascular 
adverse events and mortality.  
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Methods
Data sources
We performed a systematic literature search in Medline (1980 – April 2005), EMBASE (1986 – April 
2005) PsychInfo (1980 – April 2005), Cinahl databases (1980 – April 2005) and Cochrane controlled 
trials register (2005, issue 1) using dementia, antipsychotics and randomized, controlled trial (and 
related terms) as free text words and MeSH-headings. For BPSD no MeSH-heading exists20 In 
our primary analysis we did not consider articles published before 1984.1984 is a landmark year 
because the major scientific criteria on Alzheimer’s disease were accepted.21 Most studies used 
these criteria thereafter, which substantially reduced the heterogeneity of the study population. 
Secondarily, we searched in the same databases for studies published before 1984 with 100 or 
more patients that fulfilled all other criteria. We controlled our list of articles on completeness 
by a manual search of the references of the retrieved articles and search in SumSearch. Data 
from abstracts, letters and conference proceedings were not considered. No language restrictions 
were imposed. 
Study selection and data extraction
One reviewer (MvI) screened all titles and abstracts using the following inclusion criteria: 1) 
randomized double-blind controlled study design that compared two antipsychotic agents head-
to-head or an antipsychotic agent with placebo, 2) effect on BPSD or adverse events as primary 
outcome, 3) population of patients with dementia and 4) oral administration of drugs. Whenever 
the inclusion criteria were met, two reviewers (MvI, SZ) screened the complete article using the 
following exclusion criteria: 1) absence of an intention-to-treat analysis and 2) no diagnosis of 
dementia according to current international criteria for dementia (DSM III-R or DSM-IV22, NINCDS-
ADRDA21 or NINDS-AIREN23). Discussions between researchers resolved disagreements in the 
selection procedure.
Two researchers (MvI, SZ) independently abstracted the included articles and appraised their 
methodological quality with forms of the Cochrane Collaboration.24 Further, we investigated into 
which extent the included studies satisfied the CONSORT requirements for reporting of harms 
in RCTs.25 CONSORT is the abbreviation of Consolidated Standards of Reporting Trials. The 
CONSORT statements aim to provide evidence-based guidance in the reporting of randomised 
controlled trials to improve the reporting and to enable readers to understand a trial’s conduct 
and to assess the validity of its results.26
If clear endpoints for adverse events were defined, we calculated Numbers Needed to Harm 
(NNH) with 95% confidence intervals as an additional measure for the clinical relevance of 
adverse events. If a 95% confidence interval for NNH includes infinity, it indicates that the NNH 
of the antipsychotic compared to placebo does not differ significantly for a defined endpoint 
within the same trial.27
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Results
From the 950 retrieved abstracts, 67 RCTs were selected on the basis of our inclusion criteria, 
of which 12 RCTs fulfilled both inclusion and exclusion criteria.28-39 Of the RCTs excluded, 22 
were published before 1984, three only administered antipsychotics intramuscularly and 31 were 
excluded because of a mix of several inclusion and exclusion criteria. The studies published 
before 1984 all had small sample sizes ranging from 5 to 28, and did not pay much attention to 
adverse events. An extensive review of these older efficacy studies can be found in the review 
of Kindermann.40
Of the placebo-controlled RCTs, six evaluated haloperidol, two risperidone, two olanzapine and 
one tiapride, quetiapine and perphenazine. One RCT studied risperidone against haloperidol 
and placebo and one haloperidol against loxapine. The duration of these studies varied from 
2.5 to 16 weeks. Five studies were sponsored by the pharmaceutical industry30;32;33;35;37, five by 
independent funds29;34;36;38;39 and two did not report their financial resources.28;31 
The mean age of participants over all trials was 80.0 years and most had moderate to severe 
dementia with mean Mini-Mental State Examination scores ranging from 5.5 to 15.2 (Table 1). 
244 out of the total of 2809 (9%) participants lived in the community. Other characteristics of 
study participants were not systematically described. For example, none of the studies reported 
the co-morbidity status or co-medication of their participants.
To detect adverse events the studies used different combinations of questionnaires and physical 
performance instruments as well as spontaneous reporting.  Physical examination, vital signs, 
electrocardiogram and additional laboratory tests were used in different combinations and 
frequencies in ten trials.  Table 2 shows that no included RCT satisfies all CONSORT requirements 
for the reporting of harms. In general, the definition and collection of harms, the presentation 
of absolute risks and a balanced discussion were described with fewest details. Although Teri’s 
study described the collection of harms in detail, they did not aim to study both benefits and 
harms of antipsychotic therapy, did not describe their methods to investigate them nor discussed 
this limitation in their discussion.
Table 3 outlines the main adverse events reported in the included studies. We did not include 
Teri’s study, as they did not report on harms in their results section at all. In connection with the 
remarks made above, none of the studies gave exact outcomes for all measurement scales for all 
treatment arms and reported ‘no significant differences between treatment arms’ instead. Over 
ten studies the percentage of patients that experienced some sort of adverse event ranged from 
49 to 100%. The overall percentage of withdrawals caused by adverse events ranged from 25 
to 100% in the active treatment groups compared to 13 to 100% in the placebo groups. Higher 
dosages of antipsychotics did not cause higher percentages of withdrawals.
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Four studies28;30;35;36 made a difference between ‘any’ and ‘serious’ adverse events, the latter 
ranging from 9-13% for placebo to 13-20% for 2 mg risperidone across these three RCTs. Five 
studies28;30;31;35;39 reported serious adverse events in their results and only Brodaty gave a clear 
definition of ‘serious adverse events’. Four of the 12 studies described death rates28;30;33;35, of 
which two described all causes of death.28;30
Cerebrovascular adverse events were only reported by Brodaty et al., although he neither 
gave a definition, nor expressed significances among the two treatment groups or described 
cerebrovascular risk factors in the placebo group. In Brodaty’s study 18 patients receiving 
risperidone experienced a cerebrovascular adverse event versus 3 patients in the placebo group, 
which yields an NNH of 14 (8 – 41, 95% confidence interval). Stroke was reported as cause of 
death by Brodaty and Allain. 
The NNH for extrapyramidal symptoms was higher for atypical antipsychotics than for haloperidol 
in five of the seven studies, although this relationship was not present for higher doses of 
atypical antipsychotics. In the only direct comparison between risperidone, haloperidol and 
placebo32 , the NNH to cause one or more EPS like adverse events in one patient was lower 
for haloperidol (NNH 9) than for risperidone (NNH 25), but this difference was not statistically 
significant. The NNH of somnolence showed a similar beneficial trend for low-dose atypical 
antipsychotics.
De Deyn (2004) found an increase in weight in the 5 and 7.5 mg olanzapine groups, while 
Brodaty and Street did not. None of the studies reported an increased incidence of Diabetes 
Mellitus or significant statistical differences in laboratory findings. Ballard found a significantly 
greater cognitive decline in the quetiapine group.
Discussion 
Our systematic review included 12 studies evaluating the use of antipsychotic drugs to treat 
BPSD. Of the whole range of licensed antipsychotics, only haloperidol, tiapride, risperidone, 
loxapine, perphenazine, quetiapine and olanzapine were assessed for this indication in double-
blind RCTs with intention-to-treat analysis. Atypical antipsychotics seemed to produce fewer 
EPS, but this difference disappeared with increasing doses and was only significant in one 
head-to-head comparison of haloperidol with risperidone. Cerebrovascular adverse events and 
death were reported with insufficient detail to allow us to draw firm conclusions on the causal 
relationship with atypical antipsychotics. 
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In general, the methodological quality of the included studies that we assessed with often-used 
quality items was moderate to good. However, these items evaluate the methodological quality 
of efficacy studies and are not useful to evaluate the quality of description of adverse events. 
Although systematic reviews can convey useful large-scale information on adverse events, our 
study shows that quantitative synthesis of data on harms is problematic because of poor 
reporting of harms. This problem also exists in many other medical domains.41 In several ways 
the included RCTs give a heterogeneous and incomplete description of adverse events. First, the 
studies do not use the terminology on adverse drug events internationally agreed on.42 Adverse 
drug reactions related to the drug may be mixed up with adverse drug events not necessarily 
related to the drug. This gives room for misinterpretations and does not provide insight into 
adverse events being caused by a drug or being one of the frequently occurring concomitant 
diseases of old age. Second, the methods used to identify and quantify adverse events were 
highly variable and not standardized. One study did not even report on the method used 
for adverse events reporting. This may have influenced the results, because in patients with 
dementia, structured questioning and physical performance measures are more likely to reveal 
adverse events than spontaneous reporting. 
Presumably the short trial durations and small patient populations have increased the incomplete 
picture of adverse events of antipsychotics in this population. A minimum number of 50 patients 
per treatment arm have been advocated for a reliable estimate of the prevalence of frequently 
occurring adverse events.43 In addition, selective publication of industry-sponsored studies 
may have caused that studies with positive outcomes or fewer adverse events have been 
published more often.44-46 We did not contact the authors of the original studies, as we wanted 
to examine the safety data in the way they are presented to clinicians and other researchers. 
Empirical evidence also shows that data about harms is very difficult to obtain from primary 
investigators.43 
In clinical practice we need reliable data both to identify patients who are most likely to benefit 
from antipsychotics and to identify patients who are most likely to be substantially harmed by 
them. As physicians have to rely on RCTs and systematic reviews for information about benefits 
and harms, a better reporting of safety data is crucial. This need for adequate reporting of adverse 
events in RCTs has been recently strongly advocated.43;47 Both BMJ48 and Cochrane Library have 
taken initiatives for a better reporting of harms and recently an addendum to the CONSORT 
statements aimed at standardizing reporting of harms has been published (used in this review). 
Furthermore, the recent initiatives around pre-registration of studies are important as they can 
provide insight into publication bias in the future.49 Observational pharmacoepidemiology based 
on large databases and long-term follow up can also be a valuable supplement.50 Together with 
an accurate and complete description of adverse events in future trials, a clearer description of 
the study population is needed. For example, a specification of the co-morbidity and use of other 
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(psychotropic) drugs should be included. More extensive data on the study population would 
facilitate the search for confounders and responder characteristics and helps to estimate the 
generalizability of the study results. Finally, we plea for widespread reporting of NNHs. Together, 
Numbers Needed to Treat (NNT) and NNHs can facilitate the weighing of benefits and harms of 
an intervention.  
The safety data presented in the 12 RCTs reviewed here do not clearly alert physicians to the 
increased risk at cerebrovascular adverse events that regulatory bodies warned for, nor give 
enough data to allow physicians to make a reliable decision which drug to prescribe to minimise 
frequency and severity of adverse events. 
Better reporting on harms in RCTs with the CONSORT guidelines and full disclosure of all 
available evidence is needed to enable rational treatment decisions and to prevent that conflicts 
of interest jeopardise full reporting of all original trail data. 
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Abstract
The reason why patients with dementia fall more often and sustain more fractures than patients 
without dementia remains unclear. Therefore, the relationship between dementia and gait velocity 
as a marker for mobility and falls in a cohort of frail elderly (mean age of 77.3 years) inpatients 
was assessed. Patients with dementia were expected to walk slower than patients without 
dementia. A trend was indeed observed: absolute gait velocity of 0.59 m/s in patients with 
dementia (n=63) versus 0.65 m/s in patients without dementia (n=62; p=0.19). After adjustment 
for parkinsonism and walking aids, however, patients with dementia walked 0.44m/s faster than 
patients without dementia (p= 0.02). Probable explanations are frontal lobe disinhibition and 
lack of insight, causing patients with dementia to walk relatively too fast in context of their 
frailty. Therefore the high risk of falls in dementia may be partially explained by the loss of 
control of gait velocity.
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Introduction
Compared with cognitively normal elderly people who fall, elderly patients with dementia have 
a two-fold higher rate of falls, sustain more fractures and have a reduced life expectancy.1 The 
reason why elderly patients with dementia fall remains incompletely understood. Gait disorders, 
which are an important risk factor for falls, are common in elderly people with dementia and can 
even precede non-Alzheimer’s dementia.2 Walking velocity is an important quantitative measure 
of gait. Walking slowly may index the severity of the underlying gait or balance disorder, but 
may also reflect a purposeful adaptation to reduce the risk of falls.3 Previous research showed 
that relatively healthy elderly people with dementia walk slower than elderly people without 
dementia.4 A slow gait velocity is also associated with frailty, admittance to a nursing home and 
death.5;6 Therefore, we predicted that in frail elderly patients with dementia, gait velocity would 
be reduced even further compared to non-demented frail elderly people.
Methods
Patients 
Of 201 patients consecutively admitted to an acute geriatric or old-age psychiatric ward, we 
included a cohort of 125 elderly patients (72 women) with a mean age of 77.3 years (SD 7.7). 
Reasons for exclusion were inability to walk 10 meters without personal assistance (n=33), 
inability to understand simple instructions because of delirium or other reasons (n=19), or both 
(n=13), logistical reasons (n=9) and refusal to participate (n=2). Patients or their proxies gave 
written informed consent. The human research ethics committee at the Radboud University 
Nijmegen Medical Centre approved the study. In 63 patients, a geriatrician diagnosed dementia 
according to Diagnostic and Statistical Manual of Mental Disorder Fourth Edition, Text revision 
criteria7, and subsequently diagnosed probable Alzheimer’s disease (n=31), probable vascular 
dementia (n=17), frontotemporal dementia (n=4), Lewy body dementia (n=2) or other types of 
dementia (N=9) according to internationally accepted criteria (criteria of National Institute of 
Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement 
en Neurosciences and National Institute of Neurological and Communication Disorders and 
Stroke-Alzheimers’s Disease and Related Disorders Association, criteria of Mc Keith et al8 for 
Lewy body dementia and Manchester Lund criteria for frontotemporal dementia). 
Gait measurements
Gait velocity was measured with an electronic walkway (Gaitrite®, MAP/CIR Inc.) This 5.6 meter 
long, 0.9 meter wide walkway consists of sensor pads (12.7 mm apart from each other) connected 
to a computer. Patients walked twice at comfortable speed and twice while counting backwards 
from 45 (dual task condition). All patients counted first without walking to test if they had 
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understood the task. They counted out loud. Because the focus of our study was the association 
between dementia and gait velocity, we did not record counting rate and errors.
Analysis
The baseline gait characteristics of patients were summarised as mean (SD) and differences 
between the two groups were tested with independent t tests. We calculated proportional 
dual-task costs in gait velocity as the percentage of change from baseline in gait velocity after 
addition of the dual task. Because we aimed at investigating gait in frail elderly people, we did 
and could not exclude patients with diseases other than dementia. We used multiple regression 
analysis to adjust for variables that potentially disturbed the relationship between dementia and 
gait velocity. The multiple regression analysis made the patients in both groups “equally frail”, 
so the association between dementia and gait velocity could be investigated in two otherwise 
comparable groups. On the basis of the literature, these potentially disturbing variables were 
use of a fear of falling (yes/no question), history of falls in the year before admission, number 
of drugs used, age, score on a comorbidity index (Cumulative Illness Rating Scale-Geriatrics; 
CIRS-G)9; score on the motor section of the Unified Parkinson’s Disease Rating Scale (UPDRS); 
and an Activities of Daily Living (ADL) measure (Barthel Index). Thereafter, in the multiple linear 
regression model, we tested whether these variables indeed were confounders in this study 
– that is, whether these variables caused a change in the regression coefficient of dementia 
on gait velocity. The variables included in the final multiple regression model were, apart from 
dementia, UPDRS-motor part score, use of a walking aid and ADLscore. We ensured that the 
requirements for linear regression models were fulfilled and used log transformation for skewed 
distributions. Statistical significance for all regression models was accepted at P < 0.05.
Results
Patient characteristics are summarized in table 1. Patients with dementia walked at a mean gait 
velocity of 0.59 m/s (SD 0.26) and patients without dementia at  0.65 m/s (SD 0.31) (p=0.19). 
Stride length was comparable in patients with dementia (0.78 m) and patients without dementia 
(0.85 m) (SD 0.28), but the mean stride length variability (coefficient of variation) was 9.0% in 
patients with dementia versus 5.8% in patients without dementia (p=0.004). Walking with a dual 
task decreased gait velocity in both groups (to 0.47 m/s (SD 0.21) in patients with dementia 
and to 0.58 m/s (SD 0.31) in patients without dementia, p=0.03) and increased stride length 
variability (to coefficient of variation 11.5% (SD 13.4) in patients with dementia and to 7.6% (SD 
9.4) in patients without dementia, p=0.006). Only one patient with parkinsonism and dementia 
showed gait festination.
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Table 1. Patient characteristics on admission at a geriatric or old-age psychiatry department
Diagnosis of dementia
Yes No
Number of patients 63 62
Age (years), mean (SD) 79.8 ± 7.4 † 74.7 ± 6.5
Women, N (%) 35 (56.5%) 37 (58.7%)
Total score CIRS-G, mean (SD) 10.9 ± 3.3 9.9 ± 3.2
Number of drugs used, mean (SD)  5.7 ± 2.9 * 7.1 ± 3.3
MMSE score, mean (SD)  18.5 ± 5.3 † 25.3 ± 4.1
Barthel ADL Index score, mean (SD)  14.2 ± 3.7 † 16.2 ± 3.1
Fear of falling N (%) 27 (43.5%) 29 (46.0%)
Fall(s) in previous year N (%) 27 (46.6%)* 15 (30.0%)
Walking aid during measurements N (%) 36 (58.1%) † 20 (31.7)
UPDRS-motor section score, mean (SD) 9.9 ± 6.9 * 8.1 ± 5.9
Hand grip strength (kg) (N=96), mean (SD) 19.7 ± 8.8 * 24.9 ± 10.3
Notes: ADL = Activities in Daily Living; CIRS-G = Cumulative Illness Rating Scale-Geriatrics, a comorbidity index; 
MMSE = Mini Mental State examination; UPDRS = Unified Parkinson’s Disease Rating Scale. * p<0.05; † p<0.01
After adjustment for parkinsonism, use of walking aids and activities of daily living functioning, 
dementia was independently and positively associated with gait velocity (table 2). Moreover, 
analysis of the adjusted gait velocity showed that patients with dementia now walked relatively 
faster (by 0.44 m/s) than patients without dementia (p=0.01). 
The effect of dementia on gait velocity was also present while walking with a dual task. The 
variance in gait velocity explained by the regression models of was 42% with dual task and 48% 
without dual task. 
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Table 2. Absolute, unadjusted values for gait velocity and multiple regression models for gait velocity (m/s) 
with dementia, parkinsonism (UPDRS motor part), use of a walking aid and functional performance (ADL) 
as independent variables 
Gait velocity m/s
Without dual task With dual task
Absolute, unadjusted values Dementia, mean 
(SD)
No dementia, 
mean (SD)
Dementia mean 
(SD)
No dementia, 
mean (SD)
0.59 (0.26) 0.65 (0.31) 0.47 (0.21) 0.58 (0.31)
Multiple linear regression analysis
Independent variables Gait velocity SE p-value Gait velocity SE p-value
+0.22 0.17 0.20 +0.004 0.17 0.98
Intercept
Dementia +0.44 0.18 0.02 + 0.48 0.18 0.01
UPDRS score -0.01 0.003 0.00 -0.01 0.04 0.02
Walking aid -0.13 0.04 0.00 -0.16  0.04 0.00
ADL score +0.04 0.01 0.00 +0.04 0.11 0.00
Dementia x ADL score -0.03 0.01 0.02 -0.03  0.01 0.01
Explained variance (R2) 0.48 0.42
Notes: ADL = Activities in Daily Living; UPDRS = Unified Parkinson’s Disease Rating Scale, motor part; SE= 
standard error
Discussion
The results unexpectedly showed the opposite of our prediction: although frail elderly patients 
with dementia walked slowly, they still walked relatively too fast, given their overall degree of 
physical impairment that should have warranted a much slower gait. Two explanations seem 
most likely. First, the relatively fast gait velocity in frail patients with dementia may reflect frontal 
lobe disinhibition or recklessness. Another explanation can be a lack of insight, because of which 
patients may not have adapted their behaviour to their cognitive and physical impairments. 
Other studies that assessed gait in patients with dementia found a slower gait velocity in these 
patients than in patients without dementia.4;10 A reason for the difference with earlier findings 
maybe that these studies investigated gait in relatively healthy demented patients, without 
or with poorly described co-morbidity, whereas our patients with and without dementia were 
frail (used a high number of drugs, had a high CIRS-G score, slow mean gait velocity and low 
handgrip strength). Further, all five previous studies as discussed in the review,4;10  used a case-
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control design, creating the possibility of biased outcomes because of incorrect selection of 
controls. 
The absolute gait velocity measured in our patients with dementia corresponds with values 
reported for patients with moderate to severe dementia11;12, but is slower than the gait velocity 
of elderly people transitioning to frailty13 and much slower than gait velocity in healthy elderly 
people (range 0.97 to 1.4m/s).14 A limitation of our study is that we only measured gait variables 
at preferred walking speed, although it is known that several gait variables can vary with 
gait velocity. Measuring gait at several gait velocities, however, was not feasible in this frail 
population. Nevertheless, we were able to pick up well-know gait changes in this population, 
including both the reduced absolute velocity and the increased stride variability, which is an 
important marker of gait abnormalities. 15;16
The inappropriately fast gait in patients with dementia, in the context of their frailty, may 
partially explain the excessive fall rate in frail elderly patients with dementia. This finding opens 
avenues to future intervention studies.
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Introduction
Gait disorders and depressive symptoms are both highly prevalent in elderly people and can 
have diverse and severe consequences as an increased risk of falls and loss of independence.17;18 
Striking in the clinical observation of depressed geriatric patients is their slowness of movements 
and, during performance of a dual task, their increased gait and balance problems. The co-
occurrence of mood and gait disorders may be explained by the shared etiologic role of cerebral 
white matter lesions.19 Only three studies investigated quantitative aspects of gait in patients 
with depression and found a slower gait velocity and shorter step length.20-22 However, their 
population was young (mean age 44 years), they used methods of moderate quality and did 
not investigate gait variability, which is strongly associated with increased fall frequency.23 We 
hypothesized that non-invasive quantitative gait analysis could be used in depressed geriatric 
patients to detect and monitor decreased gait velocity and step length, increased double support 
time and an increase in their variability. 
Methods
We performed an observational study in patients consecutively admitted to an acute geriatric 
ward of an academic hospital or an acute ward of old age psychiatry of a psychiatric hospital. 
Patients were included when they could walk 10 meters, understand simple instructions and 
if they and their carers had given informed consent. The collected descriptive data about the 
participants included age, sex, the cumulative illness rating scale in geriatrics (CIRS-G), a cognition 
test (Mini Mental State Examination, MMSE), functioning in daily life (Barthel Index), number of 
drugs, use of antidepressants and walking aids. We compared two groups of patients at two 
different ways: with or without depression and with or without mild to moderate depressive 
symptoms. A psychiatrist or geriatrician made the diagnosis of depression based on the DSM-
IV criteria.24 For mild to moderate depressive symptoms we used a cut-of score of ≥ 18 of 
the Montgomery Asberg Depression Rating Scale (MADRS)25 at the time of the measurements. 
The quantitative gait variables (gait velocity, step length, cadence and percentage of double 
support phase) were measured with the Gaitrite®, an electronic walkway.26 To measure these 
gait variables the patients walked twice at comfortable speed over the Gaitrite® and twice with 
counting backwards from 45 as dual task. We used the independent sample t-test to compare 
gait variables between the two groups and the coefficient of variation (CV) for calculation of 
gait variability. Further, we used the Pearson correlation coefficient to estimate the correlation 
between MADRS-score and gait velocity and step length. 
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Results
Twenty-eight patients participated with a mean age of 78.4 ± 7.2 years, 21 were women. Thirteen 
patients were diagnosed with a depression (mean MADRS score 16.3). The distribution of co-
variables did not differ significantly between the two groups. In summary, mean scores for the 
whole group were CIRS-G 9.8, MMSE 22.6 and Barthel Index 15.5. Patients used on average 6.7 
drugs. Eight patients used an antidepressant and nine patients used a walking aid during the 
measurements.
We did not find significant differences in gait variables and their variability between the group 
with and without a depression (DSM-IV criteria). Geriatric patients being depressed based on 
the MADRS-score had a significantly decreased step length and increased double support time 
and a trend towards decreased gait velocity. (Table 1) These results were independent of the 
use of antidepressants. When going from normal walking to walking when counting backwards, 
the increase in variability of gait velocity (+ 15%) and double support phase (+16%) was larger 
in geriatric patients with MADRS score ≥18 than those with a score of <18 (increases + 2% and + 
3% respectively), but not statistically significant. There was no significant correlation of MADRS 
score with gait velocity and step length.
Table 1. Gait variables of geriatric patients with and without depression as defined with the MADRS
Gait variable Depression p-value
MADRS ≥ 18
Mean ± SD 
MADRS < 18
Mean ± SD
Gait velocity (m/s) 0.55 ± 0.25 0.71 ± 0.19 0.139
Step Length (m) 0.33 ± 0.11 0.45 ± 0.11 0.038
Cadence (steps/minute) 95.0 ± 17.1 95.1 ± 12.1 0.992
Double support phase (% of gait cycle) 44.1 ± 13.0 31.6 ± 8.2 0.049
Notes: MADRS = Montgomery Asberg Depression Rating Scale (score range 0- 60); SD = Standard deviation. 
Results are mean of two walking trials.
Conclusion
This study partially confirmed our hypothesis that depression decreases gait velocity and step 
length, increases double support phase and during dual tasks increases gait variability in geriatric 
patients. An explanation for the absence of significant differences in gait when using the DSM-
IV criteria for depression can be that the depression of participating patients was already in 
remission. Their mean MADRS score of 16.3, below the cut-off score for depression, strengthens 
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this theory. Our power was limited due to large standard deviations in gait variables and small 
groups. In the future, research with larger groups is needed together with the incorporation of 
mobility and balance scales and outcomes such as fall frequency and functioning in daily life to 
detect, monitor and prevent increased fall risk and decreased mobility in geriatric patients with 
depression.
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Introduction
Frailty is an important concept in geriatrics. It is a strong predictor of negative outcomes: new 
disabilities, institutionalisation and mortality. Interventions targeted at frail elderly patients may 
prevent or delay these adverse outcomes and are a precondition for efficient geriatric health care 
services.  Several frailty criteria have been tested in epidemiologic research and are now ready 
to use in clinical practice. However, at the moment no gold standard exists to correctly diagnose 
frailty in a heterogeneous group of elderly patients.27;28  We investigated of four often-used frailty 
criteria their feasibility and effect on the selection of frail elderly patients in clinical practice.
Methods
We assessed patients admitted consecutively to an acute geriatric or old age psychiatry ward 
to determine if they were frail according to often-used frailty criteria: Rockwood (≥ 2 items 
of cognitive decline or disabilities in activities of daily living or urinary incontinence)29; Fried 
(≥ 3 items of exhaustion, weight loss, slow gait velocity, low handgrip strength, low physical 
activity)30; low handgrip strength (women <17.5kg; men <30 kg)31 and gait velocity <1.0 m/s.5 
Ethical approval: The human research ethics committee at the Radboud University Nijmegen 
Medical Centre approved the study. 
Results
Out of 201 patients, 125 patients (72 women) with a mean age of 77.3 (SD 7.4) years participated. 
Main reasons for nonparticipation were inability to walk 10 meters (N=33), no understanding of 
simple instructions to walk (N=19) or both reasons (N=13). Eleven patients refused participation. 
The included patients used on average 6.6 drugs, 63 (50.4 %) had dementia, 69 (55.2 %) had 
fallen in the previous year and 69 (55.2 %) had a fear of falling. Mean gait velocity was 0.62 m/s 
(SD 0.30) and median time to perform the TUG was 16.9 sec (range 4.9-133.8 sec). 
The prevalence of frailty in this population varies from 47.9% (handgrip strength), 48% 
(Rockwood), 62.4% (Fried) to 88.8% (gait velocity). The patient populations identified by these 
criteria overlapped partially (Figure 1).  Only 29 subjects were considered frail by all four frailty 
criteria. The kappas for concordance in classification of patients as frail or not were poor to 
moderate and ranged from 0.18 (criteria by Fried and Rockwood) to 0.48 (criteria by Fried and 
handgrip strength). Further, the distributions of other single risk factors for negative outcomes 
also varied. The prevalence of dementia for example, ranged from 51 to 73% in the different 
groups of frail patients compared to 22 to 45% in non-frail patients. The differences in prevalence 
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of dementia in frail and non-frail patients were significant (p<0.05) for Rockwood criteria and 
handgrip strength, but not for criteria by Fried and gait velocity. 
Figure 1. Distribution of subjects (N=113) identified as frail by four different frailty criteria (Rockwood 29, Fried 
30, slow gait velocity 5 and low handgrip strength 31) in a group of elderly hospitalized patients (N=125)
Conclusion
The use of frailty criteria is feasible in a group of mobile geriatric inpatients, but the various 
criteria give highly different selections of patients. Before frailty criteria can be used to select 
frail elderly patients, each of the available criteria should be prospective validated for this 
purpose. Till then, the choice of the most appropriate frailty criterion should be based on 
the purpose, the outcome on which the criterion was originally validated, the quality of the 
validation process carried out so far, and the resemblance of the current population with the 
validation group.  Further scientific work on frailty as targeting criterion to select patients at 
high risk at adverse outcomes is urgently needed to give this promising paradigm a solid place 
in medicine for the aged.
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Abstract
Introduction
To estimate clinically relevant changes in functional mobility tests and quantitative gait measures 
at group and individual level in frail elderly patients.
Methods
Cohort study of consecutively admitted frail elderly patients. Gait velocity, Timed Up and Go-test 
(TUG) and other mobility tests were measured on admission and two weeks later. In between 
patients received multidisciplinary treatment. Three experts decided from video recordings if 
patients had a clinically relevant change in gait, defined as change in the expected risk of 
falling.  
Results
85 patients (mean age 75.8, 46 female) participated. 45% had dementia. 59 patients were stable 
and 26 showed a clinically relevant change in gait. Gait velocity and TUG were most sensitive to 
change at group level. In individual patients a 5% change from baseline in gait velocity and 9% 
change in TUG had a sensitivity of 92% and 93% for detection of clinically relevant change, but 
specificity of 27% and 34% respectively.
Conclusion
At group level gait velocity and TUG were, from all investigated tests, most sensitive to change 
and in this perspective the best outcome variables. In individual patients the high intra-individual 
variability makes these measures unsuitable as independent screening instruments for clinically 
relevant changes in gait. 
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Introduction 
Gait is an important aspect of functioning in daily life and gait problems increased the risk 
of falling32;33, led to loss of independence, reduced quality of life34 and increased mortality.5;35 
Problems with gait and mobility are prevalent in elderly people and even more so in hospitalized 
frail elderly patients. Moreover, elderly people showed a considerable risk to develop gait and 
mobility problems during hospitalization, because of the illnesses themselves, adverse effects 
of the treatment and deconditioning.36 Many frail elderly patients required rehabilitation of gait 
and mobility before discharge and even then, many do not regain the mobility level of prior to 
admission.37 
Both patients and physicians can decide whether a change in gait and mobility is clinically 
relevant. However, cognitive impairments are prevalent in frail elderly patients and make their 
decisions about changes in gait and mobility unreliable. Clinicians and physiotherapists can 
use qualitative observation and quantitative gait and mobility measures to monitor gait and 
mobility and to investigate the effects of an intervention. Qualitative observation of gait can 
give information about the underlying disease, but it is subjective, depends on the level of 
experience of the physician and decisions about clinical relevant changes can be difficult 
when time-intervals between visits are long or with changes in physicians. Quantitative gait 
assessment with functional performance tests and electronic walkways are objective, give an 
indication of the risk of falling and the severity of mobility impairment. Knowledge about which 
changes in mobility measures are clinically relevant can assist clinicians and physiotherapists 
in the decision-making process about changes in gait and mobility in their clinical practice. In 
research, this knowledge is useful in evaluating the clinical significance of an intervention and 
in determining sample sizes for intervention studies. 
Therefore, it is important in both clinical practice and research to agree on which changes in 
gait and mobility are clinically relevant. However, information on reliability and responsiveness 
(sensitivity to clinically relevant changes) of gait and mobility measures is crucial, but unknown. 
Therefore, this study aimed to investigate which of the often-used gait and mobility measures has 
the best reliability and responsiveness in hospitalized frail elderly patients, both on individual 
and group level.
Methods
Setting and patients
Participants in this prospective cohort study were patients consecutively admitted to an acute 
geriatric or old age psychiatry ward from June 2004 to April 2005. Patients were admitted directly 
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from primary care settings to the wards with one or more geriatric syndromes. Admission was 
needs based and decided upon by the general practitioner in conjunction with a geriatrician. 
A researcher (MvI) assessed the eligibility of all admitted patients. Patients were included as 
soon as they could walk 10 meters without personal assistance, if they could understand simple 
walking instructions and if they, in case of cognitive impairment also their carers, had given 
written informed consent. 
Measures 
The baseline patient characteristics included medication use, a co-morbidity index (Cumulative 
Illness Rating Scale-Geriatrics)9, performance in Activities of Daily Living (Barthel index)38, a frailty 
measure (handgrip strength)31, cognition (Mini Mental State Examination score)39, extrapyramidal 
symptoms (Unified Parkinson’s Disease Rating Scale-motor part)40, use of and type of walking aid, 
history of falls in previous year and fear of falling (yes/no question). If applicable, a geriatrician 
made the diagnosis of dementia after careful clinical and neuropsychological assessment and 
cerebral imaging according to the DSM-IV-TR.7 
The gait and mobility assessments consisted of quantitative gait analysis and functional tests 
of gait balance and mobility. Quantitative gait analysis was performed with a 5.6-meter long 
electronic walkway (GAITRite ®, MAP/CIR Inc.) with sensor pads (12.7 mm apart from each other) 
connected to a computer. The patients walked twice at their preferred walking speed over the 
walkway on low-heeled shoes. For safety purposes a physiotherapist walked alongside the 
patient during the measurements. Gait variables used in this study were gait velocity, associated 
with institutionalization and death, and stride length and stride time variability, associated with 
risk of falling.23;41 Functional test of gait, balance and mobility were Tinetti’s Gait and Balance 
Test (range 0-28)42, Berg Balance Score (BBS; range 0-56)43 and Timed-Up-and-Go test (TUG).44 
Cut-off points that indicate an increased risk of falling are: a Tinetti score below 19, a BBS score 
below 45 and more than 13.5 seconds to complete the TUG. All gait and mobility measures were 
repeated 2 weeks after the first measurements or, in case of earlier discharge, the day before 
discharge. This time interval was chosen because of a high chance to detect clinically relevant 
changes in gait and to avoid high attrition during a longer follow-up. In between the two 
measurements all patients received comprehensive geriatric assessment and multidisciplinary 
treatment of prioritized health problems. This intervention generally improves health outcomes, 
including mobility, in frail elderly patients.45 
Responsiveness analysis
How responsiveness should be quantified is still a matter of debate. Beaton 46 constructed a 
taxonomy with the three important aspects of responsiveness: 1. Which change (within persons, 
between persons or both), 2. Setting (group or individual) and 3. Magnitude of change: minimal 
or substantial. The type of change can be investigated with anchor and distribution-based 
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procedures. (See Crosby et al. for an in depth review47). This study primarily investigated 
clinically relevant changes within persons, at individual level and between groups at group 
level, as determined with an anchor-based procedure. As secondary analysis, distribution-based 
responsiveness, was determined to facilitate comparisons with other studies.
Anchor-based responsiveness compares changes in the measures under investigation with 
another judgment of change, the anchor. In this study expert opinion was chosen as anchor, 
because a high proportion of patients was expected to have cognitive impairments. This would 
make the evaluation of meaningful change in mobility by the patients themselves unreliable. 
Three experts in gait disorders (a geriatrician, neurologist and physiotherapist: MOR, RE and MM) 
independently analyzed video recordings of the two assessments, consisting of performance on 
the walkway (recorded sideways and frontal) and TUG. They used a visual gait analysis scale (Gait 
Assessment Rating Scale, Modified version; GARS)48 to direct attention to important aspects of 
gait that are associated with an increased risk of falling. The experts were blinded to all patient 
characteristics except sex and setting and for the results of all gait measures. The two video 
recordings of each patient were presented in a randomized order to prevent bias in the judgment 
of the videos among the experts who might expect improvement following hospitalization. A 
change in gait was only defined as a clinically important improvement or deterioration if the risk 
of falling had changed. Patients with minor changes in gait that did not affect the risk of falling 
were called ‘stable’. To improve interrater reliability, consensus meetings were held for 5 pilot 
patients and after the first 11 patients. After scoring all patients, disagreements were resolved 
by discussion during a final meeting. For 19 patients not all three experts agreed whether, when 
a change was present, it was clinically relevant or not. The Intraclass Correlation Coefficients 
(ICC) for the three experts was 0.77 (95% confidence interval 0.66-0.84) before the consensus 
meeting and 1.00 thereafter. It did not occur that a patient was rated as deteriorated by one 
expert and as improved by another.
At group level the standardized response means (SRM) and the responsiveness index (RI)49 were 
used as measures for anchor based responsiveness. SRM relates the mean change in unstable 
patients to the standard deviation of this change. The RI, formula: ∆ / √(2 x σ), relates the mean 
change in test score in changed patients to the standard deviation of change in stable patients. 
At the individual level we chose cutoff scores from the Receiver Operating Characteristics (ROC) 
curves with high sensitivity to test the value of the measures as screening instruments. The ROC 
curves were constructed with data from the patients with a clinically relevant change versus 
stable patients. Only a few patients deteriorated and the possibility exists that improvement 
and deterioration have different magnitudes of change. Therefore, in a secondary analysis, we 
also investigated responsiveness when the results were dichotomized into clinically relevant 
improvement versus no clinically relevant improvement (stable and deteriorated patients). 
Distribution-based responsiveness depends on the statistical characteristics of the sample, e.g. 
sample variation and measurement precision, and the magnitude of the effect of the intervention. 
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Effect size (ES) is based on sample variation: ES = (µ1 – µ2) / �1 (mean at baseline – mean at 
follow-up divided by standard deviation at baseline; all of complete sample). An effect size of 0.2 
has been defined as small, 0.5 as moderate and 0.8 or greater as large.49 Standard error of the 
mean (SEM) is based on measurement precision: SEM = �1 x √(1-r), in which r is the test-retest 
reliability of the measure.
Statistical analysis
The baseline gait characteristics of patients were summarized as mean ± standard deviation 
or as medians and ranges in skewed distributions. Variability of stride time and stride length 
were expressed in coefficients of variation (CV): standard deviation/mean x 100%). Because of 
the relation of the magnitude of change with the baseline gait value, all change outcomes were 
expressed as relative changes from baseline: (change in gait value/baseline gait value) x 100%, 
except for the CVs of stride length and stride time. Differences between the three groups (clinical 
relevant deterioration, no change or clinical relevant improvement) were tested with one-way 
analysis of variance (ANOVA). Relative change from baseline was used for the calculation of 
the anchor-based responsiveness measures. In a secondary analysis, absolute change values 
were used for anchor and distribution-based responsiveness. The direct test-retest reliability 
of the gait and mobility measurements for all participants and the reliability over the two 
measurements in stable patients was assessed with Intraclass Correlation Coefficients (ICCs), 
two-way mixed on complete agreement.  All data were analyzed using SPSS statistical software, 
version 12.0 (SPSS Inc., Chicago, IL). 
To estimate the sample size needed for this study, the following assumptions were made based 
on duplo measurements of gait velocity from a pilot study: 33% of the patients were expected 
to show a clinically relevant change in gait and mobility and 67% patients to stay stable. With 
a power of 80 percent and a significance level of 0.05, a total sample size of 90 patients was 
needed. Assuming a dropout rate of 20 percent, the total sample size had to be 108 patients. 
Because of a higher attrition than expected, more patients were included.
Results
Out of 201 consecutively admitted patients, 127 were included in the study and 85 patients were 
assessed twice. Main reasons for loss to follow up were incident immobility (N=10), incident 
delirium or further cognitive decline (N=10), withdrawal of informed consent (N=6) and logistic 
reasons (N=16), see Figure 1. The patients who refused participation in the second measurement 
all had a depression and also refused parts of their treatment. Patients with two measurements 
were significantly younger (75.8 years SD 7.1 vs 80.6 years SD 7.2; P 0.001), had a higher Barthel 
score (15.7 vs 13.9; P 0.009), less often a fall in their history (44% vs 70%, P 0.010) and used 
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less often a walking aid (no walking aid: 40% vs 62%; P 0.016) compared to patients with only 
one measurement. Patient characteristics of the final sample are summarized in Table 1. The 
experts judged that eight patients had had a clinically relevant deterioration and 18 a relevant 
improvement in gait. The ICCs for direct test-retest reliability were high for all gait measures (0.82 
to 0.98) except CV stride time (0.46), indicating overall high reliability. The ICCs for test-retest 
reliability between the two measurements in stable patients were comparable; with as exception 
a higher ICC (0.72) for CV stride time. The differences in gait values between the deteriorated, 
stable and improved patients were significant for all gait measures except CV stride time and 
Tinetti gait and balance test (Table 2). The patients who stayed stable also showed changes in 
gait, but these differences were smaller than in patients with clinically relevant changes in gait. 
Table 1. Baseline characteristics of the participating geriatric inpatients (N=85)
Characteristics Mean ± SD
Age in years 75.8 ± 7.1
Female N (%) 46 (54.0%)
Total score CIRS-G 10.5 ± 3.7
Number of drugs used 6.6 ± 3.3
MMSE score 22.2 ± 5.5
Dementia N (%) 38 (44.7%) 
Barthel ADL score 15.7 ± 3.3
Fear of falling N (%) 42 (49.4%)
Fall(s) in history N (%) 39 (45.8%)
Walking aid during measurements N (%) 32 (37.6%)
UPDRS-motor section score 9.1 ± 6.3 
Hand grip strength (kg) 23.1 ± 9.9
Gait velocity (m/s) 0.62 ± 0.29
Tinetti gait and balance test 16.5 ± 7.6
BBS score 41.9 ± 11.2
TUG (seconds) Median 19.3 (Range: 5.0 – 133.8)
Stride length variability (%CV) 4.4 ± 2.2
Stride time variability (%CV) 5.4 ± 2.4
Notes: CIRS-G = Cumulative Illness Rating Scale-Geriatrics (range 0-56; score >6 indicates frailty); MMSE=Mini 
Mental State Examination (range 0-30; score <24 indicates cognitive impairment); ADL= Activities of Daily Living 
(range 0-20; higher score indicates more independence); UPDRS=Unified Parkinson’s Disease Rating Scale-motor 
part (range 0-56; higher score indicates more parkinsonism). CV= coefficient of variation; Tinetti gait and balance 
test (range 0-28); BBS= Berg Balance Scale (range 0-56); TUG= Timed Up and Go-test; SD: Standard deviation
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Figure 1. Flow chart of patient selection and participation 
Table 2. Absolute change scores in gait and mobility measures between first and second assessment and 
relative to the first, baseline measurement in frail elderly inpatients
Deteriorated patients 
(N=8)
Stable patients (N=59) Improved patients (=18) P-value
Change Absolute Relative Absolute Relative Absolute Relative
Mean ± SD Mean ± SD Mean ± SD
Gait velocity 
(m/s)
-0.08 ± 0.27 45% 0.09 ± 0.09 15% 0.21 ± 0.14 60% <0.001
Stride length 
variability  
(% CV)
0.5 ± 6.1 - 2.1 ± 2.5 - -5.9 ± 14.0 -  0.014
Stride time 
variability  
(% CV)
5.6 ± 15.8 - 4.7 ± 9.2 - -0.9 ± 11.0 - 0 .679
TUG (sec) 5.5 ± 12.6 62% 4.2 ± 5.4 17% -10.1 ± 12.8 31% 0.001
BBS score -0.2 ± 5.2 10% 3.1 ± 3.4 8% 5.8 ± 10.9 32% 0 .001
Tinetti gait 
balance test
-0.9 ± 2.4 10% 1.2 ± 1.9 7% 0.8 ± 1.9 32% 0.418
Notes: TUG= Timed Up and Go Test; BBS= Berg Balance Scale; CV= coefficient of variation. P-value for absolute 
changes from baseline
 
All admitted
patients (N=201)
Eligible patients
(N=127)
Patients included and 
participated in 1st 
measurement
(N=127)
Patients participated 
in 2nd measurement
(N=85)
Not eligible because of
- Immobility N=33
- Not understanding short instuctions N=19
- Both reasons N=13
Loss to follow-up because of
- Refused participation N=6
- Other reasons (quick discharge, logistics)
  N=16
- Exclusion because of incident immobility 
  N=10
- Exclusion because of incident delirium of 
  further decrease in cognition N=10
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The responsiveness statistics at group level are displayed in Table 3. At group level gait velocity 
and TUG had the highest responsiveness with an SRM for gait velocity of 1.1 and RI of 4.6. 
For the TUG the SRM was 1.0 and the RI 2.6. At individual level, a clinically relevant change 
in mobility was detected best with a ROC cutoff point of 5% change from baseline in gait 
velocity (sensitivity 92%) and an 9% change in TUG (sensitivity 93%). However, false positive 
rates were high for these cutoff points, 73% and 66% respectively. For the other measures the 
specificity that accompanied a high sensitivity was even lower. The effect sizes derived from the 
distribution-based responsiveness methods were small for all measurements (Table 3). 
The secondary analysis with improved versus not improved patients showed an increase in the 
intraindividual variability in the ‘stable (i.e. not improved)’ or comparison group. This caused 
decreased values for most of the responsiveness measures (data not presented here). 
Discussion
This article showed that at group level gait velocity and TUG were most responsive to clinically 
relevant changes in gait and mobility in frail elderly patients. However, in individual patients the 
intra-individual variability was substantial and the screening cut-off points with high sensitivity 
were at the cost of very low specificity.
Gait and mobility were impaired in most patients, as reflected in a mean gait velocity far below 
1.0 m/s, the cut-of point for adverse outcomes5 and a median time for the TUG of more than 
13.5 seconds, indicative of an increased risk of falls. The ICC for stride time variability was low, 
probably because a walkway of 5.6 meter is too short to generate enough steps to calculate a 
reliable estimate. 
Comparisons with other studies that investigated changes in gait and functional mobility tests are 
difficult, because one included immobile patients50, one described data only in relation to self-
reported mobility disability51 and two used an untested intervention to distinguish changed from 
stable patients52 without an external judgment of clinically relevant change or control group.52;53 
A recent, interesting study determined meaningful changes in gait velocity in elderly people after 
a hip fracture and investigated the effect of several methods to determine responsiveness on 
the results28. However, not all patients were measured twice and their expert opinion is based 
on experience and not on direct observations of the participants under study. This makes that 
the patients measured in this study can best be compared to the stroke rehabilitation subset of 
another recent responsiveness study54. Although we used expert instead of patient opinion as 
anchor for clinically relevant changes in gait, the magnitude of the clinically relevant changes are 
comparable. In contrast to Perera’s study, this study was designed to determine responsiveness 
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of gait and mobility measures in frail elderly patients and measured both deterioration and 
improvement. Another major strength of this study is that it determined the responsiveness 
at both group and individual level. As such this study delivers important data for intervention 
trials on gait and balance, which require outcome measures that can validly capture clinically 
relevant changes. In individual patients information about clinically relevant changes can help 
to detect clinically relevant changes in gait and mobility as early as possible to prevent further 
deterioration or enforce current treatment.
Inevitably, this study also has some weaknesses. To prevent confounding by indication and to 
obtain results that can be easily generalized, patients who were less likely to change were not 
excluded, because no objective selection criteria exist. As a result, ceiling and floor effects of 
the measures may have precluded some patients to be labelled as changed and it made the 
group of stable patients relatively large. This may have diluted the effect of the intervention and 
can explain the small effect sizes derived from the distribution-based responsiveness methods. 
Another consequence of this decision was the selective dropout patients with marginal baseline 
mobility who deteriorate during admission. Second, currently no gold standard for the judgment 
of a clinically relevant change in gait and mobility exists and thus our visual gait analysis was also 
not ideal as anchor measure. However, for this study we judged the combination of the expertise 
of three different disciplines, a validated instrument for structured gait analysis in elderly people 
(GARS) and consensus meetings, as the best possible ‘gold standard’. Relating changes in gait 
to change in risk of falling gave the judgment of change in gait a clear clinical meaning. In the 
future the used gold standard for clinically relevant changes in gait can be strengthened by 
testing its predictive validity for new falls and immobility. Third, the group judged as stable 
did show changes in gait. The most likely explanation is that these stable patients had an 
improvement in gait, because they also received the intervention, but that their change in gait 
was not sufficient to be judged as a clinically relevant change. Changes, such as the change 
of 0.09 m/s in gait velocity, should also be evaluated against the high intra-individual day-to-
day variability in gait measurements in frail elderly patients. Whether or not the small changes 
are only ‘noise’ or are already a minimal clinically important difference that has consequences 
for the prognosis of immobility and other adverse outcomes has to be determined in a larger 
and longer longitudinal study. Fourth, because of the practical constraints in our study, our 
conclusions are limited to the few often used physical performance tests that we had selected 
from all available tests. Last, our participants are a selected, frail sample of all older people. This 
may limit the external generalizability of the results to community living, more healthy elderly 
people, who change very slowly (over years, not weeks). However, together with the growth in 
the number of people aged 65 and above, the proportion of frail elderly people is also growing 
(up to 35%), in the community and in hospital. Frail elderly people need research focussed on 
this group30, because they usually experience many health related changes with effects on gait 
and other functional performances in short periods of time. This makes that the point of limited 
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generalizability also counts the other way round: results available from community-living elderly 
people29 cannot be generalized to frail elderly patients, no matter whether they are inpatients 
or outpatients. As a result, the results of our study are probably more valid for frail community-
living people than the results from relatively healthy elderly people.
Conclusion
On group level gait velocity and the TUG were most sensitive to change and therefore best 
candidates as primary outcome measures in clinical trials aimed at improving gait and mobility. 
However, this recommendation is limited to the number of mobility measures investigated 
and from the perspective of sensitivity to change only. On individual level the intra-individual 
variability in test outcomes of stable patients was large. Therefore, at the moment the role of 
quantitative gait and mobility tests in the monitoring of gait and mobility is to assist in the 
decision-making process and it should be combined with a qualitative, clinical evaluation of gait 
and balance. 
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Introduction
Gait and mobility problems are prevalent in elderly people and associated with falls and loss 
of independence.17 Physicians can use quantitative gait and mobility measures such as gait 
velocity and Timed Up-and-Go test (TUG) to monitor gait and mobility and to investigate the 
effects of interventions. These measures are objective; give an indication of the risk of falling 
and the severity of mobility impairment. They have proven clinimetric properties in nondemented 
older people, but in patients with dementia their reliability is moderate and their feasibility 
questionable over long periods of time55, only assessed in very small groups56 or not presented 
separately.57 Nordin et al. recently reported good intrarater and interrater reliability of the TUG 
in patients with dementia (ICC 0.91)58, but they did not investigate other tests or sensitivity to 
change. Last, Tappen et al. investigated quantitative mobility measures in nursing home residents 
with dementia, but they were forced to modify these measures to make them applicable for 
their population.59 These modifications make their results incomparable to the standard versions 
of the tests. This lack of data on the clinimetric properties of often used-gait and mobility 
tests stands in great contrast to the high prevalence of gait disorders and falls in patients with 
dementia, which is also accompanied with a higher risk at adverse events.32 Therefore, the 
reliability, sensitivity to change and feasibility of quantitative gait and mobility measures in 
geriatric inpatients with and without dementia was investigated.
Methods
This observational study consists of patients consecutively admitted to an acute geriatric ward 
of an academic hospital or an acute ward of old age psychiatry of a psychiatric hospital. Patients 
were included when they could walk 10 meters, understand simple instructions and if they 
and their carers had given informed consent. Patients with and without dementia, diagnosed 
conform the criteria of DSM-IV-TR7, were compared. Gait velocity and stride variability (electronic 
walkway, Gaitrite®), TUG, Tinetti gait and balance test and Berg Balance Scale were measured 
on admission and two weeks later by a physiotherapist and researcher. Two-week test-retest 
reliability in stable patients was expressed in Intraclass Correlation Coefficients (ICCs). Three 
experts decided from video recordings about the clinical relevance of changes in gait, defined 
as change in the expected risk of falling. Sensitivity to change was expressed as responsiveness 
index (RI). The RI relates the mean change in test score in changed patients to the standard 
deviation of change in stable patients. The independent sample t-test compared the gait variables 
between the two groups. 
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Results
Eighty-five patients participated, 47 were women. Thirty-nine patients were diagnosed with 
mild or moderate dementia (mean Mini Mental State Examination score 19.1 ± 5.2 vs 24.8 ± 
4.6 in nondemented patients). The patients with dementia were older (78.3 vs 73.8 years), 
had significantly more comorbidity (Cumulative Illness Rating Scale in Geriatrics 11.1 vs 10.0), 
lower scores on activities of daily living (14.9 vs 16.5; Barthel ADL-index), more fallers (15 vs 
9 patients) and more often used a walking aid (22 vs 11 patients). The distribution of fear of 
falling, handgrip strength and number of drugs did not differ significantly between the two 
groups. Fifty-nine patients were stable and 26 showed a clinically relevant change in gait. Of 
the eligible patients, none refused participation in the first measurement and only two for the 
second measurement. Both had a depression and also refused parts of their treatment. Dementia 
did not preclude performance of the tests, but frequently required verbal cuing. Verbal cuing 
consisted of repetition of part of the instructions and was most necessary during the TUG, which 
consists of many short tasks.
The mean test values and the clinimetric properties are displayed in Table 1. Despite the high 
ICCs, intraindividual variability in test results was high.
Table 1. Mean values, reliability and responsiveness of often-used gait and mobility measures in geriatric 
inpatients with and without dementia
Characteristics Dementia
N=39
No dementia
N=46
Mean ± SD ICC RI Mean ± SD ICC RI
Gait velocity (m/s) 0.61 ± 0.30 0.77 7.2 0.65 ± 0.31 0.93 3.8
Stride length variability (%CV) 6.5 ± 2.2 0.88 2.9 4.5 ± 2.4* 0.88 0.5
Stride time variability (%CV) 5.0 ± 2.3 0.56 0.4 3.9 ± 2.9 0.84 0.2
TUG (seconds) Median 29.8 0.97 4.8 Median 19.3* 0.87 1.8
Tinetti gait and balance test 18.5 ± 6.3 0.96 4.7 21.5 ± 5.1* 0.96 2.0
BBS score 39.6 ± 13.1 0.97 5.7 45.1 ± 9.0* 0.94 1.9
Notes: SD= Standard deviation; ICC= Intraclass Correlation Coefficient; RI= Responsiveness Index; CV= coefficient 
of variation; Tinetti gait and balance test (range 0-28); BBS= Berg Balance Scale (range 0-56); TUG= Timed Up 
and Go-test. * P<0.05 independent t-test of demented versus nondemented patients
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Discussion
In conclusion, quantitative gait and mobility analysis with an electronic walkway and mobility 
tests was feasible, reliable and sensitive to relevant changes in geriatric inpatients, even in 
case of dementia. Essential elements for these good results seem to be the performance of 
the measurements by a physiotherapist with extensive experience in geriatrics, the fact that 
patients know (and trust) the physiotherapist, that the measurements are done in familiar 
surroundings with no time constraints and that verbal cuing is used when necessary in patients 
with dementia. These elements would also minimize external factors that can increase the 
intraindividual variability in outcomes and lead to an optimal performance of the patients. 
Thus, dementia does not preclude the use quantitative measures to test and monitor gait and 
mobility in vulnerable older patients. 
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Abstract
Introduction
Evaluation of the effect of three different cognitive dual tasks on balance during walking, without 
and with standardization for gait velocity and measured with both foot placements and trunk 
movements.
Methods
Cross-sectional study in community-living physically fit elderly people with as main outcome 
measures: Stride length and time variability, measured with an electronic walkway; body sway, 
measured with an angular velocity instrument; Gait velocity.
Results
59 physically fit elderly people, mean age 73.5 yrs participated. Overall, dual tasks decreased 
gait velocity (1.46 to 1.23m/s; P<0.001), increased stride length and time variability (1.4 to 2.6% 
and 1.3 to 2.3%; P<0.001) and had no significant effect on body sway. After standardization for 
gait velocity, the dual tasks were associated with an increased body sway (111% to 216% of 
values during walking without dual task; P < 0.001) and stride length and time variability (41 
to 223% increase; P< 0.001). The verbal fluency task causes the largest increases in gait and 
balance measures. 
Conclusion
In physically fit elderly people, cognitive dual tasks influence balance control during walking 
both directly and indirectly by decreasing gait velocity. Dual tasks increase stride variability with 
both mechanisms, but the increase in body sway is only visible after standardization for gait 
velocity.  The decreased gait velocity can be a strategy to maintain balance during walking in 
more difficult circumstances.
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Introduction
Falls are a common problem in elderly people. Thirty percent of community living elderly people 
aged 65 and over fall at least once a year, increasing to 40% in elderly people above 80. An 
important risk factor for falls are gait and balance impairments.1 In daily life people often do 
several other things while they are standing or walking. Many falls occur during the performance 
of such dual tasks.2 The explanation of this phenomenon is, that the execution of the second 
task interferes with balance control, probably because attention has to be divided or through 
structural interference in neural networks of the frontal and motor cortex.3;4 Thorough knowledge 
of the effect of dual tasks on gait and balance may increase the understanding of balance control 
and can help to identify individuals at risk of falling.5;6 
Many studies investigated balance with static measurements, but most falls occur during 
movement when the centre of mass cannot be maintained within the lateral borders of base of 
support. Balance during walking is controlled through both foot placements and trunk motion. 
However, former studies investigated balance during walking mainly with gait variables such as 
gait velocity stride width and stride variability. 
In healthy elderly people the addition of a dual task only minimally changed these gait variables.4;7;8 
In these studies the dual tasks probably were not sufficiently complex to interfere with balance 
control. Another explanation can be that the measurement of balance during walking with only 
gait variables is insufficiently sensitive for change. Menz showed that the adoption of a slower 
gait speed with longer double support phases did not stabilize the movements of head and trunk 
in community-living elderly people.9 Last, lowering gait velocity can be a strategy to maintain 
balance control in more difficult circumstances. Gait velocity decreases while performing a dual 
task10-12 and influences gait and balance variables13;14, but its contribution to the net effect of dual 
tasks on balance during walking is unknown. 
Therefore, we investigated the effects of three different cognitive dual tasks on balance control 
during walking in physically fit elderly people, as measured with both foot placements and trunk 
movements. Furthermore, we investigated the effect of the dual tasks on balance control during 
walking after adjustment for the effect of changed gait velocity on these variables.
Methods
Participants
We performed a cross-sectional study in physically fit elderly people with good mobility. All were 
participants of the international Annual Four-Day Marches Nijmegen, in which elderly hikers walk 
30 or 40 km a day on four consecutive days. We recruited our participants with advertisements 
in the local and regional newspaper and the leaflet of the Four-Days Marches. To be eligible, 
participants should have no complaints on gait and balance, had to be 70 or older, should 
have a normal gait pattern, as observed by the researchers (MI and HR), be able to perform the 
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Timed Up and Go test within 10 seconds15, and had to give written informed consent. Exclusion 
criteria were cognitive impairments (Mini Mental State Examination score (MMSE) of <24 out of 
30)16 and depressive symptoms (score ≥3 out of 4 on Geriatric Depression Scale-4).17 Because 
a lack of knowledge about balance during walking in the elderly per se, we had chosen these 
physically fit elderly people as a reference group for the optimal situation. To fall or not to fall is 
a dichotomous outcome: this very fit group had a low risk of falls and injuries, mainly because 
they had much reserve in balance. So, in most circumstances a decrease in their balance control 
would not have impaired their balance enough to increase their risk of falling. However, we 
expected that the direction of the effects of the dual tasks on balance during walking would 
be the same in vigorous and more vulnerable older people. Therefore, the results of this study 
can give a first indication of how balance during walking may be affected by dual tasks in more 
vulnerable older people and provide data about the best possible performance. 
The institutional review board of the Radboud University Nijmegen Medical Centre judged that 
the study did not need be approved, because of the very low risks and negligible burden for the 
participants, and the fact that the study was carried out in cognitively intact adults.
The baseline patient characteristics are displayed in table 1.
Procedures
Quantitative gait analysis was performed with a 5.6-meter long, 0.89-meter wide electronic 
walkway (GAITRite®) with sensor pads (12.7 mm apart from each other) connected to a computer. 
The electronic walkway has a good concurrent validity compared with a clinical stride analyzer 
(correlations of 0.99) and good test-retest reliability with intraclass correlation coefficients of 0.93 
and 0.94 at preferred and quick gait velocity.18 Balance was measured with two angular velocity 
transducers (Sway Star®) that measure mediolateral and anterioposterior angular velocities at 
100 Hz. The device was attached as a small box with a belt at the back of the participants and 
was connected to the computer with a long wire. The software calculated 90% ranges of angular 
velocities and angles in mediolateral and anterioposterior direction. Primary outcomes of our 
study were stride variability (stride length, stride time and stride width) and mediolateral body 
sway, because increased stride variability19, mediolateral displacement and angular velocity are 
associated with an increased risk of falling.20 
During the measurements, the participants walked over the walkway on low-heeled shoes. To 
be able to measure steady state walking, the subjects started 2 meters before the walkway and 
they walked towards a chair positioned 2 meters behind the walkway.  For safety purposes a 
researcher walked alongside the participant. To increase the number of steps and precision, 
all tasks were performed twice and the results were averaged for the statistical analyses. First, 
the participants walked at preferred, slow, quick and very quick speed without dual task over 
the walkway. Thereafter, they walked at their preferred speed while performing out loud three 
different dual tasks: subtracting 7 from 100 and 13 from 100 (attention-demanding tasks) and 
citing words starting with the letters ‘K and O’ (verbal fluency task). To prevent a learning 
Marianne van Iersel.indb   129 27-08-2007   15:18:00
130
Chapter 4
effect, all three cognitive tasks were practiced while standing. Further, during the second walk 
participants started from the number reached last in the subtraction task, and were asked to 
name other words with the verbal fluency task. Tasks that interfere with attention or executive 
functions most likely will also interfere with balance control. Executive functions consist of a 
wide range of functions, of which verbal fluency is an example. We asked participants to indicate 
which of the cognitive tasks had been most difficult for them.
Statistical analysis
The baseline gait characteristics of patients were summarized as mean ± standard deviation. 
We used the coefficient of variation (CV): standard deviation/mean x 100% as measure of 
variability for stride time, stride length and stride width. First, all body sway and stride variables 
were log-transformed to remove skewness (Shapiro-Wilk tests <0.00) and heteroscedastity. We 
constructed a formula based on linear regression analysis (linear mixed models with participant 
as random effect and the various tasks as fixed effect), which described how body sway and 
stride variables varied with gait velocity in each participant during walking without an additional 
task. The first step of our standardization method was the transformation of the gait and 
balance data to obtain a normal distribution and decrease the influence of outliers. Second, we 
constructed a formula, based on regression analysis that described how these data varied with 
gait velocity in each participant during walking without an additional task. Last, this formula was 
used to standardize the gait and balance data for the effect of gait velocity for each individual 
participant. Thereafter body sway and stride variables stayed the same over the whole range of 
gait velocities: the influence of gait velocity is removed. We used these results to standardize 
the variables such that the means without dual task were 100, independent of gait velocity.21 
The unstandardized and standardized results for the dual tasks were compared with the results 
without dual task. An omnibus test (likelihood ratio test) that compared all tasks simultaneously 
was carried out and in case this test was significant, the result of each dual task was compared 
to no task. Throughout, likelihood ratio tests were used and the significance level was set at 
0.01 (two-sided) in order to adjust for multiplicity. 
To estimate the sample size needed for this study, the following assumptions were made based 
on duplo-measurements of gait velocity from a pilot study: to detect a difference of 0.10 m/s in 
gait velocity with a power of 90 percent and a significance level of 0.05, a total sample size of 
58 patients was needed. All data were analyzed using SPSSc statistical software, version 12.0. 
Results
Of the 62 people recruited, we included 59 persons with a mean age of 73.5 years SD 3.5. 18 
were women (Table 1). One person was excluded because of a MMSE score of 23 and one because 
of a GDS-score of 3. Due to a technical problem in the Sway Star we had a high percentage of 
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missing data of one person, who therefore also had to be excluded. The participants were active 
and physically fit elderly people with a large range in socio-economic status. 
During walking without dual tasks, an increase in gait velocity gave increases in angular 
displacement and velocity in both directions. Variability of stride length, time and stride width 
increased if gait velocity decreased and increased from the reference (walking at preferred gait 
velocity). (Table 2) The values of the gait and balance variables during the different dual task 
conditions are displayed in Table 3. Body sway did not change significantly after the addition of 
the dual tasks. Variability in stride width also stayed the same during all conditions. Variability in 
stride length and stride time increased from 1.4% and 1.3% during walking without dual task to 
2.6% and 2.3% with the verbal fluency task (P<0.01). The spread in all variability measures was 
large. Gait velocity decreased from 1.46 m/s without dual task to 1.34 m/s during the execution 
of the 100-13 and to 1.23 m/s during the verbal fluency dual task (P<0.01). 
Table 1. Population characteristics
Mean ± SD 59 participants
Men / Women 41 / 18
Age (years) 73.5 ± 3.4 (range 70-82)
Length (m) 1.73 ± 0.09
Weight (kg) 73.7 ± 11.2
ISEI-9231 51.7 ± 12.3 (range: 16-87)
Voorrips sport32 12.6 ± 4.2
CIRS-G33 2.9 ± 2.1
Number of drugs 1.7 ± 1.7
Subjects fallen in previous year, N (%) 14 (24)
Fear of falling (yes/no question), N (%) 9 (15)
Visual complaints (N) 3 
GARS34 18.1 ± 0.4
MMSE16 28.6 ± 1.4
GDS-417 Median 0
UPDRS-motor part35 0.3 ± 0.5
TUG (sec)36 6.2 ± 1.0
Hand grip strength (kg)37 38.1 ± 9.4
Notes: ISEI-92=International Socio-Economic Index of occupational status 1992; range 16-87, higher score 
indicates higher status; Voorrips sport= sport participation subscale Voorrips, range 0-18, a higher score means 
more participation; CIRS-G=Cumulative Illness Rating Scale-Geriatrics, a co-morbidity index, score ≥6 indicates 
frailty; GARS=Groningen Activity Restriction Scale, range 18-76, 18 correspond to complete independency; 
MMSE=Mini Mental State Examination, range 0-30, score <25 indicates cognitive impairment; GDS-4=Geriatric 
Depression Scale-4; UPDRS-motor part=Unified Parkinson’s Disease Rating Scale-motor part; TUG=Timed Up and 
Go-test; SD=standard deviation
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Table 2. Gait and balance variables during walking at four different gait velocities, without dual tasking, in 
very fit elderly people
Gait velocity
Balance and gait variables Slow Preferred Quick Very quick P-value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Omnibus test
Displacement M-L (degrees) 3.8 ± 1.3‡ 4.5 ± 1.4 5.5 ± 1.5‡ 6.7 ± 1.4‡ <0.001
Angular velocity M-L (degrees/s) 30.7 ± 1.3‡ 42.8 ± 1.4 52.7 ± 1.4‡ 72.9 ± 1.4‡ <0.001
Displacement A-P (degrees) 5.6 ± 1.3‡ 8.4 ± 1.3 10.0 ± 1.3‡ 13.2 ± 1.3‡ <0.001
Angular velocity A-P (degrees/s) 37.2 ± 1.4‡ 63.0 ± 1.5 82.8 ± 1.5‡ 124.7 ± 1.5‡ <0.001
Gait velocity (m/s) 1.03 ± 0.18‡ 1.46 ± 0.18 1.63 ± 0.24‡ 2.00 ± 0.19‡ <0.001
Cadence (steps/min) 97.1 ± 9.7‡ 117.6 ± 7.6 126.3 ± 10.0‡ 146.5 ± 16.8‡ <0.001
Stride length (cm) 127.3 ± 14.5‡ 150.1 ± 16.4 155.7 ± 17.1‡ 165.3 ± 19.1‡ <0.001
Stride width (cm) 10.1 ± 2.9 10.0 ± 2.9 9.7 ± 3.0 9.6 ± 3.1 <0.001
Stride length variability (%CV) 2.0 ± 63.1‡ 1.4 ± 61.7 1.6 ± 61.4 1.8 ± 106.6 <0.001
Stride time variability (%CV) 1.8 ± 57.2‡ 1.3 ± 62.3 1.2 ± 66.6 1.3 ± 65.0 <0.001
Stride width variability (%CV) 15.6 ± 48.5 15.4 ± 88.5 14.2 ± 79.5 17.6 ± 83.1 <0.001
Notes: M-L= body sway in mediolateral direction, A-P= body sway in anterioposterior direction, CV= coefficient 
of variation. All means are back transformed from the log-transformed values, except gait velocity, cadence, stride 
length and stride width. Data were tested for difference versus reference condition (walking at preferred gait 
velocity) ‡ P < 0.001
Table 3. Gait and balance at preferred gait velocity with and without dual tasking (reference condition) 
Walking at preferred gait velocity 
Reference Cognitive dual tasks
Balance and gait variables No dual task 100-7 100-13 K and O P-value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Omnibus test
Displacement M-L (degrees) 4.6 ± 1.4 4.8 ± 1.4 4.6 ± 1.6 4.5 ± 1.4 0.905
Angular velocity M-L (degrees/s) 42.7 ± 1.4 45.1 ± 1.4 42.4 ± 1.4 40.6 ± 1.4 0.008
Displacement A-P (degrees) 8.4 ± 1.3 8.3 ± 1.4 8.3 ± 1.4 7.4 ± 1.4 0.060
Angular velocity A-P (degrees/s) 63.0 ± 1.5 65.2 ± 1.6 62.4 ± 1.6 58.3 ± 1.5 0.014
Gait velocity (m/s) 1.46 ± 0.18 1.41 ± 0.24 1.34 ± 0.26 1.23 ± 0.26* <0.001
Cadence (steps/min) 118 ± 7.6 114 ± 12.0 110 ± 15.5 105 ± 16.9 <0.001
Stride length (cm) 150.0 ± 16.4 147.4 ± 18.3 145.4 ± 19.6 141.5 ± 19.3 <0.001
Stride width (cm) 10.0 ± 2.9 10.0 ± 3.1 10.3 ± 3.3 10.7 ± 2.9 <0.001
Stride length variability (% CV) 1.4 ± 0.6 1.8 ± 0.6 2.2 ± 0.7 2.6 ± 0.7* <0.001
Stride time variability (% CV) 1.3 ± 0.6 1.6 ± 0.6 2.0 ± 1.0 2.3 ± 1.1* <0.001
Stride width variability (% CV) 15.4 ± 0.9 15.4 ± 0.6 18.5 ± 0.6 16.5 ± 0.6 <0.001
Notes: M-L= body sway in mediolateral direction, A-P= body sway in anterioposterior direction, CV= coefficient 
of variation. Data were tested for difference versus reference condition * P < 0.01 All means are back transformed 
from the log-transformed values, except gait velocity, cadence, stride length and stride width.
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After standardization of body sway and stride variability for gait velocity, the effects of dual 
tasks on body sway and stride variability were equivocal: They all pointed towards more body 
sway and increased stride variability, except for no change in stride width variability (Table 4). 
Subtracting 7 from 100 had the smallest effect on body sway and stride variability;the verbal 
fluency task had the largest effect.
Table 4. Comparison of relative values of body sway and stride variability, standardized for gait velocity, while 
walking with a dual task versus walking without dual task = reference condition = 100 
Walking without and with three different cognitive dual tasks
Reference Cognitive dual tasks
Balance and gait variables No dual task 100-7 100-13 K and O P-value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Omnibus test
Displacement M-L 100±37 122±60 133± 66† 167±127‡ <0.001
Angular velocity M-L 100±36 110±37‡ 110 ±34‡ 116±34‡ <0.001
Displacement A-P 100±41 123±62 168±140‡ 243±294‡ <0.001
Angular velocity A-P 100±55 127±70* 164±121‡ 237±259‡ <0.001
Stride length variability 100±54 107±45 175±152‡ 141±84‡ <0.001
Stride time variability 100±45 145± 64* 275± 323‡ 323±360‡ <0.001
Stride width variability 100±58 99±53 116±66 105±56 0.46
Notes: M-L= body sway in mediolateral direction, A-P= body sway in anterioposterior direction; SD= Standard 
Deviation. Data were tested for difference versus reference condition * P < 0.01, † P < 0.001 ‡ P < 0.0001.
Discussion
This study shows that in physically fit elderly people dual tasks influence balance during walking 
through a direct effect on body sway and stride variability and an indirect effect by gait velocity. 
Dual tasks decrease gait velocity and a decrease in gait velocity in itself is associated with a 
decrease in body sway and increase in stride variability. After standardization for gait velocity, 
both body sway and stride variability increased during dual task performance. The slowing of 
gait while performing a dual task may reflect a purposeful adaptation to reduce the risk of falls 
in more difficult circumstances and can be seen in a number of patient categories.10-12;22 This can 
be a reason why in some studies4;7;8 dual tasks have not changed foot placements. However, we 
found significant changes in stride length and stride time variability for all dual task conditions 
without standardization for gait velocity. In contrast, the dual tasks did not have a significant 
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effect on stride width variability. This is in line with the findings of Hausdorff23, but the opposite 
of Maki’s results.19 Grabiner and Troy24 described a decrease in step width variability with the 
addition of a dual task. Although not a full explanation, probable reasons for these conflicting 
results can be the difference in treadmill and over ground walking, a dual task with visual input 
that requires focusing on a point ahead compared to verbal input, the effect of dual tasks on 
both gait velocity and stride width variability and different units of measurement for variability 
(standard deviations versus coefficients of variation).To our knowledge, the only study that 
tested the effect of a dual task on balance during walking measured with body sway is De Hoon’s 
study. They showed that elderly people who fall had more body sway during walking than non-
fallers. However, their results are difficult to compare with our study, because they used a single 
question as dual task to test the balance reaction to an unexpected situation and not division 
of attention or structural inference during performance of a continuous dual task. They did not 
correct their findings for variation in gait velocity among the participants and our population is 
much more vigorous. 
More is known about the effect of attention and executive functions on gait and balance. They 
seem the most important cognitive functions in the regulation of gait and balance control in 
older people. This is shown in direct associations of cognitive functioning with gait velocity and 
falls.25;26 Other studies provide evidence for the usefulness of dual tasks to investigate the risk 
of falling in elderly people.27;28 Springer et al. show, that dual tasks only influence swing time 
variability in older fallers, but not in young people or older non-fallers, and that this response 
is significantly correlated with executive function.29 This information can be used as background 
for the interpretation of the clinical relevance of the current findings. With regard to the cognitive 
tasks: Our participants perceived the verbal fluency task as most difficult and subtracting 7 from 
100 as the easiest task. They made more mistakes while subtracting with 13 than with 7 from 
100 and could count less far back. The result of citing words starting with a K and O ranged from 
no to 5 good words per trial.
An important limitation is that the clinical relevance of dual tasks in balance during walking 
measurements still has to be proved. Our participants were physically very physically fit30 and 
had a small risk of falling. Therefore we cannot infer from this study which combinations of 
tests are most useful to identify fallers. In a post-hoc analysis, participants who reported a 
fall did not show differences in gait and balance results compared with non-fallers. However, 
the number of fallers was very small, so it is very likely that we did not have enough power 
to detect differences between the two groups. As explained in the method section, we expect 
that the direction of the effect of the dual tasks on gait and balance variables would be the 
same in vigorous and vulnerable older people. Whether or not this is coupled with an increased 
risk of falling depends on the basic level of balance control. Therefore, we can say something 
about the mechanism itself in an optimal situation, but we cannot infer from our results which 
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people have an increased risk of falling. As far as we know we are the first who investigated the 
effect of cognitive dual tasks on balance during walking, measured with both foot placements 
and trunk movements, and taking the effect of the dual tasks on gait velocity into account. 
Although we selected the most important outcome variables before the start of the study, it is 
an explorative study with many comparisons. This is a limitation of our study. There were two 
other limitations: Because of the relatively short length of the walkway the number of steps in 
each walk was limited. This may have reduced the precision of the measurements. Second, the 
amount of attention given to the cognitive task can influence the effect of the task on gait and 
balance. Because the primary goal of our study was to investigate the effect of cognitive dual 
tasks on balance during walking, we have not scored the performance of the subjects on the 
attention and verbal fluency tasks while standing still. Therefore we cannot calculate the cost of 
walking on the dual task.
Conclusions
This study gives more insight in the interaction of dual tasks with balance control during walking 
in physically fit elderly people. It emphasizes the importance to investigate balance during 
walking with both foot placements and body sway and with and without standardization for 
gait velocity. Prospective studies are needed to investigate the reliability and responsiveness of 
these balance measures and to test their usefulness to evaluate the effect of interventions on 
gait, balance and risk of falling in more frail elderly patients.
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Abstract
Many gait and balance variables depend on gait velocity, which seriously hinders the 
interpretation of gait and balance data derived from walks at different velocities. However, 
as far as we know there is no well-accepted method to correct for effects of gait velocity on 
other gait and balance measures. We developed a simple statistical method to obtain gait and 
balance variables for each participant that are independent of gait velocity. The first step of our 
standardization method was the transformation of the gait and balance data to obtain a normal 
distribution and decrease the influence of outliers. Thereafter, we constructed a formula, based 
on regression analysis that described how these data varied with gait velocity in each participant 
during walking without an additional task. Last, this formula was used to standardize the gait 
and balance data for the effect of gait velocity for each individual participant. As example we 
elaborate the analysis of mediolateral displacements of the trunk in fit elderly people during 
walking with and without a dual task.
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Introduction
Gait and balance problems are prevalent in elderly people, increase the risk of falling1;2, and lead 
to loss of independence and increased mortality.3;4 They can be assessed with quantitative gait 
and balance measures.  It is well known that many gait and balance variables, such as stride 
length and double support time, are speed-dependent.5-8 This phenomenon makes comparisons 
of different groups and situations difficult.
 ‘t Hof has given an overview of formulas that can be used to calculate dimensionless gait and 
balance variables.9 These methods can be used to investigate how values of gait and balance 
variables vary with different gait velocities, independent of leg length and body composition. For 
example, the gait and balance variables can be plotted against nondimensionalized gait velocity. 
However, these methods do not remove the effect of gait velocity on the gait and balance 
variables. Helbostad is the only one who describes a method to compare values of gait and 
balance variables independent of gait velocity between persons. However, this method cannot 
be used to compare gait and balance results acquired during walks with different gait velocities 
in the same person.6 Apart from statistical methods, treadmills can be used to investigate gait 
and balance at standardized gait velocity. However, this is not an ideal solution, because results 
are difficult to generalize to walking on a normal surface.10 Therefore, we developed an easy 
statistical method to correct gait and balance variables for gait velocity. With this method it 
is possible to compare gait and balance data acquired at different gait velocities in different 
situations, both within patients and between different patient groups. 
In this article we will first describe our standardization method. Thereafter we will illustrate it 
with the analysis of the mediolateral displacement of the trunk in relation to gait velocity in the 
Elderly Marchers Study, a study with physically fit elderly people with good mobility. To conclude, 
we discuss the strengths and limitations of our method. 
Standardization method of gait and balance variables for gait velocity 
In nonstatistical language:  We standardized the gait and balance variables for gait velocity (i.e. 
removed the influence of gait velocity on the other gait and balance variables). The first step was 
the transformation of the gait and balance data to obtain a normal distribution and decrease 
the influence of outliers. Thereafter, we constructed a formula, based on linear regression 
analysis, which described how these data varied with gait velocity in each participant during 
walking without an additional task. The standardization was then applied to the data when 
the participants performed a dual task. These standardized values were used to evaluate the 
influence of the dual task on gait and balance independent of gait velocity.
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Illustrative example of the standardization method 
To illustrate our standardization method, we used data from the Elderly Marchers Study. The 
group consisted of 59 participants, mean age 73, range 70-82 years. All had a normal gait pattern 
and were in training for the Annual Four-Day Marches Nijmegen in which they were going to walk 
30 or 40 km a day on four consecutive days. A quantitative gait analysis was performed with a 
5.6-meter long, 0.89-meter wide electronic walkway (GAITRite®) with sensor pads 12.7 mm apart 
from each other connected to a computer. The software calculated all gait variables, such as gait 
velocity, stride length and cadence. Balance was measured with two angular velocity transducers 
(Sway Star®) attached at the trunk at the level of approximately L3-L5. It measured body sway 
in the mediolateral en anterioposterior direction relative to the trunk position at the start of the 
measurements. The accompanying software calculated the peak-to-peak angular displacements 
of the trunk from the angular velocities.11 During the measurements, the participants were asked 
to walk at preferred, slow, quick and very quick speed over the walkway. Thereafter they walked 
at their preferred speed and simultaneously counted backwards with 13, starting from 100 (dual 
task). During walking at preferred speed, mean gait velocity ranged from 1.07 to 1.86 m/s, with 
a mean of 1.47 m/s. To be able to measure steady state walking, the subjects started 2 meters 
before the walkway and they walked towards a chair positioned 2 meters behind the walkway. 
All tasks were performed twice and the average of the two trials was used in the analysis. 
Outcomes of this study were stride variability and mediolateral body sway, both associated with 
an increased risk of falling.12-14;15 
We will now explain the method in statistical terms and use the standardization of the mediolateral 
displacement as example.
First, mediolateral displacement and gait velocity were log-transformed to reduce skewness and 
heteroscedasticity.16;17
Second, we described the relationship between velocity and displacement when the participants 
were walking without a dual task. Apart from the (natural) logarithm of the gait velocity (LGV), 
we also calculated the square of the logarithm of the gait velocity (SLGV). We then applied linear 
mixed models with participant as random effect, LGV and SLGV as fixed independent effects 
and the logarithm of the displacement as dependent variable. The resulting (unstandardized) 
regression coefficients for LGV and SLGV were a1 and a2; a0 was the constant term (intercept) of 
the regression. 
Third, for each participant, the standardized logarithmic displacement (SLD) was calculated as
SLD = logarithm of displacement – a0 – a1 * LGV – a2 * SLGV.
As the SLD may be difficult to interpret, we also determined the standardized displacement 
SD=100*exp(SLD). For each participant (at each velocity) the SD has a simple interpretation: 
SD=100 means that the displacement is equal to the median displacement of all participants; 
SD=120 means that the displacement is 20% higher than the overall median and SD=70 means 
that it is 30% lower.
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Reference ranges can be constructed for the situation when the participants were walking at 
preferred speed without dual task. If the residual error of the linear regression is e, the 95% 
reference range for the SLD is (-2*e, 2*e). The reference range for the SD then is (100*exp(-2*e), 
100*exp(2*e)). 
Interpretation of the SLD and reference ranges can best be explained with an example: We 
used the standardization formula to calculate the standardized log displacement when the 
participants performed the dual task. We then used a mixed model with fixed effect dual task 
and random effect participant to analyze the impact of the dual task on the SLD. If the dual task 
would have no influence on the mediolateral displacement, the SLD for each participant should 
remain unchanged and the median percentage during the dual task would be 100%. 
Results
Illustrative example of the standardization method with the Elderly Marchers Study 
Fig 1a shows the relationship between mediolateral displacement and gait velocity when the 
participants walk without dual task: The standard deviation of the displacement increases from 
the left to the right (heteroscedasticity) and the distribution seems positively skewed, with some 
very large outliers. Also the distribution of the velocities seems skewed, with some outliers.
Figure 1b shows the variables after logarithmic transformation. The standard deviation of the 
displacement is equal at all velocities. The outliers are less pronounced and the distribution of 
the displacement seems symmetric about the curve shown in the graph. This curve was derived 
using the mixed model regression. The coefficients of the regression were a0= 8.42 a1= -3.52 
and a2= +0.43. So the formula for the standardized, logtransformed mediolateral displacement 
for each participant at each velocity was:
SLD = logarithm of displacement – 8.42 + 3.52 * LGV - 0.43 * SLGV.
We determined the 95% reference range for the SLD and the SD. The dotted lines in figure 2a 
indicate the lines –2 times the residual error of the regression and +2 times the residual error, 
i.e. the lines with SLD=–0.47 and SLD=+0.47, respectively. The majority (95%) of the results laid 
between these (reference) lines. Taking exp and multiplying by 100, we converted the logarithmic 
values to percentages. These percentages are shown at the left hand site of figure 2b. The figure 
shows that the median value at each velocity is 100(%) and that the reference range for the 
standardized displacement is between 63(%) and 160(%). The standardized log-transformed 
displacement and the standardized displacement in percentages show no relationship with gait 
velocity (Figures 2a and 2b).
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Fig 1a. Peak-to-peak mediolateral displacement of the trunk in fit elderly people during walking at preferred 
speed. The mediolateral displacement shows larger variability at larger values, which results in a non-normal 
distribution, with heteroscedasticity, skewness and some large outliers. 
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Fig 1b. The peak-to-peak mediolateral displacement of the trunk after logarithmic transformation. The 
distribution of the points around the curve is approximately normal and the variance is equal at all gait 
velocities.
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Fig 2a. Logtransformed peak-to-peak mediolateral displacement of the trunk, standardized for gait velocity, 
in fit elderly people. The mean standardized mediolateral displacement stays the same over the whole range 
of gait velocities: the influence of gait velocity on mediolateral displacement is removed. The dotted lines 
indicate the lower and upper bounds of the 95% reference range (-0.47; +0.47)
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Fig 2b. Peak-to-peak mediolateral displacement of the trunk, standardized for gait velocity and displayed as 
percentages. The median value of the mediolateral displacement at each velocity is set at 100% and its 95% 
reference range is 63% - 160%.
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We investigated how the dual task changed the mediolateral displacement: Without 
standardization, the dual task increased the displacement from 4.60 to 4.84 degrees (P=0.17, 
95% confidence interval –0.10 to 0.59). After standardization the difference between walking 
with and without dual task was statistically significant (P=0.01) and the difference was 0.10, 
with confidence interval 0.03 to 0.17. After taking the exp of these values and multiplying them 
by 100, we found that the dual task increased the mediolateral displacement by 11% (95% 
confidence interval 3% to 19%).
Discussion
This study describes a statistical method to standardize gait and balance variables for gait 
velocity. The example shows its feasibility and is an illustration of how the method can be 
used. 
Several choices in our method need further explanation: the use of log-transformation, the use 
of linear mixed models and the choice of the curve.
First, the method uses a logarithmic transformation. Although this step is not strictly necessary, 
it has several advantages:
– Gait and balance variables cannot have negative values and tend to show larger variability 
at larger values. This results in a non-normal distribution, with heteroscedasticity, outliers 
and skewness (Fig. 1a). In general, the logarithmic transformation results in variables with a 
distribution that is closer to normal (Fig. 1b)16;17  
– A difference on a logarithmic scale can be back transformed to a percentage change, so 
relative changes are evaluated rather than absolute changes. This facilitates the interpretation 
and makes it possible to compare results across variables. When a study contains a reference 
group (placebo group in a trial, healthy subjects in an observational study) or a reference 
condition (participants walking under normal circumstances), the results can be expressed 
as percent difference from the reference group or reference condition.
– If the log-transformed variable follows a normal distribution, the method produces estimates 
of the medians rather than the means (lognormal distribution)16;17 It can also provide estimates 
for other percentiles, and can be used to construct reference ranges.
Second, because we had multiple observations per participant, we used a mixed linear model 
approach18 with random factor participant to analyze the mediolateral displacement. Mixed linear 
model is also known as multilevel analysis, because the analysis takes place at two levels. 
At the lowest level, the relationship between displacement and velocity is estimated for each 
participant separately and the ‘within subject’ variance is estimated. On a higher level these 
relationships are ‘averaged’ or ‘pooled’ over all participants. This results in an overall estimate 
of the relationship between gait velocity and mediolateral displacement and an estimate of the 
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‘between subject’ and overall variability. Rather than carrying out the analysis at these levels 
sequentially, a mixed linear model performs them simultaneously. 
Third, mixed model regression, like ordinary linear regression, makes it possible to fit various 
curves to the data. We have opted for polynomials and we selected the lowest degree polynomial 
that described the data appropriately. This turned out to be a quadratic curve in our example, 
but also other curves, e.g. exponential curves, would have been a possible choice.
Last, the method can also be used with only one observation per participant. In this case the 
statistical analysis is even simpler, because straightforward linear regression can be used. An 
important disadvantage is, that it is impossible to distinguish between within and between 
variance. As a consequence, the method will be statistically less efficient, analogous to the 
difference in efficiency between the paired versus the independent t-test.
In contrast to the methods described by ‘t Hof9, our method does not standardize gait velocity 
for the effects of leg length and body composition, but it removes the complete effect of gait 
velocity on the other gait and balance variables. This makes it possible to compare gait and 
balance variables of the same group, but derived from walks at different gait velocities. As far 
as we know Helbostad’s study6 is the only one that also corrected gait and balance variables 
for the effect of gait velocity in a natural situation. Helbostad et al. used curvilinear estimates 
of balance variables at different gait velocities within participants to calculate a standardized 
value. They chose 1.0 m/s as a reference velocity to compare gait and balance variables between 
participants. Such a choice is rather arbitrary and the need to choose a reference velocity can 
give problems if this value is not included in the range of gait velocities of a certain person. This 
is very likely in frail elderly people who walk slowly, with a mean preferred gait velocity of 0.62 
m/s [own data]. Further, with Helbostad’s method it is impossible to compare gait and balance 
variables from different situations within participants and to standardize them for gait velocity. 
The advantages of our method are, that it has no restrictions to the range of gait velocities 
at which patients walk and that it offers the possibility to compare gait and balance variables 
measured at different walking conditions in the same patient, for example with and without dual 
task. Our standardization method offers the possibility to present the results as percentages of 
the ‘normal’ values for the gait and balance variables, which helps interpretation. The procedure 
can easily be carried out using SPSS or SAS software, for example.  
In summary, our statistical method offers an easily applicable method to standardize gait and 
balance variables for the effect of gait velocity. The standardized values can then be used for 
comparisons of gait and balance variables in different conditions within patients and between 
groups.
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Abstract
Background
Cognition influences gait and balance in elderly people. Executive function seems to play a key 
role in this mechanism. Previous studies used only a single test to probe executive functions, and 
outcome measures were restricted to gait variables. We extend this prior work by examining the 
association between two different executive functions and measures of both gait and balance, 
with and without two different cognitive dual tasks.
Methods
A cross-sectional study with randomly selected community-living elderly people. Executive 
function was tested with the Trail Making Test and Stroop Color Word Test; memory with CANTAB 
subtests. Patients walked without and with two dual tasks (subtracting serial sevens and animal 
naming). Main outcomes focused on gait (velocity, stride length and stride time variability), 
measured with an electronic walkway, and balance, measured as trunk movements during 
walking. Associations were assessed with multiple regression models.
Results
100 elderly people, mean age 80.6 (range 75-93) participated. Both dual tasks decreased gait 
velocity and increased variability and trunk sway. Executive function was only associated with 
stride length variability and mediolateral trunk sway during performance of animal naming as 
dual task. Memory was not associated with the gait and balance variables.
Conclusions
In community-living elderly people, executive function is associated with gait and balance 
impairment during a challenging dual task condition that also depends on executive integrity. 
Next steps will be to explore the value of executive function in defining fall risk profiles and in 
fall prevention interventions for frail patients.
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Introduction
Walking is traditionally seen as an automatic motor task that requires little, if any, higher mental 
functions. However, it is becoming increasingly clear that walking is in fact tightly linked to 
cognitive functioning, and this interplay takes place at several levels.1 First, both gait impairment 
and cognitive problems are common with ageing, and they frequently coincide in elderly people. 
Second, gait and cognitive problems both have a great impact on quality of life and everyday 
functioning of older people and their carers. In the last decade evidence is also emerging for 
an actual pathophysiological interaction between gait and cognition; Having a gait disorder 
increases the chance to develop non-Alzheimer dementia by threefold.2 Conversely, people with 
dementia more often have gait disorders and also sustain an increased risk of falling.3;4 This 
interdependence between cognition with gait and balance can also be found in healthy older 
people.5 Dual tasks are one of the methods to investigate the effect of cognition on gait and 
balance control.5 Dual tasks may result in a suboptimal performance in gait, cognition or both 
because attention has to be divided or through structural inference in neural networks of the 
frontal and motor cortex.5;6 Another explanation is that the demands of cognition and gait go 
beyond the limited central processing capacity.
A key cognitive factor in gait and balance control seems to be executive functioning. Executive 
functions are defined as a set of cognitive skills that are necessary to plan, monitor and execute 
a sequence of goal-directed complex actions.7 Older people with poor executive functioning walk 
slower, have an increased stride variability, fall more often and have a worse performance on 
complex mobility tasks.8;9
These previous studies clearly showed that executive function plays an important role in gait 
control. In the present study, we aimed to extend this prior work in three ways. First, previous 
studies probed executive functions with only a single test. In contrast, we aimed to use a more 
extensive cognitive test battery, including two different executive functioning tests and two 
memory tests. These memory tests were included since memory decline in old age is highly 
prevalent, and the effects of memory impairment on gait have been scarcely studied.8-12 We also 
included two different cognitive dual tasks, because execution of a secondary task during walking 
(talking, route planning) partially depends on executive functions such as concept shifting and 
mental flexibility.5;6 Second, previous studies concentrated on a selected population of elderly 
people without dementia or other neurological disorders. Here, we included an unselected 
population of elderly persons living in the community. Finally, because executive functions have 
thus far only been linked with gait variables, the present study quantitative studies both gait 
and balance. 
We hypothesize that in unselected community-living elderly people, executive functions would 
have a stronger relation with gait and balance than memory itself, and that this association 
would be particularly evident during walking under dual task conditions. 
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Methods
Participants
We performed a cross-sectional study in community-living elderly people. We recruited our 
participants from the Nijmegen Biomedical Study (NBS), a population-based survey conducted 
by the Department of Epidemiology and Biostatistics of the Radboud University Nijmegen 
Medical Centre that started in 2002-2003. 22,500 age and sex stratified randomly selected 
adult inhabitants of the municipality of Nijmegen received an invitation to complete a postal 
questionnaire on lifestyle and medical history. From the second survey in 2005-2006, we randomly 
invited a subset of 300 elderly people to participate in additional measurements. Participants 
were eligible when they were 75 or older, could walk short distances, understood simple tasks 
and were willing to give written informed consent. Exclusion criteria were visual impairments 
that prevented the participant from reading a newspaper, eventually with correction/glasses. 
Baseline characteristics are displayed in Table 1. The institutional review board of the Radboud 
University Nijmegen Medical Centre approved the study.
Cognitive measures
We used the Mini Mental State Examination (MMSE) score (range 0-30; a score below 24 
indicates clear cognitive impairment) to characterize the subjects and assess global cognitive 
status.13  We assessed executive function with the Trail Making Test (TMT), a well-established 
psychomotor test that is used clinically for the assessments of deficits in psychomotor speed 
(Part A) and mental flexibility (Part B).7 The TMT consists of a part A and B. In this study we used 
a ratio score, calculated as (TMT B-TMT A)/TMT A that controls for the effect of motor speed. 
Furthermore, the Stroop Color Word Test was used as test of response inhibition.7 It measures 
the ability to suppress an overlearned response (i.e. automatic reading of a word while the 
incongruent color of the ink has to be named) and consists of three parts: I: reading of color 
words, II: naming of colors, III: naming of the color of incongruent color words. In the analysis 
we used a ratio score {Stroop III- (I+II)}/ {I+II}, to control for motor speed and reading ability. As 
memory tests we used subtests of the Cambridge Neuropsychological Testing Automated Battery 
(CANTAB), that is the Paired Associates Learning (PAL) to assess learning and episodic memory 
and Pattern Recognition Memory (PRM) to assess visual recognition memory.14 
Gait and balance measures
Quantitative gait analysis was performed with a 5.6-meter long, 0.89-meter wide electronic 
walkway (GAITRite) with sensor pads (12.7 mm apart from each other) connected to a computer. 
The electronic walkway has a good concurrent validity and test-retest reliability.15 Balance was 
measured with two angular velocity transducers (Sway Star) that recorded medio-lateral and 
anterior-posterior angular velocities at 100 Hz. The device was attached as a small box with 
a belt to the lower back of the participants and was connected to the computer with a long 
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wire. The software calculated 90% ranges of angular velocities and angles in mediolateral and 
anterioposterior direction. Primary outcomes of our study were stride variability (stride length 
and stride time) and mediolateral body sway, all associated with an increased risk of falling.16;17 
During the measurements, participants walked over the walkway on low-heeled shoes. In order 
to measure steady state walking, they started 2 meters before the walkway and walked towards 
a chair positioned 2 meters behind the walkway. First, the participants were instructed to walk 
at their preferred, slow, quick and very quick speed over the walkway without a dual task. 
Subsequently, they walked at their preferred speed while performing two different dual tasks in 
a fixed order: subtracting serial sevens from 100, and then naming as many animals as possible 
during walking over the walkway (verbal fluency task). Subjects had to verbalize their answers, 
permitting us to score secondary task performance. The participants started simultaneously 
with walking and the cognitive task. We did not prioritize the tasks in the instructions for 
the participants.18 Single task performance on the cognitive tasks was tested an hour after 
completion of the walking tests. We had chosen these two cognitive tasks because performance 
of the serial sevens during walking primarily requires division of attention and animal naming 
more abstract thinking and word generation and probably tests more aspects of executive 
functioning19. We did not use a physical secondary task such as carrying a tray, because such 
a task would also require more motor coordination and would diminish rescue reflexes by the 
arms, in which aspects we were not interested. 
Statistical analysis
The baseline gait characteristics of patients were summarized as mean ± standard deviation. 
We used the coefficient of variation (CV): standard deviation/mean x 100% as measure of 
variability for stride time, stride length and stride width. We used ANCOVA analyses to compare 
the outcomes for each primary variable over the three different walks within each participant 
and used paired t-tests in a secondary analysis to compare the results of the dual task condition 
with the reference condition (walking without a dual task). The effect of the addition of a dual 
task on the gait and balance variables was expresses in effect sizes with Cohen’s �, of which 0.5 
has to be interpreted as moderate and 0.8 as a large change.
We used multiple linear regression models to investigate the relationship between cognition (as 
measured by TMT ratio, Stroop ratio, PAL and PRM) and gait (gait velocity, stride length and 
time variability) and balance during walking (mediolateral displacement and velocity) with and 
without dual task. We ensured that the requirements for linear regression models were fulfilled 
and used log-transformation in skewed distributions. Potential confounders tested for inclusion 
in the regression models were: use of a walking aid; fear of falling with Activities-specific 
Balance Confidence (ABC) score20; history of falls in the year before measurements; number 
of medications; age; score on a co-morbidity index (Cumulative Illness Rating Scale-Geriatrics; 
CIRS-G)21; depressive symptoms (MADRS)22; handgrip strength.23 A decrease in gait velocity is 
often used as strategy to maintain balance in more difficult circumstances. Because gait velocity 
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has a strong influence on other gait and balance variables, we investigated the associations of 
executive function and memory with the primary gait and balance outcomes standardized for 
gait velocity.24 
All data were analyzed using SPSS statistical software, version 12.0. Because of the multiple 
comparisons statistical significance for all regression models was accepted at P < .01.
Results 
Of the 300 people who received an invitation to participate, 118 agreed to be approached. Seven 
eligible people declined participation because they perceived the burden of the measurements 
as too high and 11 people could not participate because of an acute illness of themselves or 
their partner. The final sample consisted of 100 persons (36 women) with a mean age of 80.6 
years SD 4.0. The values in Table 1 show that most participants had several health problems, 
need some assistance in activities of daily living and come from all social layers. The participants 
had a mean gait velocity of 0.96 m/s ± 0.23 with a stride length of 115 cm ± 20 and cadence of 
99 steps/minute ± 14. 
Table 2 displays the primary gait and balance variables during the different dual task conditions. 
Of the balance variables, mediolateral trunk displacement increased significantly after the addition 
of the dual tasks, but mediolateral angular velocity remained unchanged during all conditions. 
Gait velocity was reduced during dual task performance. Of the gait variables, variability in stride 
length and stride time increased after addition of the dual tasks (P<0.001). The effect sizes varied 
from 0.37 to 0.75. Standardization for gait velocity showed that both dual tasks significantly 
increased stride length variability, stride time variability and mediolateral displacement by 30 to 
40% (p<0.01). The mean number of responses on the serial sevens was 3.1 SD 1.8 and for the 
animal naming condition 6.5 SD 1.7. The percentage of correct answers decreased from 90% 
during the single task to 77% during the dual task condition for the serial sevens and from 100% 
to 97% for the animal naming test (changes not statistically significant). 
After addition of the dual task (animal naming) in the multiple regression analysis, the TMT ratio 
became significantly associated with stride length variability and mediolateral angular velocity 
(Table 3). Neither of the two memory tests was independently associated with gait or balance 
variables (data not shown). CIRS-G, MADRS, ABC and hand grip strength were confounders in 
the multiple regression analyses. During the single task condition none of the tests for executive 
function or memory were independently associated with gait and balance variables. Stride width 
variability remained constant during all conditions.
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Table 1. Population Characteristics
Mean ± SD 100 participants
Men / Women 64 / 36
Age (years) 80.6 ± 4.0 (range 75-93)
Height (m) 1.72 ± 0.09
Weight (kg) 75.7 ± 10.9
ISEI-9230 48.7 ± 16.9 (range: 16-80)
GARS31 25.7 ± 8.4
Voorrips sport32 7.4 ± 5.1
CIRS-G21 7.1 ± 3.5
Number of drugs 3.5 ± 2.7
Subjects Fallen in Previous Year, N (%) 32 (32) 
Number of Falls per Person 0.6 ± 1.5 (N=26 1 Fall; N=6 ≥2 Falls)
Fear of Falling (yes/no Question), N (%) 24 (25.2)
ABC score20 74.9 ± 17.7
MMSE13 28.4 ± 1.5
TMT ratio7 1.6 ± 0.8
Stroop interference ratio7 1.1 ± 0.5
PAL (total number of mistakes)14 11.3 ± 9.1
PRM (% correct answers) 14 79.9 ± 12.0
MADRS22 2.1 ± 4.2 (Median 1.0)
Walking Aid during Measurement, N (%) 7 (7.1%)
UPDRS-motor part33 3.2 ± 3.8
TUG (s)34 10.4 ± 4.1
Hand Grip Strength (kg)23 32.5 ± 8.7
Notes: ISEI-92=International Socio-Economic Index of occupational status 1992; range 16-87, higher score 
indicates higher status; Voorrips sport= sport participation subscale Voorrips, range 0-18, a higher score means 
more participation; CIRS-G=Cumulative Illness Rating Scale-Geriatrics, a co-morbidity index, score ≥6 indicates 
frailty; GARS=Groningen Activity Restriction Scale, range 18-76, 18 correspond to complete independency; 
MMSE=Mini Mental State Examination, range 0-30, score <24 indicates cognitive impairment; ABC score=Activity 
Balance Confidence, range 0-100%, score <67% indicates fear of falling; TMT=Trail making test ratio (TMT part 
B- part A)/TMT part A; Stroop= Stroop colour word test ratio ({Stroop III- (I+II)}/ {I+II}); PAL= Paired Associated 
Learning test, short version, range 0-72 errors; PRM=Paired Recognition Memory, range 0-100%, higher score 
means better memory; MADRS-Montgomery Asberg Depression Rating Scale, range 0 - 60, a score >18 indicates 
depression; UPDRS-motor part=Unified Parkinson’s Disease Rating Scale-motor part, a higher score indicates more 
parkinsonism; TUG=Timed Up and Go-test (time >13.5 seconds indicates an increased risk of falling). 
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Table 2. Gait and Balance Variables with and without Dual Tasking (Reference Condition); Measured Values 
and Values Standardized for Gait Velocity in Percentages
Walking at preferred gait velocity 
No dual task Cognitive Dual Tasks
Reference Condition Serial 7’s Animal Naming
Mean ± SD Standard (%) Mean ± SD
Standardized 
Mean ± SD 
(%) Mean ± SD
Standardized 
Mean ± SD 
(%)
Balance
Displacement  
M-L (degrees)
3.6 ± 1.6 100 4.5 ± 1.6† 135 ± 96* 4.4 ± 1.5† 128 ± 69*
Angular velocity  
M-L (degrees/s)
27.6 ± 1.6 100 28.8 ± 1.4 107 ± 32 28.8 ± 1.5 107 ± 33
Gait
Gait velocity (m/s) 0.96 ± 0.23 NA 0.91 ± 0.28* NA 0.92 ± 0.28 NA
Stride length 
variability (%CV)
2.3 ± 1.9 100 3.0 ± 2.0† 145 ± 82* 2.8 ± 1.9* 136 ± 76*
Stride time 
variability (%CV)
1.4 ± 2.7 100 2.6 ± 1.9† 140 ± 76* 2.4 ± 2.0 131 ± 83*
Notes: M-L= body sway in mediolateral direction, CV= coefficient of variation. 
Mean ± SD refers to measured values. All means are back transformed from the log-transformed values, except 
gait velocity. 
Standardized mean ± SD (%) refers to percent change in the variable relative to the reference condition (walking 
without a dual task; set at 100%) after standardization for gait velocity.
Data were tested for difference versus reference condition (walking without a dual task) with ANCOVAs. Paired  
t-tests, relative to the reference condition; * P < 0.01, † P < 0.001
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Discussion
This study shows that in community-living elderly people, executive function (i.e., mental 
flexibility) is independently associated with both an important gait variable (stride length 
variability) and a measure of balance instability (mediolateral trunk sway) while walking under 
dual task circumstances. Both dual tasks influenced gait and balance, but in the multiple 
regression analysis this effect was only seen with the verbal fluency (animal naming) dual task, 
but not during a mental arithmetic dual task (subtracting serial sevens). While it can be argued 
that both dual-tasks rely on executive functioning, animal naming probably will apply more 
cognitive resources than serial subtraction.7 The larger effect of the verbal fluency dual task on 
gait and balance may thus be the result of a higher cognitive load, and interferes with frontal 
neural pathways to a greater extent. Memory tasks were not related to any of the gait or balance 
measures. 
Our results fit in with the results of the group of Alexander25;26, but are partially in contrast to the 
results reported by the groups of Hausdorff and Holtzer. They found that even normal walking 
(without secondary tasks) was related to executive function, suggesting that simple undisturbed 
gait is already a complex process that requires input from executive functions.8;27 Corresponding 
with our results, both groups also found that the associations with executive functions increased 
further during dual tasks conditions and Hausdorff reported that memory was not independently 
associated with gait performance.8;27 There are three possible explanations for the discrepancy. 
First, we used a ratio score for the TMT and Stroop test, while others used absolute differences 
in test scores.10;11 The use of absolute differences, however, may have increased the contrast 
between the extremes in test scores and made a spurious finding of an association more 
likely. Furthermore, in contrast to previous studies, we have applied a correction for multiple 
comparisons, which obviously has restricted the number of independent associations but results 
in statistically more robust findings. Last, our population of community-living elderly people is 
different compared to the idiopathic fallers or healthy older adults in the studies of Hausdorff8;12 
and the younger and quicker (mean gait velocity 1.20 m/s) participants in the InChianti study10;11. 
However, the participants in the Einstein aging study27 were comparable in gait velocity and TMT 
performance; therefore population differences do not seem to be the main explanation. 
A major strength of our study is that we examined both gait and balance variables during 
walking. Our results showed that frontal executive functioning was related not only to stride 
length variability (an important gait variable that is related to falls in elderly persons and patients 
with neurological diseases28), but also to balance instability during walking (as reflected by an 
increased mediolateral trunk sway (related to lateral falls and hip fractures). Another strength 
is that we have used several cognitive tests and two different cognitive dual tasks. Executive 
function consists of various, complex cognitive processes that differ in nature and consequently 
cannot be assessed using one single test. We have selected the TMT and Stroop because they 
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represent executive abilities that are probably most important to everyday walking: mental 
flexibility and response inhibition. An explanation for the difference in results between the TMT 
and Stroop can be that the ability to adapt to changing circumstances during walking requires 
more mental flexibility, tested with the TMT, than response inhibition, tested with the Stroop. 
We refrained from including additional executive function tests because the limited attention 
span of our elderly participants could have influenced their performance negatively by fatigue 
and decreased motivation. Another concern would be the increased risk of finding a chance 
association when the number of variables increases. Such risks were already considered for 
the present experimental design which was essentially an explorative study with many possible 
comparisons. To accommodate this, we selected the most important outcome variables before 
start of the study, and set the alpha level at 0.01. 
We should note one additional drawback, related to use of the relatively short (5.6 meters) 
electronic walkway which limited the number of steps available (on average 5.6 steps, SD 1.4) 
for analysis in each walk. This may have reduced the precision of our measurements compared to 
approaches where subjects wear pressure-sensitive insoles during prolonged walking episodes.9 
However, Holzer and Coppin et al measured gait velocity over an equally short distance. 
Furthermore, even our short walkway was sensitive enough to detect effects of dual tasking on 
gait variability. Furthermore, previous studies have shown that changes in trunk sway under dual 
task circumstances can be detected during a comparably short walking trajectory.29 Changes in 
stride length or time variability or trunk sway cannot be used on their own to indicate the risk 
of falling in individual patients and have to be combined with all other clinical findings. Future 
studies should explore the underlying pathophysiological mechanisms behind the associations 
of executive function with gait and balance, as well as their ability to predict the development 
of gait disorders and risk of falling.
Conclusion
This study gives more insight in the interaction of executive function and memory with gait 
and balance control during walking in community-living elderly people: executive functions 
are associated with gait and balance, but only in a dual task condition. In future research the 
pathophysiology and further clinical implications should be investigated.
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The important thing in science is not so much to obtain new facts 
as to discover new ways of thinking about them
- Sir William Bragg -
General discussion 
Gait and cognitive problems are common in older people, they interact and both can have 
serious consequences such as an increased risk of falling and functional decline. Therefore 
the interplay between gait and cognitive (dys)function is the subject of this thesis. In the first 
section of this chapter the results will be discussed within the framework of a general disease 
model applicable to geriatrics. In the second section, I will discuss the interpretation of the 
gait, mobility and balance data and highlight some methodological issues specifically related to 
research with older people. Section three discusses some limitations and directions for future 
research and patient care. 
1. Research findings placed within a theoretical model
In the introduction I used a simple model (see page 19, fig 2) to discuss current knowledge 
of the interaction between gait and cognition. In this paragraph I will again use a model, now 
a more complex one, to place the interaction between gait and cognition within the general 
context of functioning, disability and health. I will also use a part of this model to integrate 
current knowledge with new insights in the interaction between gait and cognition as described 
in this thesis. 
A general theoretical model of health and health-related problems is the International Classification 
of Functioning, Disability and Health (ICF-model; WHO, 2002)1, Figure 1. It is a biopsychosocial 
model with three levels of functioning: at the level of the body, as a person and as a person 
in a social context. Disability involves dysfunction at one or more of these levels: impairments, 
activity limitations and participation restrictions. 
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Figure 1. International Classification of Functioning, Disability and Health (WHO, 2002) 
Body functions: physiological functions of body systems, including psychological functions. For 
example memory.
Body structures are anatomical parts of the body such as organs and limbs.
Impairments are problems in body function or structure, such as a significant deviation from 
normality or loss of previous functions. For example decreased short-term memory, disorientation 
and osteoarthritis of the hip. 
Activity is the execution of a task or action by the individual, such as walking.
Participation is involvement in a life situation, such as work and a family meeting.
Environmental factors the physical, social and attitudinal environment in which people live and 
conduct their lives; for example the house, aids and appliances and received help from carers. 
The research in this thesis is concentrated on a small part of the model, namely function and 
health conditions (encircled in Figure 1); concentrated on cognition and mobility in figure 1a.
Figure 1a. Elaboration of the abovementioned ICF-based model with arrows that locate the new information 
obtained from the research projects described in this thesis.
Contextual factors
Personal factors Environmental 
factors
Body functions 
& structures
Activity Participation
Health condition
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Both the collective terms of the ICF-model (mental and movement function) and the terms used 
in this thesis (cognition, gait, balance and mobility) are displayed.
From disease to functional level (6 upward pointing arrows)
Previous research shows that dementia in patients without co-morbidity is associated with 
a slowing of gait and increased variability in stride length.2 However, frail older people with 
dementia walked too quick relative to their level of frailty (Chapter 3A). The most likely 
explanation seems to be a lack of insight, because of which patients may not have adapted 
their behaviour to their cognitive and physical impairments. Division of attention may be another 
cognitive function involved because it can be impaired in dementia and can influence gait and 
mobility.3 Presumably executive functions also play an important role: dementia but not Mini 
Mental State Examination scores (a cognitive test with no extensive item on executive function) 
were associated with gait velocity and gait variability.  
Another mechanism through which dementia can influence gait is drugs (see literature review 
Chapter 1C; not displayed in figure 1a). Antipsychotics, frequently used to treat behavioural 
and psychological symptoms of dementia, may impair gait, balance and mobility by causing 
a parkinsonian gait, other extrapiramidal features and somnolence.4;5 Gait impairment and 
increased risk of falls are also reported for other psychotropics.6 The first, preliminary, evidence 
about positive effects of dementia drugs (eg memantine) on gait and mobility is emerging.7 In our 
study with geriatric inpatients, the number of patients with dementia who also used rivastigmine 
(N=2) was too small to investigate its effect on gait and mobility. Parkinsonism is often present 
in people with dementia, but was only used as a potential confounder in this thesis. Finally, 
dementia is associated with a particular gait pattern that can be described as ‘cautious gait’, 
‘higher-level gait disorder’ or ‘wide-based gait’. But as we demonstrated for waddling gait8 in 
Chapter 1B, gait observations are subjective and highly variable among clinicians, which made 
them unsuitable as outcome variables in our studies.
We showed that in geriatric inpatients depression is associated with a decreased gait velocity 
and increased stride length variability during dual tasks.9 The similar effects of dementia and 
depression on gait velocity and stride length variability may be explained by their (partially) 
shared aetiology: white matter lesions can underlie both cognitive problems and depression and 
can lead through the intersection of frontal neuronal pathways to impaired gait and balance.10 
Second, patients with a depression often have problems with concentration, the division of 
attention and memory, comparable to patients with dementia. In more severe cases depression 
therefore is easily called pseudodementia.11;12 In patients with depression medication did not 
significantly influence gait.9 
Multimorbidity, depictured as ovals at disease level in figure 1a, does influence mobility and 
cognition and the way their interplay can be tested. The partially overlapping ovals also represent 
the numerous interactions that are possible in patients with multimorbidity. 
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Functional level (horizontal arrows in figure 1b)
At the functional level, we investigated the effect of cognition on gait and balance with cognitive 
dual tasks (Chapter 3, 4 and 5). A cognitive dual task that requires the (division of ) attention or 
the use of executive functions impairs gait in older people. We showed that dual tasking slowed 
velocity and increased variability in stride length and time and balance (increased trunk sway) 
in older people. In our study with fit non-demented older people the duals tasks needed to be 
more difficult to impair gait and balance.13 In contrast to frail older people physically fit older 
people have much reserve in gait, balance and balance recovery strategies and only difficult 
dual tasks impair their balance control and may eventually increase their risk of falling. This 
explanation is visualized in Figure 2, with the assumption of a limited but different reserve in 
balance and a fixed threshold for falls. 
Figure 2. The effect of a simple dual task on balance and the risk of falling in fit and frail older subjects
Last, in community-living older people we found a better performance of executive function 
tests to be associated with better gait and balance performance during walking with a cognitive 
dual task (Chapter 5A). All our results fit in with the central processing theory named in the 
introduction (section 2B.2); the central processing of gait and balance control and the execution 
of cognitive processes can interfere with each other through structural inference in neural 
networks of the frontal and motor cortex or because the demands of cognition and gait control 
go beyond the limited central processing capacity.
Without task prioritizing, walking itself did not influence the performance on the cognitive tests 
in elderly marchers and community-living older people. 
Thus, the results of this thesis support the hypothesis that cognition influences gait in older 
people, shown as arrows in the interaction model presented here.
2. Assessment and interpretation of gait, balance and cognition in older people
The assessment and interpretation of gait, balance and cognition in older people is not 
straightforward. We discuss some issues below.  
A: Fit subjects B: Frail subjects
Dual task -
Dual task +
Dual task -
Dual task +
No risk of falling
Risk of falling
Balance
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A. Interpretation of patient characteristics
In this thesis we investigated three groups of older people with a very different level of frailty, 
cognitive and physical fitness. The differences are reflected in the baseline characteristics and 
gait and balance values between the groups (Table 1 and 2).
Table 1. Characteristics of participants of the three studies in this thesis
Study characteristics
Geriatric inpatients
Chapter 3
Community-living
Chapter 5
4-Day marchers
Chapter 4
Mean ± SD Mean ± SD Mean ± SD
Number of participants 125 100 59
Age in years (range) 77.6 ± 7.0 (63-94)* 80.6 ± 4.0 (75-94) 73.5 ± 3.4 (70-82)
Female N (%) 72 (58) 36 (36) 18 (31)
Total score CIRS-G14 9.9 ± 3.5* 7.1 ± 3.5 2.9 ± 2.1
ISEI-9215 - 48.7 ± 16.9 51.7 ± 12.3
Number of drugs used 6.4 ± 3.2* 3.5 ± 2.7 1.7 ± 1.7
MMSE16 score 21.8 ± 5.9* 28.4 ± 1.5 28.6 ± 1.4
GARS17 - 25.7 ± 8.4* 18.1 ± 0.4
Voorrips sport18 - 7.4 ± 5.1* 12.6 ± 4.2
Fear of falling (yes/no) N (%) 69 (55)* 24 (24) 9 (15)
Fallers 42 (34) 32 (32) 14 (24)
Walking aid during measurements N (%) 56 (45)* 7 (7) 0 (0)
UPDRS-motor part score19 9.0 ± 6.5* 3.2 ± 3.8 0.3 ± 0.5
Hand grip strength20 (kg) 22.5 ± 9.9* 32.5 ± 8.7 38.1 ± 9.4
Notes: ISEI-92=International Socio-Economic Index of occupational status 1992; range 16-87, higher score 
indicates higher status; Voorrips sport= sport participation subscale Voorrips, range 0-18, a higher score means 
more participation; CIRS-G=Cumulative Illness Rating Scale-Geriatrics, a co-morbidity index, score ≥6 indicates 
frailty; GARS=Groningen Activity Restriction Scale, range 18-76, 18 correspond to complete independency; 
MMSE=Mini Mental State Examination, range 0-30, score <25 indicates cognitive impairment; Faller= a person 
who had fallen once or more during the last 12 months before the measurements, as reported by the subject 
himself; UPDRS-motor part=Unified Parkinson’s Disease Rating Scale-motor part; SD=standard deviation. 
Differences between the three groups were tested with Chi-square tests or one-way ANOVAs; between two groups 
with independent t-tests; * p< 0.001 
Unexpected at first sight is the relatively small difference in the percentage of fallers between the 
three groups. According to the test results (mean Timed-Up and Go time>13.5 sec21, low Tinetti 
gait and balance test and Berg Balance Scale scores and high stride variability, all indicative 
of an increased risk of falls), the geriatric inpatients should have the highest percentage of 
fallers and the 4-Day marchers the lowest. An explanation for this remarkable finding can be the 
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underreporting of falls in the group of geriatric inpatients; half of them had dementia, which 
might have increased recall bias. Furthermore, the falls in the very fit group are probably of a 
different type: these are not the ‘geriatric’ falls with a complex underlying aetiology, but ‘simple’ 
once-only stumbles, for example over tree roots while walking fast in the woods. Another 
explanation can be that the percentage of geriatric inpatients with a fear of falling was higher 
and that these patients had effectively adapted their gait. Although we have not systematically 
followed the participants over time, from the hospital-based records of the Radboud University 
Nijmegen Medical Centre it became clear that at least 9 of the 125 participants of the vulnerable 
group had experienced a hip fracture against none in the other two groups in the year after the 
measurements. These results show the complexity of falls as health problem and the caution 
needed for a correct interpretation of (retrospective) fall histories. 
Focussing on gait, balance and mobility, the frailty of the geriatric inpatients is visible in the 
highest percentage of walking disability (use of a walking aid), lowest gait velocity and highest 
time needed to complete the Timed Up and Go test (Table 2). Their gait velocity is far below the 
cut-off point of 1.0 m/s, below which people are at increased risk at functional decline.22 The 
community-living older people are also slower than normal for their age: normal gait velocity for 
people aged 70-79 years is 1.30 m/s23 and normal TUG time is 8.5 sec.24 These data directly show 
how fast the 4-day marchers still are. However, gait velocity does not say much about the relative 
and absolute intensity of the walking activity: walking during the International 4 day marches 
is an activity of moderate to high intensity for fit older participants25 and is comparable to the 
activity level required to walk with a walking aid for vulnerable older people.26
The slowness in gait velocity of the geriatric patients can only be partially explained by a higher 
usage of walking aids in the vulnerable group. First, the effect of the cause (gait and balance 
problem) and consequence (use of a walking aid) on gait velocity is difficult to distinguish. 
Second, the effect of a walking aid on gait velocity is not unequivocal: some people walk slower 
with a walking aid because its use requires attention27 and some people cannot handle their 
walker properly. On the other hand, some other people feel much safer and therefore walk faster 
with a walking aid [data pilot study, not presented in this thesis]. 
Table 2 shows the differences in gait and balance outcomes between the groups and facilitates 
comparisons between groups, but conclusions have to be made with caution: in these groups of 
different fitness the preferred gait velocity differs greatly. We showed in chapter 4 that gait and 
balance variables are strongly related with gait velocity and these differences in gait velocity 
can distort the comparison of the other gait and balance variables. For example, the difference 
in gait and balance variables almost disappears when the data during walking at preferred gait 
velocity of the community-living elderly people are compared with walking at slow pace by the 
4-day marchers. Therefore we developed a standardisation method for gait velocity, described 
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in chapter 4, which is a sophisticated and valid method to make gait and balance variables 
comparable over different groups or different situations with different gait velocities. Thus, data 
as presented in Table 2 are useful to describe the level of mobility of a population. However, 
when gait and balance of two groups of different level of mobility need to be compared, the 
interpretation needs much caution. Best would be to standardise the data for gait velocity or 
use data derived from walks at the same gait velocity. 
Table 2. Gait and balance characteristics of the participants of the three studies in this thesis
Study characteristics Geriatric inpatients Community-living 4-Day marchers
Mean ± SD Mean ± SD Mean ± SD
Number of participants 125 100 59
Mobility
TUG (seconds) 25.3 ± 19.3  
(median 19.9)*
10.4 ± 4.1 6.2 ± 1.0
Gait
Gait velocity (m/s) 0.64 ± 0.28* 0.96 ± 0.23 1.46 ± 0.18
Cadence (steps/min) 89.8 ± 18.9* 99.0 ± 14.5 118 ± 7.6
Stride length (cm) 83.7 ± 26.7* 115.2 ± 20.2 150.0 ± 16.4
Stride width (cm) 8.4 ± 3.5* 11.8 ± 3.8 10.0 ± 2.9
Stride length variability (% CV) 6.7 ± 7.0* 2.3 ± 1.9 1.4 ± 0.6
Stride time variability (% CV) 7.2 ± 12.3* 1.4 ± 2.7 1.3 ± 0.6
Balance
Displacement M-L (degrees) - 3.6 ± 1.6* 4.6 ± 1.4
Angular velocity M-L (degrees/s) - 27.6 ± 1.6* 42.7 ± 1.4
Displacement A-P (degrees) - 6.5 ± 1.5* 8.4 ± 1.3
Angular velocity A-P (degrees/s) - 42.1 ± 1.6* 63.0 ± 1.5
Notes: M-L=mediolateral; A-P= anterior-posterior trunk movement; TUG= Timed Up and Go-test; BBS= Berg 
Balance Scale, range 0-56 higher score indicates better balance; CV= coefficient of variation. * P< 0.000 with 
independent t-tests and one-way ANOVAs.
B. Representativeness of the patients in the study 
Study designs should have a good internal validity to answer the research question and deliver 
results that can be generalized to the target population. One aspect of the study design is the 
selection of the correct population. For a good internal validity, a homogeneous population 
is helpful. Therefore, patients with multimorbidity are often excluded. However, this makes 
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generalisation of the results to the target population difficult. Further, results obtained from 
young or healthy older adults cannot be directly generalised to frail, geriatric patients.28-30 A 
better external validity can be obtained by a loosening of inclusion and exclusion criteria. This 
may also increase recruitment efficiency, although at the same time the inclusion of more frail 
subjects may increase the number of dropouts during the study. This complicates the statistical 
analysis, makes it less efficient and makes the interpretations of the results more difficult. 
Loose inclusion and exclusion criteria also increase the variability, thus making the study less 
statistically efficient. 
In our studies we had chosen to restrict the inclusion criteria to those that guarantee that 
participants can complete the measurements. With our minimal inclusion and exclusion criteria, 
attrition (32%; N=40) was indeed an issue for the second measurements in the geriatric inpatients 
(Chapter 3). This percentage is comparable to other studies with frail patients.29 Reasons were 
incident immobility (N=10), quick discharge and logistics (N=24) and refusal (N=6). The incident 
immobility fits in with the quick changes in health in these vulnerable patients and the refusals 
were all of patients with a severe depression who also refused parts of their treatment. This 
attrition due to logistic problems may be partially preventable in future studies when staff and 
equipment are available at an even more flexible basis. 
To know how externally valid study results are, at least sufficient information about the recruitment 
and selection procedure and the baseline characteristics of the participants is needed.28-31 
Concerning the latter, the pros of measuring many characteristics have to be weighted against 
the increased burden on frail participants and the budget needed. We tried to find the optimum 
in the number of characteristics.  With our data we can conclude that our study groups are 
comparable to other populations reported in literature.25;32-34 This does not directly mean that 
our study populations accurately reflects the target population. For example, the percentage of 
women in the studies with the community-living elderly people and 4-day marchers is relatively 
low (36% and 31%) compared with the percentage of women in the whole community (65+ 59% 
women; 80+ 70% women; www.RIVM.nl). This phenomenon occurred more often in studies that 
recruited directly from the community. Probable explanations can be that men are more eager to 
test themselves and like more to be the cock of the walk. Literature suggests that the way and 
extent of the influence of gender on gait, balance and mobility differs and ranges from influence 
through height and muscle strength to a complex of activity level, hormone levels, osteoporosis, 
and selective survival.35-37 Gender was not a confounder or effect modifier in the associations 
studied in this thesis, but the difference in gender distribution may nevertheless restrict the 
external validity of the results.
C. The measurement of dual tasks
The effect of cognition on gait and balance can be made visible with dual tasks; in this thesis 
the simultaneous performance of a secondary, cognitive task during walking. This task can 
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impair gait, cognitive performance, or both.38,32;34  The explanation of this phenomenon may be 
that execution of the secondary task interferes with balance control, probably because attention 
has to be divided or through structural inference in neural networks of the frontal and motor 
cortex.39;40 The interactions between mental processes and gait and balance control can be 
modulated by factors such as stimulus and response modalities (auditive or visual), difficulty 
of the concurrent secondary task, type and difficulty of walking task, individual differences in 
sensorimotor (dys)function and differences in mental and physical impairments.41;42 Although 
vulnerability of the participants should play an important role in the choice of the type and 
difficulty of the dual task, this is not often discussed in literature. Table 3 shows (by combining 
data from chapters 4 and 5) the effect of one cognitive dual task (serially subtracting 7 from 
100) on gait and balance variables in two groups of older people of different fitness. This 
task significantly influenced most gait and balance variables (standardised for gait velocity) in 
both groups, although probably less in the 4-Day Marchers group. The other tasks (100-13 and 
naming words with a K and O) used in the very fit group are too difficult for most of the geriatric 
patients, as many of them already struggled with counting backwards. If the difficult dual tasks 
had been used, most patients would have refused performing the whole test or ignored the 
cognitive task. [own experience and 43;44] Thus the answer to which task is best as secondary 
cognitive task is not straightforward. The cognitive and motor tasks should always be adapted 
to the level of frailty and cognitive function and piloted in the target population. 
Table 3. Gait and balance variables during performance of a cognitive dual task, standardized for gait 
velocity, in two different groups of older people.
Walking at preferred speed
Cognitive dual task 100-7
Balance and gait variables No dual task (Reference) Community-living 4-Day Marchers
Mean % ± SD Mean % ± SD Mean % ± SD
Displacement M-L 100 ± 37 135 ± 96* 122 ± 60
Angular velocity M-L 100 ± 36 107 ± 32 110 ± 37†
Stride length variability 100 ± 54 145 ± 82† 107 ± 45
Stride time variability 100 ± 45 140 ± 76* 145 ± 64*
Notes: The reference condition, walking at preferred gait velocity without dual task, is set at 100% after 
standardisation for gait velocity (for each group apart). Dependent t-test * P < 0.01, † P < 0.001 
M-L = mediolateral trunk movement (Data from research presented in chapter 4 and 5)
In the choice of the best cognitive dual task for a certain study the different cognitive functions 
need also to be taken into account. Dual tasks that require the use of executive functions seem 
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to have more effect on gait and balance outcomes than attention-dividing tasks (Chapters 4 
and 5). Given the ideas about the underlying mechanisms of dual tasks, the different effects of 
different types of cognitive tasks on gait and balance seem obvious. However, most previous 
studies only used one cognitive dual task, such as counting backwards with one or serial sevens, 
reciting (animal) names or numbers or performing a verbal or visual Stroop test (executive 
function test). One study in older adults transitioning to frailty used both counting backwards 
and citing animal names.45 Both tasks decreased gait velocity, of which animal naming had the 
greatest influence on gait velocity. Lateral stepping only increased during counting backwards. 
Their result differs from our findings, as presented in Chapter 5, in which we found an association 
between executive function and stride variability and lateral trunk sway. The differences may be 
explained by a practice effect and the imprecise measurement techniques used in that study. 
In our studies we did not use a physical task as secondary task, for example carrying a tray or 
a glass of water, because this would interfere with the normal walking position and movements. 
More important, physical dual tasks would only partially test the effect of cognition on gait and 
balance control, the focus of this thesis. For the same reasons we did not use multiple tasking.
In daily life people often perform dual tasks and training them would yield large profits. A first case 
report describes that older adults may be able to improve their balance under dual-task conditions 
only following specific types of balance training.46 How this can be done effectively and how this 
knowledge can be transferred to other situations than the training situation is not known yet.
3. From study limitations and constraints to future research 
A. Methodological constraints and limitations
This thesis changed the focus from the investigation of one health problem towards the 
interaction between two health problems, impairments in gait and cognition. We were able 
to answer some questions, but numerous others are still open, ranging from questions about 
common aetiological pathways to questions on how the interaction between gait and cognition 
can be influenced. Without the aim to be comprehensive I will name some limitations of the 
studies in this thesis and corresponding implications for future research.
One limitation is that brain imaging as part of the research protocol was not possible for logistic 
reasons (long waiting time for scans at the radiology department at the time the research was 
carried out). Brain imaging could have supported hypotheses about which neurological systems 
are exactly involved and would have extended the knowledge about the pathophysiological 
mechanisms. For this purpose the use of Diffuse Tensor Imaging or Functional MRI coupled with 
gait performance would already be a large improvement.
Second, this thesis is only focussed on the interaction between gait and cognition at disease and 
functional level, while given the many older people with multimorbidity, much more interactions 
at many different levels are present. However, this is already an improvement and more valid for 
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geriatric patients than a lot of research in elderly patients that is still solely directed at isolated 
diseases and their pathophysiology.47 To answer the question if the combination of gait and 
cognitive dysfunction has a synergistic effect on outcomes such as quality of life and function, 
longitudinal studies will have to be performed. But complicating factors are that gait and balance 
play an important role in daily activities and impaired functioning in activities of daily life is part 
of the diagnostic criteria of dementia. These aspects are difficult to disentangle. 
Third, the studies presented in this thesis were highly explorative and already indicate that 
the investigation of interactions and multimorbidity asks for new research methodologies 
and collaboration of multiple disciplines. Just as frail patients with multiple problems require 
multidisciplinary care, this type of research requires multidisciplinary research teams with great 
creativity, an open mind and willingness to cooperate.
The high interindividual and intraindividual variability in outcome variables also imposes 
challenges, although this issue can be solved by making biological variability itself the subject 
of research. Another option to deal with the heterogeneity in older subjects is the development 
of methods that do not rely on large groups and can pay attention to the unique characteristics 
of an individual, for example the N=1 design.48
Last, more knowledge about the interaction between gait and cognition is only a first but necessary 
step to improve patient care. To really make a difference for older patients, interventions have to 
be tested that promise to improve gait and mobility and reduce the risk of falling. 
B. Financial constraints
As always, funds are needed to realise studies on multimorbidity and to answer the above 
mentioned questions. So far, non-governmental organisation and funds were still mainly disease-
oriented and not very interested in this type of crossing-border, multidisciplinary research, but 
while writing this thesis, very promising research calls specifically directed towards frail elderly are 
prepared. This makes stimulation by the government and related organisations highly desirable 
and eagerly awaited for. The awareness that more attention is needed to multimorbidity is 
growing, as shown by the recent advice of the Council for Health related Research (Raad voor 
GezondsheidsOnderzoek, 2006) and the rapport of the Health Council (Gezondsheidsraad, 2007). 
“The times they are a changing.”
4. Implications for patient care
In general, scientific information about interactions can help alert clinicians to pay attention to 
comorbid diseases that may cause or increase disability given the problems that are already 
present.49 As such, the information about the interaction between cognition and gait in this 
thesis can alert clinicians to search for this particular combination. However, when interacting 
health problems are detected, current guidelines provide physicians with little guidance; the 
interacting effects of diseases and their management require complex and individualised care 
instead of simply the sum of separate guideline components.50 51 
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Nevertheless, some practical tips and tricks can be distilled from the research described here:
A. Test cognition in fallers and older patients with a gait disorder.
B. Test gait, balance and mobility in older patients with cognitive impairments.
In both cases the risk profile of falls and functional decline can be refined and in case B 
additional information about the aetiology of the cognitive impairment can be obtained.
C. Perform dual tasks to test the interaction between gait and cognition.
D. Combine clinical observations of gait, balance and mobility with quantitative tests such as 
gait velocity and the Timed-Up-and-Go to combine ideas about underlying diseases with an 
indication of severity of the gait, balance and mobility problem and the possibility to monitor 
them.
E. Stop psychoactive drugs whenever possible because of their detrimental effect on both gait 
and cognition.
In conclusion
With the increasing importance of multimorbidity in our greying societies we have to learn more 
about the complex interactions between diseases, their treatment and functional performance. 
The interplay between gait and cognitive function is one of these interactions. 
The clinical relevance of this interaction leads to the central message: If gait is impaired in frail 
elderly people, also investigate cognitive function and if cognitive function is impaired, also 
measure gait!
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Samenvatting
In de komende 10 jaar zal het aantal Nederlanders van 65 en ouder toenemen met 650.000 tot 
3.0 miljoen mensen. Oudere mensen hebben vaak vele, elkaar beïnvloedende problemen die 
nadelige effecten op gezondheid en kwaliteit van leven hebben. Toch is het meeste onderzoek 
en zijn de meeste richtlijnen voor behandeling gericht op enkelvoudige gezondheidsproblemen. 
Daarom is in dit proefschrift onderzocht hoe twee vaak bij ouderen voorkomende problemen, 
problemen met lopen en cognitie, elkaar beïnvloeden. Het onderzoek startte met het formuleren 
van een aantal pathofysiologisch en diagnostisch gerichte onderzoeksvragen. Kort samengevat 
leverde het promotieonderzoek hierop de volgende antwoorden:
V. Met welke methoden kunnen lopen, cognitie en hun interactie het best worden gemeten en 
onderzocht in de geriatrie?
A. Observatie en kwalitatieve beschrijving van looppatronen lopen geeft informatie over de 
onderliggende ziekte(n), maar is ook subjectief en blijkt daardoor erg variabel tussen de 
verschillende observatoren. Het voorbeeld van ‘waddling gait’ (waggelgang) laat zien hoeveel 
verschillende klinische beschrijvingen en interpretaties er zijn van een enkel looppatroon 
(Hoofdstuk 2). Sommigen zien vooral de wiegende heupbewegingen, terwijl anderen alleen 
het opzij zwaaien van de romp en hoe wijd de voeten uiteen zijn tijdens het lopen beschrijven. 
Kwantitatieve metingen van het looppatroon, zoals bepaling van de loopsnelheid en het 
uitvoeren van de Timed-Up-and-Go test (TUG-test: tijd nodig voor opstaan, 3 meter lopen, 
draaien en weer gaan zitten), zijn beter geschikt om objectief de ernst van de loopstoornis 
te meten of de verandering hierin. Uit de bij geriatrische patiënten verrichtte metingen is 
gebleken dat zowel loopsnelheid als de TUG-test op groepsniveau betrouwbaar zijn en 
gevoelig voor verandering. Op individueel niveau verschillen de uitkomsten op deze maten 
binnen stabiele oudere personen al erg, waardoor een verslechtering of verbetering groot 
moet zijn om zeker te weten dat deze klinisch belangrijk is (Hoofdstuk 3). 
 Geheugen en andere cognitieve functies kunnen worden gemeten met korte globale testen 
zoals de Mini Mental State Examination, maar veel nauwkeuriger met testen gericht op de 
specifieke cognitieve functies. Uiteindelijk kan met deze en andere informatie eventueel de 
diagnose dementie worden gesteld. 
 Het effect van cognitie op lopen kan zichtbaar worden gemaakt met dubbeltaken. In dit 
proefschrift bestonden de dubbeltaken uit het uitvoeren van een cognitieve taak tijdens 
het lopen. Deze dubbeltaak kan het presteren op de cognitieve taak, de looptaak of beide 
beïnvloeden, bijvoorbeeld doordat de aandacht verdeeld moet worden tussen beide taken. 
 Ouderen blijken onderling, zelfs bij gelijke kalenderleeftijd, veel te verschillen. Dit opmerkelijke 
verschil tussen ouderen wordt ondermeer uitgedrukt in de onderlinge verschillen in 
kwetsbaarheid. Frailty is een vaakgebruikte term om deze kwetsbaarheid aan te geven. Met 
het oog op preventie zijn inmiddels veel verschillende frailty-maten in gebruik om ouderen 
te selecteren met een hoog risico op nadelige gezondheid gerelateerde uitkomsten. Door 
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de grote verschillen in frailty-maten kan de selectie van kwetsbare personen echter erg 
verschillen per maat (Hoofdstuk 3). 
 Concluderend is het duidelijk geworden dat voor het meten van lopen, cognitie  en hun 
interactie in de geriatrie gevoelige uitkomstmaten nodig zijn, maar ook maten om de 
diversiteit in oudere mensen duidelijk te maken. De kwetsbaarheid van de te onderzoeken 
groep bepaalt namelijk mede welke methoden en uitkomstmaten gebruikt kunnen worden.
 Welke definitie ook wordt gebruikt voor frailty, kwetsbare oudere mensen lopen langzamer dan 
fitte ouderen. Omdat loopsnelheid veel invloed heeft op de andere loop- en balanswaarden 
is een standaardisatiemethode ontwikkeld, waarmee een niet van loopsnelheid afhankelijke 
vergelijking van kwantitatieve loop- en balanswaarden mogelijk is geworden (Hoofdstuk 4).
V. Beïnvloeden problemen van cognitie en lopen elkaar of zijn het min of meer toevallig vaak 
samen voorkomende gezondheidsproblemen? 
A. Problemen met lopen en cognitie komen te vaak samen voor om het alleen als ‘toevallig’ 
te zien. De literatuur samen met de resultaten uit dit proefschrift ondersteunt het idee dat 
lopen en cognitie elkaar beïnvloeden bij ouderen. Problemen op deze terreinen hebben 
waarschijnlijk deels een gezamenlijke oorzaak en behandeling van de een kan effect hebben 
op de ander. Zo beïnvloedt de behandeling van cognitieve dysfunctie met antipsychotica 
vaak ook de loopfunctie
V. Hoe beïnvloedt cognitie lopen, balans en mobiliteit bij oudere mensen? 
A. In patiënten met een dementie zonder bijkomende problemen is dementie geassocieerd 
met een langzamere loopsnelheid (Hoofdstuk 2). Maar oudere patiënten met dementie en 
ernstige bijkomende gezondheidsproblemen lopen juist sneller dan ouderen met die co-
morbiditeit maar zonder dementie. De ouderen met dementie lopen dus sneller dan past 
bij hun niveau van frailty, waarschijnlijk door een verminderd inzicht in hun cognitieve 
problemen en lichamelijke (on)mogelijkheden (Hoofdstuk 3). Depressieve symptomen blijken 
ook samen te gaan met een langzamere loopsnelheid en grotere variatie in stap lengte, wat 
weer een grotere valkans voorspelt (Hoofdstuk 3).
 Een cognitieve dubbeltaak vermindert de loopprestatie (langzamer lopen met meer variatie 
in staplengte en –tijd) en balans (grotere rompbewegingen) van oudere mensen. Maar de 
cognitieve taak moet bij fitte ouderen wel veel moeilijker zijn dan bij kwetsbaardere ouderen 
om eenzelfde effect te hebben (Hoofdstuk 4). 
V. Welke specifieke cognitieve functies zijn betrokken bij lopen?
A. Het antwoord op vorige vragen heeft al laten zien dat het verdelen van aandacht en het 
inzicht in eigen mogelijkheden en beperkingen een rol spelen in de regulatie van lopen. 
Andere cognitieve functies die in de regulatie van het lopen een rol spelen zijn het hebben 
van voldoende overzicht, het op kunnen stellen van een strategie (voor het lopen) en 
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deze kunnen aanpassen als de omstandigheden veranderen. Een betere prestatie op deze 
cognitieve functies hangt samen met een betere loop- en balansprestatie tijdens lopen met 
een cognitieve dubbeltaak (Hoofdstuk 5).
 Hoewel er nog vele vragen niet beantwoord zijn (Hoofdstuk 6), is er wel al genoeg bewijs om 
te kunnen zeggen: Als een oudere persoon een loopstoornis heeft, onderzoek dan ook diens 
cognitie en andersom, onderzoek bij een oudere met een cognitief probleem ook het lopen! 
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Summary
In the next 10 years the number of Dutch people aged 65 and over will increase with 650,000 to 
3.0 million people. The prevalence of multiple and often interacting problems in elderly people 
is high and have many adverse effects on health and quality of life. However, most research 
and guidelines are directed at isolated health problems. Therefore the research in this thesis is 
directed towards the interplay between gait and cognition, which both are highly prevalent in old 
age, have a great impact on the quality of life and functioning of older people and their carers 
and increase the risk of falling. 
The key questions and their corresponding answers obtained from the studies presented in this 
thesis are displayed below.
Q. With which methods can gait and cognitive function and their possible interplay be assessed 
best in geriatrics?
A. Qualitative gait observations may give an idea about the underlying disease(s), but they 
are subjective and variable between and within investigators. The example of waddling gait 
shows the many descriptions and interpretations that can exist for one gait pattern (Chapter 
2). Quantitative gait measurements derived from electronic walkways, accelerometers and 
mobility tests such as the Timed-Up-and-Go test, are more suitable to estimate the severity 
of the gait and balance impairment or to assess change. Quantitative gait, balance and 
mobility measures are feasible in all three groups of elderly people, from frail to fit. At group 
level the measures are reliable and the responsiveness of gait and mobility measures in even 
frail geriatric patients with dementia is good. However, on individual level the intra-individual 
variability in test outcomes of stable patients is large, which hampers the possibility to 
detect clinically relevant changes (Chapter 3). 
 Cognitive function can be measured with a global test such as the Mini Mental State 
Examination, specific cognitive tests and on disease level with the diagnosis of dementia. 
 The effect of cognition on gait and balance can be made visible with dual tasks. In this thesis 
we tested the simultaneous performance of a secondary, cognitive task during walking. This 
secondary task can impair gait, cognitive performance or both. Hypotheses for these effects 
are that attention has to be divided or that simultaneous performance of two tasks causes 
structural inference in neural networks of the frontal and motor cortex. 
 The group of older people is heterogeneous and individuals can differ much from each 
other in their level of vulnerability. Frailty is often used to indicate the vulnerability of older 
people, and may be used to select elderly subjects with highest risk at adverse events 
and interactions. However, depending on the criteria used, this single term can give highly 
different selections of participants and warrants caution in the interpretation of outcomes 
(Chapter 3). Thus, the answer to the question posed does not only require sensitive outcome 
measures, but also sufficient measures to characterize the heterogeneity among the elderly 
people studied, which may also determine which outcome measures and dual task are best 
in a specific sub-population. 
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 Whatever definition is used, frail older people have a much slower gait velocity than fit older 
people. Because gait velocity influences the outcomes of other gait and balance variables, 
standardisation for gait velocity should be used to make a valid comparison of gait and 
balance values between groups of different frailty (Chapter 4).
Q. Do gait disturbances and cognitive dysfunction really influence each other or is their co-
occurrence merely a coincidental appearance of two common problems? 
A. Impairments in gait and cognition too often co-occur to be just determined by coincidence. 
Literature together with the results of this thesis supports the hypothesis that gait and 
cognition influence each other in older people. They probably have a shared pathophysiology 
and treatment given for a cognitive problem, for example antipsychotics, can also influence 
gait (Chapter 1 + 2).
Q. How does cognition influence gait and balance in older people?  
A. In patients without co-morbidity dementia is associated with a slowing of gait (Chapter 
2). However, frail older people with dementia walk much faster than frail patients without 
dementia: too quick for their level of frailty, presumably because of a lack of insight in 
their own physical and cognitive impairments (Chapter 3). Depressive symptoms are also 
associated with a decrease in gait velocity and increase in stride length variability, associated 
with an increased risk of falling (Chapter 3). 
 A cognitive dual task impairs gait (slower and more variability in stride length and time) and 
balance (increased trunk sway) in older people. However, in fit older people with a normal 
cognition the duals tasks need to be more difficult to impair gait and balance (Chapter 4).
Q. Which specific cognitive functions are involved in the coordination of gait and balance?
A. The answer to the former questions already revealed the importance of the division of 
attention and insight in cognitive and physical abilities in the cognitive regulation of walking. 
Executive functions, such as planning and mental flexibility, are also involved and better 
executive functioning is associated with better gait and balance performance during walking 
with a cognitive dual task (Chapter 5).
 Although numerous questions are still open (Chapter 6) enough knowledge is already present 
to be able to recommend: If gait is impaired also assess cognitive function and if cognitive 
function is impaired, also assess gait!  
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Onderzoek doen is als een spannende ontdekkingsreis. De start was duidelijk en de ‘rode draad’ 
bleef, maar onderweg was er het avontuur: vele verrassende wegen, interessante zijpaden, soms 
kuilen en gaandeweg vele metgezellen die de reis naast avontuurlijk ook zeer plezierig hebben 
gemaakt. 
Vanaf het begin van de reis lonkte het land geriatrie: met zulke mooie, bijzondere mensen, 
daar zou het interessant zijn onderzoek mee te doen! Alle deelnemers, van de zeer kwetsbare 
geriatrische patiënten, thuiswonende Nijmeegse ouderen tot fanatieke 4-daagse lopers: jullie 
hebben de belofte met alle verhalen, wijsheden en jullie grote diversiteit meer dan waar gemaakt! 
Ik kan niets anders dan de grootste waardering hebben voor jullie moeite en inspanningen 
tijdens de metingen tot soms op de grens van jullie mogelijkheden. 
Al heel vroeg tijdens deze reis was er professor Olde Rikkert. Beste Marcel, je had al veel 
vertrouwen in me toen ik dat zelf nog lang niet had. Je gaf me bergen met kansen, dacht 
met veel humor en enthousiasme mee over nieuwe ontdekkingen, kon in discussies een hoog 
gehalte aan ‘waarom’ en ‘ja maar’ handelen en ondertussen liet je me uitstijgen boven mezelf. 
Chapeau terug!
From the start there was also an English geriatrician, professor Mulley. Dear Graham, although 
most of the time from a distance, you have been and continue to be a source of inspiration: to 
wonder about common phenomena, to do research with elderly people and to become a good 
geriatrician in the future. Thank you for being such a brilliant teacher, geriatrician and kind 
man! 
Dr Bloem, beste Bas: enthousiasme, interesse in beweging en het uitvoeren van grootse plannen 
staan voorop bij je. Je leerde me de basics van de geriatrische neurologie en was altijd direct te 
porren om mee nadenken over ‘gekke’ bevindingen en hoe die te ‘verkopen’.
Dr Borm, beste George: je hebt als statisticus data over denkende, lopende ouderen omgezet 
tot een prachtig eenvoudige, nieuwe standaardisatiemethode. Maar je deed veel meer dan 
dat, door met humor allerlei prikkelende opmerkingen en goedgestelde, basale vragen op 
onderzoeksplannen los te laten. Het was altijd een groot plezier om bij je langs te komen met 
‘ik heb een vraag’.
Naast de al eerder genoemden kon ik kon tijdens de reis rekenen op een heel multidisciplinair 
team van begeleiders en adviseurs: Rianne Esselink, neuroloog, was als sprankelend mens 
betrokken en goed als tegenwicht bij al m’n manvolk. Carolien Benraad, klinisch geriater, heeft 
onderzoek in Maria Mackenzie mede mogelijk gemaakt en was een graag geziene, enthousiaste 
supportster.
Vanuit de fysiotherapie was er het enthousiasme en veel discussie: hoe wat te meten, te 
interpreteren en naar de directe patiëntenzorg te vertalen. In het bijzonder wil ik hiervoor en 
voor de hulp tijdens het meten Hans, Saskia, Mike (UMC St Radboud) en Jos (Maria Mackenzie) 
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bedanken! Marten Munneke zorgde hiernaast voor prettige begeleiding met net weer een andere, 
bewegingswetenschappelijke invalshoek. Professor André Verbeek zette de epidemiologische 
puntjes op de i. Verder was er Indrag Lampe van de psychiatrie en op het allerlaatst van de reis 
ook Roy Kessels, neuropsycholoog, vol enthousiasme en met vele waardevolle adviezen.
Met velen heb ik de onderzoekerskamer gedeeld. Een (soms wat rumoerige) rustplaats om de 
begaanbaarheid van de wegen te bediscussiëren, het bereiken van toppen te vieren en tegenvallers 
af te reageren. Jullie support en gezelligheid waren onmisbaar. Om speciaal te noemen: Jurgen 
Claassen, die me overhaalde de 7-heuvelen te gaan lopen, maar zelf als captain zijn snor tot nu 
toe drukt. Hij liet zien hoe alles altijd goed komt en voorzag ‘de (onderzoeks)wereld’ boven de 
dampen van zijn koffiemok van een eigen visie. Arenda zorgde voor een nuchtere kijk en Marieke 
voor levendigheid, humor en veel support. 
Mijn twee paranimfen springen daar zelfs nog bovenuit: René Melis als zeer gewaardeerd 
onderzoeksmaatje voor discussie, overleg en uitgestoken hand bij struikelpartijen, de hele 
reis door. Lia Middeljans, voor je grote luisterende oor en belangstelling, je gezelligheid en 
constructieve overleg over vanalles. Heel fijn!
Tijdens de reis is er veel gedaan en gemeten. Dit was veel moeilijker geweest zonder de 
enthousiaste hulp van mijn wetenschappelijke stagiaires: Loes, Paul, Aleid, Heleen en Miriam, 
en op ’n zijpad Ellis en Jan. Bedankt voor jullie hulp en gezelligheid!
Klinisch geriaters, arts-assistenten en alle andere afdelingsmedewerkers: bedankt voor het 
meeleven en de belangstelling! Gemma en Cynthia van het stafsecretariaat ook voor het zo en-
passant aanhoren van verhalen over nieuwe ontdekkingen en veroveringen, frustraties, en jullie 
hulp bij het geregel van proviand onderweg. 
Tijdens de zoek- en struintochten waren er altijd mensen die even letterlijk en/of figuurlijk 
mee wilden wandelen, me voor laaghangende takken behoedden en me uit kuilen tevoorschijn 
toverden. Lieve Mayke, Thijs, Miranda, Pieter, Paula, Marjanne, Pernill, Rachel: dank voor alle 
thee, gekletst, boswandelingen, nou ja: heel veel!
Met anderen en dan vooral Inez, Gerda en Eline was het wekelijkse paardrijden en de uitjes 
daarbuiten een feest. Meestal dan… Djamilla, je had vaak groot gelijk en het was ware biofeedback, 
maar na een poos begon ik het te snappen en nu vind ik op je rijden helemaal geweldig! Net 
als op je soortgenoten trouwens.
En dan was er steeds opnieuw belangstelling van vele anderen waar geen volledig lijstje van 
te maken is: Ine en Adriaan, familie, buren in Nijmegen en Uden, STERmensen, en alle andere 
bekenden: bijzonder en lief. 
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‘Thuis’ volgde alles op de voet en diende als zeer luxe en gezellige pleisterplaats. Pap, bedankt 
voor de soep en wijze raad tijdens wandelen en fietsen. Mam, met je nieuwtjes bleef ik altijd op 
de hoogte van alle belangrijke zaken in buurt en familie en bleef m’n huis (en ik) toonbaar. Joost 
en Danielle voor alle vanzelfsprekend getoonde belangstelling die toch zo bijzonder en heel fijn 
is! Van alle vier: jullie liefde en betrokkenheid waardeer ik zeer!
’t was een bijzondere reis en hij gaat voort:
Nu is het tijd om me als dokter verder te bekwamen in de geriatrie en dan …
… op naar wat de toekomst brengt! 
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